bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
ENBREL, ENBREL, methotrexate, ENBREL, anakinra, ENBREL, ENBREL, anakinra, sulfasalazine, ENBREL, ENBREL, sulfasalazine	Etanercept_ddi_task2	Sentence: Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown.	[ "Specific", "drug", "interaction", "studies", "have", "not", "been", "conducted", "with", "ENBREL", ".", "However", ",", "it", "was", "observed", "that", "the", "pharmacokinetics", "of", "ENBREL", " ", "was", "unaltered", "by", "concomitant", "methotrexate", "in", "rheumatoid", "arthritis", "patients", ".", "In", "a", "study", "in", "which", "patients", "with", "active", "RA", "were", "treated", "for", "up", "to", "24", "weeks", "with", "concurrent", "ENBREL", " ", "and", "anakinra", "therapy", ",", "a", "7", "%", "rate", "of", "serious", "infections", "was", "observed", ",", "which", "was", "higher", "than", "that", "observed", "with", "ENBREL", " ", "alone", "(", "0", "%", ")", ".", "Two", "percent", "of", "patients", "treated", "concurrently", "with", "ENBREL", " ", "and", "anakinra", "developed", "neutropenia", "(", "ANC", " ", "1", "x", "109", "/", "L", ")", ".", "Patients", "in", "a", "clinical", "study", "who", "were", "on", "established", "therapy", "with", "sulfasalazine", ",", "to", "which", "ENBREL", "was", "added", ",", "were", "noted", "to", "develop", "a", "mild", "decrease", "in", "mean", "neutrophil", "counts", "in", "comparison", "to", "groups", "treated", "with", "either", "ENBREL", "CI", "or", "sulfasalazine", "alone", ".", "The", "clinical", "significance", "of", "this", "observation", "is", "unknown", "." ]	[ "DRUG", "BRAND" ]
Patienten is an umlsterm, Lupus is an umlsterm, Autoantikoerperprofil is an umlsterm, Antikoerper is an umlsterm, ANCA is an umlsterm, Assoziation is an umlsterm, Hautsymptome is an umlsterm, Dapson is an umlsterm	DerHautarzt.80490403.ger.abstr_task0	Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .	[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Lupus is an umlsterm, Autoantikoerperprofil is an umlsterm, Antikoerper is an umlsterm, ANCA is an umlsterm, Assoziation is an umlsterm, Hautsymptome is an umlsterm, Dapson is an umlsterm	DerHautarzt.80490403.ger.abstr_task1	Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please typing these entity words according to sentence: Patienten, Lupus, Autoantikoerperprofil, Antikoerper, ANCA, Assoziation, Hautsymptome, Dapson Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .	[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]	[ "umlsterm" ]
Patienten, Lupus, Autoantikoerperprofil, Antikoerper, ANCA, Assoziation, Hautsymptome, Dapson	DerHautarzt.80490403.ger.abstr_task2	Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .	[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]	[ "umlsterm" ]
TRF2 is a GENE-Y, human telomeric protein TRF2 is a GENE-Y, TRF2 is a GENE-Y, TRF2 is a GENE-Y, histone acetyltransferase p300 is a GENE-Y, p300 is a GENE-Y, lysine is a CHEMICAL, TRF2 is a GENE-Y, TRF2 is a GENE-Y, ubiquitin is a GENE-N, TRF2 is a GENE-Y, K293R is a GENE-N, TRF2 is a GENE-Y, p300 is a GENE-Y	1113_task0	Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.	[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
TRF2 is a GENE-Y, human telomeric protein TRF2 is a GENE-Y, TRF2 is a GENE-Y, TRF2 is a GENE-Y, histone acetyltransferase p300 is a GENE-Y, p300 is a GENE-Y, lysine is a CHEMICAL, TRF2 is a GENE-Y, TRF2 is a GENE-Y, ubiquitin is a GENE-N, TRF2 is a GENE-Y, K293R is a GENE-N, TRF2 is a GENE-Y, p300 is a GENE-Y	1113_task1	Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please typing these entity words according to sentence: TRF2, human telomeric protein TRF2, TRF2, TRF2, histone acetyltransferase p300, p300, lysine, TRF2, TRF2, ubiquitin, TRF2, K293R, TRF2, p300 Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.	[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
TRF2, human telomeric protein TRF2, TRF2, TRF2, histone acetyltransferase p300, p300, lysine, TRF2, TRF2, ubiquitin, TRF2, K293R, TRF2, p300	1113_task2	Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.	[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, cellular is a Cell, p53 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, DNA is a Cellular_component, tumor is a Cancer, p53 is a Gene_or_gene_product, extracellular is a Immaterial_anatomical_entity, cell surface is a Cellular_component, tissue is a Tissue, p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, embryos is a Developing_anatomical_structure, cancer is a Cancer	269_task0	Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Immaterial_anatomical_entity, Developing_anatomical_structure, Cancer, Cellular_component, Cell	[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.	[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]	[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]
p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, cellular is a Cell, p53 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, DNA is a Cellular_component, tumor is a Cancer, p53 is a Gene_or_gene_product, extracellular is a Immaterial_anatomical_entity, cell surface is a Cellular_component, tissue is a Tissue, p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, embryos is a Developing_anatomical_structure, cancer is a Cancer	269_task1	Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please typing these entity words according to sentence: p53, TGF - beta, p53, cells, cellular, p53, p53, cells, DNA, tumor, p53, extracellular, cell surface, tissue, p53, TGF - beta, TGF - beta, embryos, cancer Options: Tissue, Gene_or_gene_product, Immaterial_anatomical_entity, Developing_anatomical_structure, Cancer, Cellular_component, Cell	[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.	[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]	[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]
p53, TGF - beta, p53, cells, cellular, p53, p53, cells, DNA, tumor, p53, extracellular, cell surface, tissue, p53, TGF - beta, TGF - beta, embryos, cancer	269_task2	Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]	Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.	[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]	[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]
baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, Baicalin is a CHEMICAL, baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP3A is a GENE-N, baicalin is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N	25939_task0	Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]	Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.	[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]	[ "CHEMICAL", "GENE-N" ]
baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, Baicalin is a CHEMICAL, baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP3A is a GENE-N, baicalin is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N	25939_task1	Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please typing these entity words according to sentence: baicalin, dextromethorphan, CYP2D, CYP3A, Baicalin, baicalin, dextromethorphan, DXM, CYP2D, CYP3A, baicalin, CYP2D, CYP3A, baicalin, DXM, DXM, DXM, baicalin, baicalin, DXM, CYP3A, baicalin, baicalin, baicalin, DXM, CYP2D, CYP3A Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]	Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.	[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]	[ "CHEMICAL", "GENE-N" ]
baicalin, dextromethorphan, CYP2D, CYP3A, Baicalin, baicalin, dextromethorphan, DXM, CYP2D, CYP3A, baicalin, CYP2D, CYP3A, baicalin, DXM, DXM, DXM, baicalin, baicalin, DXM, CYP3A, baicalin, baicalin, baicalin, DXM, CYP2D, CYP3A	25939_task2	Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]	Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.	[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]	[ "CHEMICAL", "GENE-N" ]
man is an umlsterm, right is an umlsterm, vocal cord paralysis is an umlsterm, treatment is an umlsterm, medication is an umlsterm, treatment is an umlsterm, time is an umlsterm, speech therapy is an umlsterm, date is an umlsterm	HNO.90470825.eng.abstr_task0	Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .	[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]	[ "umlsterm" ]
man is an umlsterm, right is an umlsterm, vocal cord paralysis is an umlsterm, treatment is an umlsterm, medication is an umlsterm, treatment is an umlsterm, time is an umlsterm, speech therapy is an umlsterm, date is an umlsterm	HNO.90470825.eng.abstr_task1	Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please typing these entity words according to sentence: man, right, vocal cord paralysis, treatment, medication, treatment, time, speech therapy, date Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .	[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]	[ "umlsterm" ]
man, right, vocal cord paralysis, treatment, medication, treatment, time, speech therapy, date	HNO.90470825.eng.abstr_task2	Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .	[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]	[ "umlsterm" ]
PU.1 is a Protein, macrophage colony - stimulating factor receptor is a Protein, macrophage colony - stimulating factor ( M - CSF ) receptor is a Protein, M - CSF receptor is a Protein, M - CSF receptor is a Protein, PU.1 is a Protein, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, specific site is a Entity, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein	8264604_task0	Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.	[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]	[ "Protein", "Entity" ]
PU.1 is a Protein, macrophage colony - stimulating factor receptor is a Protein, macrophage colony - stimulating factor ( M - CSF ) receptor is a Protein, M - CSF receptor is a Protein, M - CSF receptor is a Protein, PU.1 is a Protein, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, specific site is a Entity, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein	8264604_task1	Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please typing these entity words according to sentence: PU.1, macrophage colony - stimulating factor receptor, macrophage colony - stimulating factor ( M - CSF ) receptor, M - CSF receptor, M - CSF receptor, PU.1, PU.1, M - CSF receptor, promoter, PU.1, PU.1, specific site, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1 Options: Entity, Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.	[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]	[ "Protein", "Entity" ]
PU.1, macrophage colony - stimulating factor receptor, macrophage colony - stimulating factor ( M - CSF ) receptor, M - CSF receptor, M - CSF receptor, PU.1, PU.1, M - CSF receptor, promoter, PU.1, PU.1, specific site, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1	8264604_task2	Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.	[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]	[ "Protein", "Entity" ]
tumors is an umlsterm, patients is an umlsterm, therapy is an umlsterm, squamous cell carcinomas is an umlsterm, neoplastic transformation is an umlsterm, risk factors is an umlsterm, alcohol is an umlsterm, tobacco is an umlsterm, abuse is an umlsterm, chemoprevention is an umlsterm, squamous cell carcinomas is an umlsterm, review is an umlsterm, squamous cell carcinomas is an umlsterm, patients is an umlsterm, -carotene is an umlsterm, ascorbic acid is an umlsterm, patients is an umlsterm, leukoplakia is an umlsterm, oral cavity is an umlsterm, patients is an umlsterm, premalignant is an umlsterm, squamous cell carcinoma is an umlsterm, Biopsies is an umlsterm, therapy is an umlsterm, Flow cytometry is an umlsterm, analyses is an umlsterm, overall is an umlsterm, cell is an umlsterm, kinetic is an umlsterm, cell nucleus is an umlsterm, premalignant is an umlsterm, research is an umlsterm, biomarkers is an umlsterm, chemoprevention is an umlsterm	MundKieferGesichtschirurgie.0004s160.eng.abstr_task0	Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .	[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]	[ "umlsterm" ]
tumors is an umlsterm, patients is an umlsterm, therapy is an umlsterm, squamous cell carcinomas is an umlsterm, neoplastic transformation is an umlsterm, risk factors is an umlsterm, alcohol is an umlsterm, tobacco is an umlsterm, abuse is an umlsterm, chemoprevention is an umlsterm, squamous cell carcinomas is an umlsterm, review is an umlsterm, squamous cell carcinomas is an umlsterm, patients is an umlsterm, -carotene is an umlsterm, ascorbic acid is an umlsterm, patients is an umlsterm, leukoplakia is an umlsterm, oral cavity is an umlsterm, patients is an umlsterm, premalignant is an umlsterm, squamous cell carcinoma is an umlsterm, Biopsies is an umlsterm, therapy is an umlsterm, Flow cytometry is an umlsterm, analyses is an umlsterm, overall is an umlsterm, cell is an umlsterm, kinetic is an umlsterm, cell nucleus is an umlsterm, premalignant is an umlsterm, research is an umlsterm, biomarkers is an umlsterm, chemoprevention is an umlsterm	MundKieferGesichtschirurgie.0004s160.eng.abstr_task1	Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please typing these entity words according to sentence: tumors, patients, therapy, squamous cell carcinomas, neoplastic transformation, risk factors, alcohol, tobacco, abuse, chemoprevention, squamous cell carcinomas, review, squamous cell carcinomas, patients, -carotene, ascorbic acid, patients, leukoplakia, oral cavity, patients, premalignant, squamous cell carcinoma, Biopsies, therapy, Flow cytometry, analyses, overall, cell, kinetic, cell nucleus, premalignant, research, biomarkers, chemoprevention Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .	[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]	[ "umlsterm" ]
tumors, patients, therapy, squamous cell carcinomas, neoplastic transformation, risk factors, alcohol, tobacco, abuse, chemoprevention, squamous cell carcinomas, review, squamous cell carcinomas, patients, -carotene, ascorbic acid, patients, leukoplakia, oral cavity, patients, premalignant, squamous cell carcinoma, Biopsies, therapy, Flow cytometry, analyses, overall, cell, kinetic, cell nucleus, premalignant, research, biomarkers, chemoprevention	MundKieferGesichtschirurgie.0004s160.eng.abstr_task2	Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .	[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]	[ "umlsterm" ]
N - hydroxysuccinimide is a compound, alkaline phosphatase is a protein, ALP is a protein	DS.d1776_task0	Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.	[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]	[ "compound", "protein" ]
N - hydroxysuccinimide is a compound, alkaline phosphatase is a protein, ALP is a protein	DS.d1776_task1	Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please typing these entity words according to sentence: N - hydroxysuccinimide, alkaline phosphatase, ALP Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.	[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]	[ "compound", "protein" ]
N - hydroxysuccinimide, alkaline phosphatase, ALP	DS.d1776_task2	Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.	[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]	[ "compound", "protein" ]
Ramiro is a NOMBRE_SUJETO_ASISTENCIA, Alfaro Soto is a NOMBRE_SUJETO_ASISTENCIA, 4835758 is a ID_SUJETO_ASISTENCIA, 28 76235749 90 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28046 is a TERRITORIO, 21/07/1944 is a FECHAS, España is a PAIS, 68 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2013 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, 28 28 79354 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 68 años is a EDAD_SUJETO_ASISTENCIA, marzo de 2005 is a FECHAS, julio de 2007 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, dcrespo@fhalcorcon.es is a CORREO_ELECTRONICO	296_task0	Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Ramiro is a NOMBRE_SUJETO_ASISTENCIA, Alfaro Soto is a NOMBRE_SUJETO_ASISTENCIA, 4835758 is a ID_SUJETO_ASISTENCIA, 28 76235749 90 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28046 is a TERRITORIO, 21/07/1944 is a FECHAS, España is a PAIS, 68 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2013 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, 28 28 79354 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 68 años is a EDAD_SUJETO_ASISTENCIA, marzo de 2005 is a FECHAS, julio de 2007 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, dcrespo@fhalcorcon.es is a CORREO_ELECTRONICO	296_task1	Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please typing these entity words according to sentence: Ramiro, Alfaro Soto, 4835758, 28 76235749 90, Madrid, 28046, 21/07/1944, España, 68 años, 10/05/2013, David Crespo Marcos, 28 28 79354, Varón, 68 años, marzo de 2005, julio de 2007, David Crespo Marcos, dcrespo@fhalcorcon.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Ramiro, Alfaro Soto, 4835758, 28 76235749 90, Madrid, 28046, 21/07/1944, España, 68 años, 10/05/2013, David Crespo Marcos, 28 28 79354, Varón, 68 años, marzo de 2005, julio de 2007, David Crespo Marcos, dcrespo@fhalcorcon.es	296_task2	Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
hERG is a GENE-Y, amiodarone is a CHEMICAL, amiodarone is a CHEMICAL	18604229_task0	Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]	Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.	[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]	[ "CHEMICAL", "GENE-Y" ]
hERG is a GENE-Y, amiodarone is a CHEMICAL, amiodarone is a CHEMICAL	18604229_task1	Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please typing these entity words according to sentence: hERG, amiodarone, amiodarone Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]	Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.	[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]	[ "CHEMICAL", "GENE-Y" ]
hERG, amiodarone, amiodarone	18604229_task2	Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]	Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.	[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]	[ "CHEMICAL", "GENE-Y" ]
Risikofaktoren is an umlsterm, Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Literatur is an umlsterm, Risikofaktoren is an umlsterm, weibliches is an umlsterm, Geschlecht is an umlsterm, Anaesthetika is an umlsterm, Opioide is an umlsterm, Menstruationszyklus is an umlsterm, Risikofaktoren is an umlsterm, Schmerz is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Saeure - Basen - Haushalts is an umlsterm, Adipositas is an umlsterm, Inhalationsanaesthetika is an umlsterm, Opioide is an umlsterm, Patienten is an umlsterm, Frauen is an umlsterm	DerAnaesthesist.00490629.ger.abstr_task0	Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .	[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]	[ "umlsterm" ]
Risikofaktoren is an umlsterm, Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Literatur is an umlsterm, Risikofaktoren is an umlsterm, weibliches is an umlsterm, Geschlecht is an umlsterm, Anaesthetika is an umlsterm, Opioide is an umlsterm, Menstruationszyklus is an umlsterm, Risikofaktoren is an umlsterm, Schmerz is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Saeure - Basen - Haushalts is an umlsterm, Adipositas is an umlsterm, Inhalationsanaesthetika is an umlsterm, Opioide is an umlsterm, Patienten is an umlsterm, Frauen is an umlsterm	DerAnaesthesist.00490629.ger.abstr_task1	Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please typing these entity words according to sentence: Risikofaktoren, Uebelkeit, Erbrechen, Literatur, Risikofaktoren, weibliches, Geschlecht, Anaesthetika, Opioide, Menstruationszyklus, Risikofaktoren, Schmerz, Hypoxie, Hyperkapnie, Saeure - Basen - Haushalts, Adipositas, Inhalationsanaesthetika, Opioide, Patienten, Frauen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .	[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]	[ "umlsterm" ]
Risikofaktoren, Uebelkeit, Erbrechen, Literatur, Risikofaktoren, weibliches, Geschlecht, Anaesthetika, Opioide, Menstruationszyklus, Risikofaktoren, Schmerz, Hypoxie, Hyperkapnie, Saeure - Basen - Haushalts, Adipositas, Inhalationsanaesthetika, Opioide, Patienten, Frauen	DerAnaesthesist.00490629.ger.abstr_task2	Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .	[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Stent is an umlsterm, Polyesterflicken is an umlsterm, ASD is an umlsterm, Stent is an umlsterm, ASD is an umlsterm, Patienten is an umlsterm, ASD is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Komplikationen is an umlsterm	ZfuerKardiologie.80870185.ger.abstr_task0	Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .	[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Stent is an umlsterm, Polyesterflicken is an umlsterm, ASD is an umlsterm, Stent is an umlsterm, ASD is an umlsterm, Patienten is an umlsterm, ASD is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Komplikationen is an umlsterm	ZfuerKardiologie.80870185.ger.abstr_task1	Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please typing these entity words according to sentence: Patienten, Stent, Polyesterflicken, ASD, Stent, ASD, Patienten, ASD, Komplikationen, Patienten, Komplikationen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .	[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]	[ "umlsterm" ]
Patienten, Stent, Polyesterflicken, ASD, Stent, ASD, Patienten, ASD, Komplikationen, Patienten, Komplikationen	ZfuerKardiologie.80870185.ger.abstr_task2	Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .	[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]	[ "umlsterm" ]
2 or more doses is a Multiplier, methylprednisolone / prednisone is a Scope, Steroids is a Drug, other than is a Negation, methylprednisolone or prednisone is a Scope, Pregnancy is a Condition, estimated glomerular filtration rate ( eGFR ) is a Measurement, < 45 ml / min/1.73m2 is a Value	NCT03511521_exc_task0	Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Multiplier, Negation, Scope, Measurement, Drug	[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]	Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2	[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]	[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]
2 or more doses is a Multiplier, methylprednisolone / prednisone is a Scope, Steroids is a Drug, other than is a Negation, methylprednisolone or prednisone is a Scope, Pregnancy is a Condition, estimated glomerular filtration rate ( eGFR ) is a Measurement, < 45 ml / min/1.73m2 is a Value	NCT03511521_exc_task1	Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please typing these entity words according to sentence: 2 or more doses, methylprednisolone / prednisone, Steroids, other than, methylprednisolone or prednisone, Pregnancy, estimated glomerular filtration rate ( eGFR ), < 45 ml / min/1.73m2 Options: Condition, Value, Multiplier, Negation, Scope, Measurement, Drug	[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]	Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2	[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]	[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]
2 or more doses, methylprednisolone / prednisone, Steroids, other than, methylprednisolone or prednisone, Pregnancy, estimated glomerular filtration rate ( eGFR ), < 45 ml / min/1.73m2	NCT03511521_exc_task2	Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]	Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2	[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]	[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]
Polyneuropathie is an umlsterm, Kernspintomographie is an umlsterm, Kopfes is an umlsterm, Hirnatrophie is an umlsterm, Diagnose is an umlsterm, Stoffwechseldefekte is an umlsterm, Leukozyten is an umlsterm, Kindern is an umlsterm, Normalbereichs is an umlsterm, peripheren Nervensystems is an umlsterm, Patienten is an umlsterm	DerNervenarzt.90700745.ger.abstr_task0	Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .	[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]	[ "umlsterm" ]
Polyneuropathie is an umlsterm, Kernspintomographie is an umlsterm, Kopfes is an umlsterm, Hirnatrophie is an umlsterm, Diagnose is an umlsterm, Stoffwechseldefekte is an umlsterm, Leukozyten is an umlsterm, Kindern is an umlsterm, Normalbereichs is an umlsterm, peripheren Nervensystems is an umlsterm, Patienten is an umlsterm	DerNervenarzt.90700745.ger.abstr_task1	Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please typing these entity words according to sentence: Polyneuropathie, Kernspintomographie, Kopfes, Hirnatrophie, Diagnose, Stoffwechseldefekte, Leukozyten, Kindern, Normalbereichs, peripheren Nervensystems, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .	[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]	[ "umlsterm" ]
Polyneuropathie, Kernspintomographie, Kopfes, Hirnatrophie, Diagnose, Stoffwechseldefekte, Leukozyten, Kindern, Normalbereichs, peripheren Nervensystems, Patienten	DerNervenarzt.90700745.ger.abstr_task2	Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .	[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]	[ "umlsterm" ]
Sandro is a NOMBRE_SUJETO_ASISTENCIA, Gonzalez Morales is a NOMBRE_SUJETO_ASISTENCIA, 370562 is a ID_SUJETO_ASISTENCIA, 43 23598635 20 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 27/03/1946 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 21/05/2016 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, 28 28 14723 is a ID_TITULACION_PERSONAL_SANITARIO, Hombre is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, septiembre 2014 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, ale.delgam@gmail.com is a CORREO_ELECTRONICO	396_task0	Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com	[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]
Sandro is a NOMBRE_SUJETO_ASISTENCIA, Gonzalez Morales is a NOMBRE_SUJETO_ASISTENCIA, 370562 is a ID_SUJETO_ASISTENCIA, 43 23598635 20 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 27/03/1946 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 21/05/2016 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, 28 28 14723 is a ID_TITULACION_PERSONAL_SANITARIO, Hombre is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, septiembre 2014 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, ale.delgam@gmail.com is a CORREO_ELECTRONICO	396_task1	Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please typing these entity words according to sentence: Sandro, Gonzalez Morales, 370562, 43 23598635 20, Madrid, 27/03/1946, España, 70 años, 21/05/2016, Alejandro Delgado Gamboa, 28 28 14723, Hombre, 70 años, septiembre 2014, Alejandro Delgado Gamboa, ale.delgam@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com	[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]
Sandro, Gonzalez Morales, 370562, 43 23598635 20, Madrid, 27/03/1946, España, 70 años, 21/05/2016, Alejandro Delgado Gamboa, 28 28 14723, Hombre, 70 años, septiembre 2014, Alejandro Delgado Gamboa, ale.delgam@gmail.com	396_task2	Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com	[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]	[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]
Rheumatoid arthritis is an umlsterm, disease is an umlsterm, cytokines is an umlsterm, blood is an umlsterm, IL-1 is an umlsterm, TNF is an umlsterm, concentrations is an umlsterm, disease is an umlsterm, cortisol is an umlsterm, secretion is an umlsterm, overall is an umlsterm, cortisol is an umlsterm, release is an umlsterm, disease is an umlsterm	ZfuerRheumatologie.0059ii62.eng.abstr_task0	Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .	[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]	[ "umlsterm" ]
Rheumatoid arthritis is an umlsterm, disease is an umlsterm, cytokines is an umlsterm, blood is an umlsterm, IL-1 is an umlsterm, TNF is an umlsterm, concentrations is an umlsterm, disease is an umlsterm, cortisol is an umlsterm, secretion is an umlsterm, overall is an umlsterm, cortisol is an umlsterm, release is an umlsterm, disease is an umlsterm	ZfuerRheumatologie.0059ii62.eng.abstr_task1	Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please typing these entity words according to sentence: Rheumatoid arthritis, disease, cytokines, blood, IL-1, TNF, concentrations, disease, cortisol, secretion, overall, cortisol, release, disease Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .	[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]	[ "umlsterm" ]
Rheumatoid arthritis, disease, cytokines, blood, IL-1, TNF, concentrations, disease, cortisol, secretion, overall, cortisol, release, disease	ZfuerRheumatologie.0059ii62.eng.abstr_task2	Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .	[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]	[ "umlsterm" ]
naloxone - steroid hybrid azine is a CHEMICAL, delta receptors is a GENE-Y, naloxone estrone azine is a CHEMICAL, N - EH is a CHEMICAL, opioid receptor is a GENE-N, naloxone is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, D - Ala2-Leu5-enkephalin is a CHEMICAL, normorphine is a CHEMICAL, N - EH is a CHEMICAL, 3H - D - Ala2-Leu5-enkephalin is a CHEMICAL, 3H - dihydromorphine is a CHEMICAL, 3H - ethylketocyclazocine is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, naloxone is a CHEMICAL, N - EH is a CHEMICAL	21549_task0	Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.	[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
naloxone - steroid hybrid azine is a CHEMICAL, delta receptors is a GENE-Y, naloxone estrone azine is a CHEMICAL, N - EH is a CHEMICAL, opioid receptor is a GENE-N, naloxone is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, D - Ala2-Leu5-enkephalin is a CHEMICAL, normorphine is a CHEMICAL, N - EH is a CHEMICAL, 3H - D - Ala2-Leu5-enkephalin is a CHEMICAL, 3H - dihydromorphine is a CHEMICAL, 3H - ethylketocyclazocine is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, naloxone is a CHEMICAL, N - EH is a CHEMICAL	21549_task1	Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please typing these entity words according to sentence: naloxone - steroid hybrid azine, delta receptors, naloxone estrone azine, N - EH, opioid receptor, naloxone, N - EH, naloxone, D - Ala2-Leu5-enkephalin, normorphine, N - EH, 3H - D - Ala2-Leu5-enkephalin, 3H - dihydromorphine, 3H - ethylketocyclazocine, N - EH, naloxone, naloxone, N - EH Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.	[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
naloxone - steroid hybrid azine, delta receptors, naloxone estrone azine, N - EH, opioid receptor, naloxone, N - EH, naloxone, D - Ala2-Leu5-enkephalin, normorphine, N - EH, 3H - D - Ala2-Leu5-enkephalin, 3H - dihydromorphine, 3H - ethylketocyclazocine, N - EH, naloxone, naloxone, N - EH	21549_task2	Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]	A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.	[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Interleukin-2 is a Protein, promoter is a Entity, interleukin ( IL)-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, reporter constructs with is a Entity, binding sites from the IL-2 promoter is a Entity, sites is a Entity, chi B site is a Entity, NF - AT binding sites is a Entity, IL-2 is a Protein, promoter is a Entity, NF - chi B site is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, human immunodeficiency virus promoter is a Entity, IL-2 is a Protein, IL-2 NF - chi B probe is a Entity, chi B complexes is a Entity, p50 is a Protein, p65 is a Protein, complexes is a Entity, chi B complex is a Entity, IL-2 NF - chi B site is a Entity, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein	459_task0	Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.	[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
Interleukin-2 is a Protein, promoter is a Entity, interleukin ( IL)-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, reporter constructs with is a Entity, binding sites from the IL-2 promoter is a Entity, sites is a Entity, chi B site is a Entity, NF - AT binding sites is a Entity, IL-2 is a Protein, promoter is a Entity, NF - chi B site is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, human immunodeficiency virus promoter is a Entity, IL-2 is a Protein, IL-2 NF - chi B probe is a Entity, chi B complexes is a Entity, p50 is a Protein, p65 is a Protein, complexes is a Entity, chi B complex is a Entity, IL-2 NF - chi B site is a Entity, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein	459_task1	Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please typing these entity words according to sentence: Interleukin-2, promoter, interleukin ( IL)-2, IL-2, IL-2, IL-2, promoter, IL-2, reporter constructs with, binding sites from the IL-2 promoter, sites, chi B site, NF - AT binding sites, IL-2, promoter, NF - chi B site, IL-2, IL-2, promoter, IL-2, human immunodeficiency virus promoter, IL-2, IL-2 NF - chi B probe, chi B complexes, p50, p65, complexes, chi B complex, IL-2 NF - chi B site, IL-2, promoter, IL-2 Options: Entity, Protein	[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.	[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
Interleukin-2, promoter, interleukin ( IL)-2, IL-2, IL-2, IL-2, promoter, IL-2, reporter constructs with, binding sites from the IL-2 promoter, sites, chi B site, NF - AT binding sites, IL-2, promoter, NF - chi B site, IL-2, IL-2, promoter, IL-2, human immunodeficiency virus promoter, IL-2, IL-2 NF - chi B probe, chi B complexes, p50, p65, complexes, chi B complex, IL-2 NF - chi B site, IL-2, promoter, IL-2	459_task2	Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please extract entity words from the input sentence	[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]	Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.	[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
tumor is a Cancer, tumors is a Cancer, tumor is a Cancer, tumor is a Cancer, tumor is a Cancer, endothelial cell is a Cell, tumor is a Cancer, tumor is a Cancer, cancer is a Cancer	PMID-16406676_task0	Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Cell	[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]	Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.	[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]	[ "Cell", "Cancer" ]
tumor is a Cancer, tumors is a Cancer, tumor is a Cancer, tumor is a Cancer, tumor is a Cancer, endothelial cell is a Cell, tumor is a Cancer, tumor is a Cancer, cancer is a Cancer	PMID-16406676_task1	Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please typing these entity words according to sentence: tumor, tumors, tumor, tumor, tumor, endothelial cell, tumor, tumor, cancer Options: Cancer, Cell	[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]	Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.	[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]	[ "Cell", "Cancer" ]
tumor, tumors, tumor, tumor, tumor, endothelial cell, tumor, tumor, cancer	PMID-16406676_task2	Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]	Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.	[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]	[ "Cell", "Cancer" ]
profilin is a Individual_protein, muscle actin is a Individual_protein, profilin is a Gene/protein/RNA, actin is a Gene/protein/RNA	16_task0	Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein	[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]	Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.	[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
profilin is a Individual_protein, muscle actin is a Individual_protein, profilin is a Gene/protein/RNA, actin is a Gene/protein/RNA	16_task1	Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please typing these entity words according to sentence: profilin, muscle actin, profilin, actin Options: Gene/protein/RNA, Individual_protein	[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]	Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.	[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
profilin, muscle actin, profilin, actin	16_task2	Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please extract entity words from the input sentence	[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]	Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.	[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]	[ "Individual_protein", "Gene/protein/RNA" ]
Human immunodeficiency viruses is a virus, heterologous enhancer / promoters is a DNA_domain_or_region, lymphocyte tropisms is an other_name	83044_task0	Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, DNA_domain_or_region, virus	[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.	[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]	[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]
Human immunodeficiency viruses is a virus, heterologous enhancer / promoters is a DNA_domain_or_region, lymphocyte tropisms is an other_name	83044_task1	Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please typing these entity words according to sentence: Human immunodeficiency viruses, heterologous enhancer / promoters, lymphocyte tropisms Options: other_name, DNA_domain_or_region, virus	[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.	[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]	[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]
Human immunodeficiency viruses, heterologous enhancer / promoters, lymphocyte tropisms	83044_task2	Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please extract entity words from the input sentence	[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]	Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.	[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]	[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]
c - fos is a Protein, c - jun is a Protein, AP-1 is a Entity, proto - oncogenes is a Entity, c - jun is a Protein, c - fos is a Protein, AP-1 element is a Entity, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, AP-1 element is a Entity	110_task0	Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.	[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]	[ "Entity", "Protein" ]
c - fos is a Protein, c - jun is a Protein, AP-1 is a Entity, proto - oncogenes is a Entity, c - jun is a Protein, c - fos is a Protein, AP-1 element is a Entity, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, AP-1 element is a Entity	110_task1	Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please typing these entity words according to sentence: c - fos, c - jun, AP-1, proto - oncogenes, c - jun, c - fos, AP-1 element, c - fos, c - jun, c - fos, c - fos, c - jun, c - fos, c - jun, c - fos, c - jun, AP-1 element Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.	[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]	[ "Entity", "Protein" ]
c - fos, c - jun, AP-1, proto - oncogenes, c - jun, c - fos, AP-1 element, c - fos, c - jun, c - fos, c - fos, c - jun, c - fos, c - jun, c - fos, c - jun, AP-1 element	110_task2	Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.	[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]	[ "Entity", "Protein" ]
tissue factor is a Protein, Sp1 is a Protein, Tissue factor is a Protein, TF is a Protein, TF is a Protein, TF is a Protein, c - Rel is a Protein, p65 is a Protein, Egr-1 is a Protein, Sp1 is a Protein, Sp1 is a Protein, TF is a Protein, Sp1 is a Protein, c - Fos is a Protein, c - Jun is a Protein, TF is a Protein, promoter is a Entity, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, Sp1 is a Protein, TF is a Protein	689_task0	Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.	[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]	[ "Protein", "Entity" ]
tissue factor is a Protein, Sp1 is a Protein, Tissue factor is a Protein, TF is a Protein, TF is a Protein, TF is a Protein, c - Rel is a Protein, p65 is a Protein, Egr-1 is a Protein, Sp1 is a Protein, Sp1 is a Protein, TF is a Protein, Sp1 is a Protein, c - Fos is a Protein, c - Jun is a Protein, TF is a Protein, promoter is a Entity, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, Sp1 is a Protein, TF is a Protein	689_task1	Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please typing these entity words according to sentence: tissue factor, Sp1, Tissue factor, TF, TF, TF, c - Rel, p65, Egr-1, Sp1, Sp1, TF, Sp1, c - Fos, c - Jun, TF, promoter, c - Fos, c - Jun, c - Rel, p65, c - Jun, p65, c - Jun, p65, c - Fos, c - Jun, c - Rel, p65, Sp1, TF Options: Entity, Protein	[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.	[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]	[ "Protein", "Entity" ]
tissue factor, Sp1, Tissue factor, TF, TF, TF, c - Rel, p65, Egr-1, Sp1, Sp1, TF, Sp1, c - Fos, c - Jun, TF, promoter, c - Fos, c - Jun, c - Rel, p65, c - Jun, p65, c - Jun, p65, c - Fos, c - Jun, c - Rel, p65, Sp1, TF	689_task2	Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]	Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.	[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]	[ "Protein", "Entity" ]
medical specialties is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, perception is an umlsterm, treatment is an umlsterm, instruments is an umlsterm, cardiac diseases is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, instrument is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, psychometric is an umlsterm, standards is an umlsterm, proven is an umlsterm, use is an umlsterm, Questionnaire is an umlsterm, Quality of Life is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, stages is an umlsterm, chronic venous insufficiency is an umlsterm, Stage is an umlsterm, Stage is an umlsterm, patients is an umlsterm, leg is an umlsterm, fears is an umlsterm, perception is an umlsterm, disease is an umlsterm, set is an umlsterm, clinical studies is an umlsterm, Germany is an umlsterm	DerHautarzt.80490372.eng.abstr_task0	Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .	[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]	[ "umlsterm" ]
medical specialties is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, perception is an umlsterm, treatment is an umlsterm, instruments is an umlsterm, cardiac diseases is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, instrument is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, psychometric is an umlsterm, standards is an umlsterm, proven is an umlsterm, use is an umlsterm, Questionnaire is an umlsterm, Quality of Life is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, stages is an umlsterm, chronic venous insufficiency is an umlsterm, Stage is an umlsterm, Stage is an umlsterm, patients is an umlsterm, leg is an umlsterm, fears is an umlsterm, perception is an umlsterm, disease is an umlsterm, set is an umlsterm, clinical studies is an umlsterm, Germany is an umlsterm	DerHautarzt.80490372.eng.abstr_task1	Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please typing these entity words according to sentence: medical specialties, quality of life, disease - related, coping behavior, patients, perception, treatment, instruments, cardiac diseases, quality of life, disease - related, coping behavior, patients, chronic venous insufficiency, instrument, quality of life, patients, psychometric, standards, proven, use, Questionnaire, Quality of Life, patients, quality of life, patients, stages, chronic venous insufficiency, Stage, Stage, patients, leg, fears, perception, disease, set, clinical studies, Germany Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .	[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]	[ "umlsterm" ]
medical specialties, quality of life, disease - related, coping behavior, patients, perception, treatment, instruments, cardiac diseases, quality of life, disease - related, coping behavior, patients, chronic venous insufficiency, instrument, quality of life, patients, psychometric, standards, proven, use, Questionnaire, Quality of Life, patients, quality of life, patients, stages, chronic venous insufficiency, Stage, Stage, patients, leg, fears, perception, disease, set, clinical studies, Germany	DerHautarzt.80490372.eng.abstr_task2	Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .	[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]	[ "umlsterm" ]
Schmerzmessung is an umlsterm, -dokumentation is an umlsterm, Schmerzskala is an umlsterm	DerSchmerz.80120406.ger.abstr_task0	Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .	[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]	[ "umlsterm" ]
Schmerzmessung is an umlsterm, -dokumentation is an umlsterm, Schmerzskala is an umlsterm	DerSchmerz.80120406.ger.abstr_task1	Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please typing these entity words according to sentence: Schmerzmessung, -dokumentation, Schmerzskala Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .	[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]	[ "umlsterm" ]
Schmerzmessung, -dokumentation, Schmerzskala	DerSchmerz.80120406.ger.abstr_task2	Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .	[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]	[ "umlsterm" ]
embryoid bodies is a Developing_anatomical_structure, cell is a Cell, embryoid bodies is a Developing_anatomical_structure	PMC-2192393-sec-06_task0	Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Developing_anatomical_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.	[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]	[ "Developing_anatomical_structure", "Cell" ]
embryoid bodies is a Developing_anatomical_structure, cell is a Cell, embryoid bodies is a Developing_anatomical_structure	PMC-2192393-sec-06_task1	Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please typing these entity words according to sentence: embryoid bodies, cell, embryoid bodies Options: Developing_anatomical_structure, Cell	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.	[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]	[ "Developing_anatomical_structure", "Cell" ]
embryoid bodies, cell, embryoid bodies	PMC-2192393-sec-06_task2	Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.	[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]	[ "Developing_anatomical_structure", "Cell" ]
Iobitridol 300 is a Intervention_Pharmacological, iopromide 300 -- a is a Intervention_Pharmacological, total body CT . is a Participant_Condition, iobitriodol 300 mg I / ml and iopromide 300 mg I / ml is a Intervention_Pharmacological, onset is a Outcome_Other, adverse reaction is a Outcome_Adverse-effects, imaging quality is a Outcome_Other, side effects is a Outcome_Adverse-effects, iobitridol is a Intervention_Pharmacological, excellent image quality is a Outcome_Other, low rate of side effects is a Outcome_Adverse-effects, effective nonionic contrast agent is a Outcome_Other	86900_task0	Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Outcome_Adverse-effects	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]	Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .	[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]
Iobitridol 300 is a Intervention_Pharmacological, iopromide 300 -- a is a Intervention_Pharmacological, total body CT . is a Participant_Condition, iobitriodol 300 mg I / ml and iopromide 300 mg I / ml is a Intervention_Pharmacological, onset is a Outcome_Other, adverse reaction is a Outcome_Adverse-effects, imaging quality is a Outcome_Other, side effects is a Outcome_Adverse-effects, iobitridol is a Intervention_Pharmacological, excellent image quality is a Outcome_Other, low rate of side effects is a Outcome_Adverse-effects, effective nonionic contrast agent is a Outcome_Other	86900_task1	Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please typing these entity words according to sentence: Iobitridol 300, iopromide 300 -- a, total body CT ., iobitriodol 300 mg I / ml and iopromide 300 mg I / ml, onset, adverse reaction, imaging quality, side effects, iobitridol, excellent image quality, low rate of side effects, effective nonionic contrast agent Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Outcome_Adverse-effects	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]	Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .	[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]
Iobitridol 300, iopromide 300 -- a, total body CT ., iobitriodol 300 mg I / ml and iopromide 300 mg I / ml, onset, adverse reaction, imaging quality, side effects, iobitridol, excellent image quality, low rate of side effects, effective nonionic contrast agent	86900_task2	Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]	Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .	[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]	[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]
Fernando is a NOMBRE_SUJETO_ASISTENCIA, López Franco is a NOMBRE_SUJETO_ASISTENCIA, 798246 is a ID_SUJETO_ASISTENCIA, 78 14651695 54 is a ID_ASEGURAMIENTO, Cádiz is a TERRITORIO, 11004 is a TERRITORIO, 23/10/1948 is a FECHAS, España is a PAIS, 69 años is a EDAD_SUJETO_ASISTENCIA, 04/04/2018 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, 11 11 54263 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 69 años is a EDAD_SUJETO_ASISTENCIA, 1985 is a FECHAS, 1996 is a FECHAS, 1999 is a FECHAS, julio de 2006 is a FECHAS, noviembre de 2006 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, Instituto de Medicina Legal is a INSTITUCION, 11071 is a TERRITORIO, Cádiz is a TERRITORIO, 956 203 145 is a NUMERO_TELEFONO, 956 203 146 is a NUMERO_TELEFONO	295_task0	Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]	Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.	[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]	[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Fernando is a NOMBRE_SUJETO_ASISTENCIA, López Franco is a NOMBRE_SUJETO_ASISTENCIA, 798246 is a ID_SUJETO_ASISTENCIA, 78 14651695 54 is a ID_ASEGURAMIENTO, Cádiz is a TERRITORIO, 11004 is a TERRITORIO, 23/10/1948 is a FECHAS, España is a PAIS, 69 años is a EDAD_SUJETO_ASISTENCIA, 04/04/2018 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, 11 11 54263 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 69 años is a EDAD_SUJETO_ASISTENCIA, 1985 is a FECHAS, 1996 is a FECHAS, 1999 is a FECHAS, julio de 2006 is a FECHAS, noviembre de 2006 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, Instituto de Medicina Legal is a INSTITUCION, 11071 is a TERRITORIO, Cádiz is a TERRITORIO, 956 203 145 is a NUMERO_TELEFONO, 956 203 146 is a NUMERO_TELEFONO	295_task1	Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please typing these entity words according to sentence: Fernando, López Franco, 798246, 78 14651695 54, Cádiz, 11004, 23/10/1948, España, 69 años, 04/04/2018, Pedro Martínez - García, 11 11 54263, Varón, 69 años, 1985, 1996, 1999, julio de 2006, noviembre de 2006, Pedro Martínez - García, Instituto de Medicina Legal, 11071, Cádiz, 956 203 145, 956 203 146 Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]	Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.	[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]	[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Fernando, López Franco, 798246, 78 14651695 54, Cádiz, 11004, 23/10/1948, España, 69 años, 04/04/2018, Pedro Martínez - García, 11 11 54263, Varón, 69 años, 1985, 1996, 1999, julio de 2006, noviembre de 2006, Pedro Martínez - García, Instituto de Medicina Legal, 11071, Cádiz, 956 203 145, 956 203 146	295_task2	Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]	Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.	[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]	[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Nerve is an umlsterm, cell is an umlsterm, cells is an umlsterm, lamina is an umlsterm, nerve is an umlsterm, patient is an umlsterm, Zollinger - Ellison syndrome is an umlsterm, electron is an umlsterm, non - antral is an umlsterm, gastric mucosa is an umlsterm, gastric mucosa is an umlsterm	DerPathologe.50160404.eng.abstr_task0	Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .	[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]	[ "umlsterm" ]
Nerve is an umlsterm, cell is an umlsterm, cells is an umlsterm, lamina is an umlsterm, nerve is an umlsterm, patient is an umlsterm, Zollinger - Ellison syndrome is an umlsterm, electron is an umlsterm, non - antral is an umlsterm, gastric mucosa is an umlsterm, gastric mucosa is an umlsterm	DerPathologe.50160404.eng.abstr_task1	Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please typing these entity words according to sentence: Nerve, cell, cells, lamina, nerve, patient, Zollinger - Ellison syndrome, electron, non - antral, gastric mucosa, gastric mucosa Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .	[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]	[ "umlsterm" ]
Nerve, cell, cells, lamina, nerve, patient, Zollinger - Ellison syndrome, electron, non - antral, gastric mucosa, gastric mucosa	DerPathologe.50160404.eng.abstr_task2	Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .	[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]	[ "umlsterm" ]
fosfatasa alcalina is a PROTEINAS, antígeno galactomanano is a PROTEINAS, itraconazol is a NORMALIZABLES, voriconazol is a NORMALIZABLES	413_task0	Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).	[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
fosfatasa alcalina is a PROTEINAS, antígeno galactomanano is a PROTEINAS, itraconazol is a NORMALIZABLES, voriconazol is a NORMALIZABLES	413_task1	Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please typing these entity words according to sentence: fosfatasa alcalina, antígeno galactomanano, itraconazol, voriconazol Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).	[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
fosfatasa alcalina, antígeno galactomanano, itraconazol, voriconazol	413_task2	Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).	[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]	[ "PROTEINAS", "NORMALIZABLES" ]
Patienten is an umlsterm, Status asthmaticus is an umlsterm, medikamentoesen Therapie is an umlsterm, Behandlung is an umlsterm, Theophyllin is an umlsterm, Ketamin is an umlsterm, Intensivtherapie is an umlsterm, Fluessigkeitstherapie is an umlsterm, Bronchiallavage is an umlsterm, Hypoventilation is an umlsterm, lebensbedrohliche is an umlsterm, Patienten is an umlsterm	IntensiveMedizin.00370293.ger.abstr_task0	Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .	[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Status asthmaticus is an umlsterm, medikamentoesen Therapie is an umlsterm, Behandlung is an umlsterm, Theophyllin is an umlsterm, Ketamin is an umlsterm, Intensivtherapie is an umlsterm, Fluessigkeitstherapie is an umlsterm, Bronchiallavage is an umlsterm, Hypoventilation is an umlsterm, lebensbedrohliche is an umlsterm, Patienten is an umlsterm	IntensiveMedizin.00370293.ger.abstr_task1	Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please typing these entity words according to sentence: Patienten, Status asthmaticus, medikamentoesen Therapie, Behandlung, Theophyllin, Ketamin, Intensivtherapie, Fluessigkeitstherapie, Bronchiallavage, Hypoventilation, lebensbedrohliche, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .	[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]	[ "umlsterm" ]
Patienten, Status asthmaticus, medikamentoesen Therapie, Behandlung, Theophyllin, Ketamin, Intensivtherapie, Fluessigkeitstherapie, Bronchiallavage, Hypoventilation, lebensbedrohliche, Patienten	IntensiveMedizin.00370293.ger.abstr_task2	Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .	[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]	[ "umlsterm" ]
Zellulitis is an umlsterm, phlegmonenartig - imponierende is an umlsterm, Erytheme is an umlsterm, Lymphozyten is an umlsterm, Blut- is an umlsterm, Therapie is an umlsterm, Dapson is an umlsterm, Proteins is an umlsterm, Lymphozyten is an umlsterm, Zellen is an umlsterm, Lymphozyten is an umlsterm, Zellkultur is an umlsterm, Interleukin is an umlsterm, Interleukin is an umlsterm, Interferon is an umlsterm, T - Zellen is an umlsterm, Blut- is an umlsterm	DerHautarzt.00510182.ger.abstr_task0	Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .	[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]	[ "umlsterm" ]
Zellulitis is an umlsterm, phlegmonenartig - imponierende is an umlsterm, Erytheme is an umlsterm, Lymphozyten is an umlsterm, Blut- is an umlsterm, Therapie is an umlsterm, Dapson is an umlsterm, Proteins is an umlsterm, Lymphozyten is an umlsterm, Zellen is an umlsterm, Lymphozyten is an umlsterm, Zellkultur is an umlsterm, Interleukin is an umlsterm, Interleukin is an umlsterm, Interferon is an umlsterm, T - Zellen is an umlsterm, Blut- is an umlsterm	DerHautarzt.00510182.ger.abstr_task1	Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please typing these entity words according to sentence: Zellulitis, phlegmonenartig - imponierende, Erytheme, Lymphozyten, Blut-, Therapie, Dapson, Proteins, Lymphozyten, Zellen, Lymphozyten, Zellkultur, Interleukin, Interleukin, Interferon, T - Zellen, Blut- Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .	[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]	[ "umlsterm" ]
Zellulitis, phlegmonenartig - imponierende, Erytheme, Lymphozyten, Blut-, Therapie, Dapson, Proteins, Lymphozyten, Zellen, Lymphozyten, Zellkultur, Interleukin, Interleukin, Interferon, T - Zellen, Blut-	DerHautarzt.00510182.ger.abstr_task2	Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]	Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .	[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]	[ "umlsterm" ]
tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, nortriptyline is a DRUG, fluoxetine hydrochloride is a DRUG, Fluoxetine is a DRUG, norfluoxetine is a DRUG_N, reserpine is a DRUG, tricyclic antidepressant is a GROUP, nortriptyline hydrochloride is a DRUG, anticholinergic drugs is a GROUP, sympathomimetic drugs is a GROUP, alcohol is a DRUG, debrisoquin is a DRUG, dextromethorphan is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, tricyclic antidepressants is a GROUP, selective serotonin reuptake inhibitors is a GROUP, tricyclic antidepressants is a GROUP, tricyclic antidepressant is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, phenothiazines is a GROUP, carbamazepine is a DRUG, Type 1C antiarrhythmics is a GROUP, propafenone is a DRUG, flecainide is a DRUG, encainide is a DRUG, quinidine is a DRUG	Nortriptyline_ddi_task0	Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG_N, DRUG	[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]	[ "GROUP", "DRUG", "DRUG_N" ]
tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, nortriptyline is a DRUG, fluoxetine hydrochloride is a DRUG, Fluoxetine is a DRUG, norfluoxetine is a DRUG_N, reserpine is a DRUG, tricyclic antidepressant is a GROUP, nortriptyline hydrochloride is a DRUG, anticholinergic drugs is a GROUP, sympathomimetic drugs is a GROUP, alcohol is a DRUG, debrisoquin is a DRUG, dextromethorphan is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, tricyclic antidepressants is a GROUP, selective serotonin reuptake inhibitors is a GROUP, tricyclic antidepressants is a GROUP, tricyclic antidepressant is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, phenothiazines is a GROUP, carbamazepine is a DRUG, Type 1C antiarrhythmics is a GROUP, propafenone is a DRUG, flecainide is a DRUG, encainide is a DRUG, quinidine is a DRUG	Nortriptyline_ddi_task1	Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please typing these entity words according to sentence: tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, cimetidine, tricyclic antidepressants, tricyclic antidepressants, cimetidine, tricyclic antidepressants, antidepressants, nortriptyline, fluoxetine hydrochloride, Fluoxetine, norfluoxetine, reserpine, tricyclic antidepressant, nortriptyline hydrochloride, anticholinergic drugs, sympathomimetic drugs, alcohol, debrisoquin, dextromethorphan, tricyclic antidepressants, tricyclic antidepressants, antidepressants, tricyclic antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, tricyclic antidepressant, tricyclic antidepressants, antidepressants, phenothiazines, carbamazepine, Type 1C antiarrhythmics, propafenone, flecainide, encainide, quinidine Options: GROUP, DRUG_N, DRUG	[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]	[ "GROUP", "DRUG", "DRUG_N" ]
tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, cimetidine, tricyclic antidepressants, tricyclic antidepressants, cimetidine, tricyclic antidepressants, antidepressants, nortriptyline, fluoxetine hydrochloride, Fluoxetine, norfluoxetine, reserpine, tricyclic antidepressant, nortriptyline hydrochloride, anticholinergic drugs, sympathomimetic drugs, alcohol, debrisoquin, dextromethorphan, tricyclic antidepressants, tricyclic antidepressants, antidepressants, tricyclic antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, tricyclic antidepressant, tricyclic antidepressants, antidepressants, phenothiazines, carbamazepine, Type 1C antiarrhythmics, propafenone, flecainide, encainide, quinidine	Nortriptyline_ddi_task2	Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]	[ "GROUP", "DRUG", "DRUG_N" ]

ENBREL, ENBREL, methotrexate, ENBREL, anakinra, ENBREL, ENBREL, anakinra, sulfasalazine, ENBREL, ENBREL, sulfasalazine

Etanercept_ddi_task2

Sentence: Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Specific drug interaction studies have not been conducted with ENBREL . However, it was observed that the pharmacokinetics of ENBREL was unaltered by concomitant methotrexate in rheumatoid arthritis patients. In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL alone (0%). Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L). Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone. The clinical significance of this observation is unknown.

[ "Specific", "drug", "interaction", "studies", "have", "not", "been", "conducted", "with", "ENBREL", ".", "However", ",", "it", "was", "observed", "that", "the", "pharmacokinetics", "of", "ENBREL", " ", "was", "unaltered", "by", "concomitant", "methotrexate", "in", "rheumatoid", "arthritis", "patients", ".", "In", "a", "study", "in", "which", "patients", "with", "active", "RA", "were", "treated", "for", "up", "to", "24", "weeks", "with", "concurrent", "ENBREL", " ", "and", "anakinra", "therapy", ",", "a", "7", "%", "rate", "of", "serious", "infections", "was", "observed", ",", "which", "was", "higher", "than", "that", "observed", "with", "ENBREL", " ", "alone", "(", "0", "%", ")", ".", "Two", "percent", "of", "patients", "treated", "concurrently", "with", "ENBREL", " ", "and", "anakinra", "developed", "neutropenia", "(", "ANC", " ", "1", "x", "109", "/", "L", ")", ".", "Patients", "in", "a", "clinical", "study", "who", "were", "on", "established", "therapy", "with", "sulfasalazine", ",", "to", "which", "ENBREL", "was", "added", ",", "were", "noted", "to", "develop", "a", "mild", "decrease", "in", "mean", "neutrophil", "counts", "in", "comparison", "to", "groups", "treated", "with", "either", "ENBREL", "CI", "or", "sulfasalazine", "alone", ".", "The", "clinical", "significance", "of", "this", "observation", "is", "unknown", "." ]

[ "DRUG", "BRAND" ]

Patienten is an umlsterm, Lupus is an umlsterm, Autoantikoerperprofil is an umlsterm, Antikoerper is an umlsterm, ANCA is an umlsterm, Assoziation is an umlsterm, Hautsymptome is an umlsterm, Dapson is an umlsterm

DerHautarzt.80490403.ger.abstr_task0

Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .

[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Lupus is an umlsterm, Autoantikoerperprofil is an umlsterm, Antikoerper is an umlsterm, ANCA is an umlsterm, Assoziation is an umlsterm, Hautsymptome is an umlsterm, Dapson is an umlsterm

DerHautarzt.80490403.ger.abstr_task1

Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please typing these entity words according to sentence: Patienten, Lupus, Autoantikoerperprofil, Antikoerper, ANCA, Assoziation, Hautsymptome, Dapson Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .

[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]

[ "umlsterm" ]

Patienten, Lupus, Autoantikoerperprofil, Antikoerper, ANCA, Assoziation, Hautsymptome, Dapson

DerHautarzt.80490403.ger.abstr_task2

Sentence: Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wir berichten ueber einen 44jaehrigen Patienten mit Lupus erythematodes profundus ( LEP ) der rechten Wange/Infraorbitalregion , der sich klinisch als rezidivierende Schwellung aeusserte . Das Autoantikoerperprofil wies nur antineutrophile zytoplasmatische Antikoerper ( ANCA ) auf , die bislang nicht in Assoziation mit einem LEP beschrieben wurden . Es gab keine Hinweise fuer einen systemischen LE . Waehrend Chloroquin keinen Effekt zeigte , besserten sich die Hautsymptome prompt unter Dapson . Durch schrittweise Reduktion wurde die Erhaltungsdosis von 50-75 mg pro Woche ermittelt . Parallel zur klinischen Besserung stellten wir einen abfall des ANCA-Titers fest .

[ "Wir", "berichten", "ueber", "einen", "44jaehrigen", "Patienten", "mit", "Lupus", "erythematodes", "profundus", "(", "LEP", ")", "der", "rechten", "Wange", "/", "Infraorbitalregion", ",", "der", "sich", "klinisch", "als", "rezidivierende", "Schwellung", "aeusserte", ".", "Das", "Autoantikoerperprofil", "wies", "nur", "antineutrophile", "zytoplasmatische", "Antikoerper", "(", "ANCA", ")", "auf", ",", "die", "bislang", "nicht", "in", "Assoziation", "mit", "einem", "LEP", "beschrieben", "wurden", ".", "Es", "gab", "keine", "Hinweise", "fuer", "einen", "systemischen", "LE", ".", "Waehrend", "Chloroquin", "keinen", "Effekt", "zeigte", ",", "besserten", "sich", "die", "Hautsymptome", "prompt", "unter", "Dapson", ".", "Durch", "schrittweise", "Reduktion", "wurde", "die", "Erhaltungsdosis", "von", "50", "-", "75", "mg", "pro", "Woche", "ermittelt", ".", "Parallel", "zur", "klinischen", "Besserung", "stellten", "wir", "einen", "abfall", "des", "ANCA", "-", "Titers", "fest", "." ]

[ "umlsterm" ]

TRF2 is a GENE-Y, human telomeric protein TRF2 is a GENE-Y, TRF2 is a GENE-Y, TRF2 is a GENE-Y, histone acetyltransferase p300 is a GENE-Y, p300 is a GENE-Y, lysine is a CHEMICAL, TRF2 is a GENE-Y, TRF2 is a GENE-Y, ubiquitin is a GENE-N, TRF2 is a GENE-Y, K293R is a GENE-N, TRF2 is a GENE-Y, p300 is a GENE-Y

1113_task0

Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.

[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

TRF2 is a GENE-Y, human telomeric protein TRF2 is a GENE-Y, TRF2 is a GENE-Y, TRF2 is a GENE-Y, histone acetyltransferase p300 is a GENE-Y, p300 is a GENE-Y, lysine is a CHEMICAL, TRF2 is a GENE-Y, TRF2 is a GENE-Y, ubiquitin is a GENE-N, TRF2 is a GENE-Y, K293R is a GENE-N, TRF2 is a GENE-Y, p300 is a GENE-Y

1113_task1

Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please typing these entity words according to sentence: TRF2, human telomeric protein TRF2, TRF2, TRF2, histone acetyltransferase p300, p300, lysine, TRF2, TRF2, ubiquitin, TRF2, K293R, TRF2, p300 Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.

[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

TRF2, human telomeric protein TRF2, TRF2, TRF2, histone acetyltransferase p300, p300, lysine, TRF2, TRF2, ubiquitin, TRF2, K293R, TRF2, p300

1113_task2

Sentence: p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

p300-mediated acetylation of TRF2 is required for maintaining functional telomeres. The human telomeric protein TRF2 is required to protect chromosome ends by facilitating their organization into the protective capping structure. Post-translational modifications of TRF2 such as phosphorylation, ubiquitination, SUMOylation, methylation and poly(ADP-ribosyl)ation have been shown to play important roles in telomere function. Here we show that TRF2 specifically interacts with the histone acetyltransferase p300, and that p300 acetylates the lysine residue at position 293 of TRF2. We also report that p300-mediated acetylation stabilizes the TRF2 protein by inhibiting its ubiquitin-dependent proteolysis and is required for efficient telomere binding of TRF2. Furthermore, overexpression of the acetylation-deficient mutant, K293R, induces DNA-damage response foci at telomeres, thereby leading to induction of impaired cell growth, cellular senescence and altered cell cycle distribution. A small but significant number of metaphase chromosomes show no telomeric signals at chromatid ends, suggesting an aberrant telomere structure. These findings demonstrate that acetylation of TRF2 by p300 plays a crucial role in the maintenance of functional telomeres as well as in the regulation of the telomere-associated DNA-damage response, thus providing a new route for modulating telomere protection function.

[ "p300-mediated", "acetylation", "of", "TRF2", "is", "required", "for", "maintaining", "functional", "telomeres", ".", "\n", "The", "human", "telomeric", "protein", "TRF2", "is", "required", "to", "protect", "chromosome", "ends", "by", "facilitating", "their", "organization", "into", "the", "protective", "capping", "structure", ".", "Post", "-", "translational", "modifications", "of", "TRF2", "such", "as", "phosphorylation", ",", "ubiquitination", ",", "SUMOylation", ",", "methylation", "and", "poly(ADP", "-", "ribosyl)ation", "have", "been", "shown", "to", "play", "important", "roles", "in", "telomere", "function", ".", "Here", "we", "show", "that", "TRF2", "specifically", "interacts", "with", "the", "histone", "acetyltransferase", "p300", ",", "and", "that", "p300", "acetylates", "the", "lysine", "residue", "at", "position", "293", "of", "TRF2", ".", "We", "also", "report", "that", "p300-mediated", "acetylation", "stabilizes", "the", "TRF2", "protein", "by", "inhibiting", "its", "ubiquitin", "-", "dependent", "proteolysis", "and", "is", "required", "for", "efficient", "telomere", "binding", "of", "TRF2", ".", "Furthermore", ",", "overexpression", "of", "the", "acetylation", "-", "deficient", "mutant", ",", "K293R", ",", "induces", "DNA", "-", "damage", "response", "foci", "at", "telomeres", ",", "thereby", "leading", "to", "induction", "of", "impaired", "cell", "growth", ",", "cellular", "senescence", "and", "altered", "cell", "cycle", "distribution", ".", "A", "small", "but", "significant", "number", "of", "metaphase", "chromosomes", "show", "no", "telomeric", "signals", "at", "chromatid", "ends", ",", "suggesting", "an", "aberrant", "telomere", "structure", ".", "These", "findings", "demonstrate", "that", "acetylation", "of", "TRF2", "by", "p300", "plays", "a", "crucial", "role", "in", "the", "maintenance", "of", "functional", "telomeres", "as", "well", "as", "in", "the", "regulation", "of", "the", "telomere", "-", "associated", "DNA", "-", "damage", "response", ",", "thus", "providing", "a", "new", "route", "for", "modulating", "telomere", "protection", "function", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, cellular is a Cell, p53 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, DNA is a Cellular_component, tumor is a Cancer, p53 is a Gene_or_gene_product, extracellular is a Immaterial_anatomical_entity, cell surface is a Cellular_component, tissue is a Tissue, p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, embryos is a Developing_anatomical_structure, cancer is a Cancer

269_task0

Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Immaterial_anatomical_entity, Developing_anatomical_structure, Cancer, Cellular_component, Cell

[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.

[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]

[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]

p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, cellular is a Cell, p53 is a Gene_or_gene_product, p53 is a Gene_or_gene_product, cells is a Cell, DNA is a Cellular_component, tumor is a Cancer, p53 is a Gene_or_gene_product, extracellular is a Immaterial_anatomical_entity, cell surface is a Cellular_component, tissue is a Tissue, p53 is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, TGF - beta is a Gene_or_gene_product, embryos is a Developing_anatomical_structure, cancer is a Cancer

269_task1

Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please typing these entity words according to sentence: p53, TGF - beta, p53, cells, cellular, p53, p53, cells, DNA, tumor, p53, extracellular, cell surface, tissue, p53, TGF - beta, TGF - beta, embryos, cancer Options: Tissue, Gene_or_gene_product, Immaterial_anatomical_entity, Developing_anatomical_structure, Cancer, Cellular_component, Cell

[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.

[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]

[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]

p53, TGF - beta, p53, cells, cellular, p53, p53, cells, DNA, tumor, p53, extracellular, cell surface, tissue, p53, TGF - beta, TGF - beta, embryos, cancer

269_task2

Sentence: Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Immaterial_anatomical_entity", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O" ]

Convergence of p53 and TGF-beta signaling networks. p53 is a protein with many talents. One of the most fundamental is the ability to act as essential growth checkpoint that protects cells against cellular transformation. p53 does so through the induction of genes leading to growth arrest or apoptosis. Most of the studies focusing on the mechanisms of p53 activity have been performed in cultured cells upon treatment with well-established p53-activating inputs, such as high doses of radiations, DNA-damaging drugs and activated oncogenes. However, how the tumor suppressive functions of p53 become concerted with the extracellular cues arriving at the cell surface during tissue homeostasis, remains largely unknown. Intriguingly, two recent papers have shed new light into this unexplored field, indicating that p53 plays a key role in TGF-beta-induced growth arrest and, unexpectedly, in the developmental effects of TGF-beta in early embryos. Here we review and comment on these findings and on their implications for cancer biology.

[ "Convergence", "of", "p53", "and", "TGF", "-", "beta", "signaling", "networks", ".", "\n", "p53", "is", "a", "protein", "with", "many", "talents", ".", "One", "of", "the", "most", "fundamental", "is", "the", "ability", "to", "act", "as", "essential", "growth", "checkpoint", "that", "protects", "cells", "against", "cellular", "transformation", ".", "p53", "does", "so", "through", "the", "induction", "of", "genes", "leading", "to", "growth", "arrest", "or", "apoptosis", ".", "Most", "of", "the", "studies", "focusing", "on", "the", "mechanisms", "of", "p53", "activity", "have", "been", "performed", "in", "cultured", "cells", "upon", "treatment", "with", "well", "-", "established", "p53-activating", "inputs", ",", "such", "as", "high", "doses", "of", "radiations", ",", "DNA", "-", "damaging", "drugs", "and", "activated", "oncogenes", ".", "However", ",", "how", "the", "tumor", "suppressive", "functions", "of", "p53", "become", "concerted", "with", "the", "extracellular", "cues", "arriving", "at", "the", "cell", "surface", "during", "tissue", "homeostasis", ",", "remains", "largely", "unknown", ".", "Intriguingly", ",", "two", "recent", "papers", "have", "shed", "new", "light", "into", "this", "unexplored", "field", ",", "indicating", "that", "p53", "plays", "a", "key", "role", "in", "TGF", "-", "beta", "-", "induced", "growth", "arrest", "and", ",", "unexpectedly", ",", "in", "the", "developmental", "effects", "of", "TGF", "-", "beta", "in", "early", "embryos", ".", "Here", "we", "review", "and", "comment", "on", "these", "findings", "and", "on", "their", "implications", "for", "cancer", "biology", ".", "\n" ]

[ "Immaterial_anatomical_entity", "Cellular_component", "Gene_or_gene_product", "Cell", "Developing_anatomical_structure", "Tissue", "Cancer" ]

baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, Baicalin is a CHEMICAL, baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP3A is a GENE-N, baicalin is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N

25939_task0

Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]

Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.

[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]

[ "CHEMICAL", "GENE-N" ]

baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, Baicalin is a CHEMICAL, baicalin is a CHEMICAL, dextromethorphan is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N, baicalin is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, DXM is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP3A is a GENE-N, baicalin is a CHEMICAL, baicalin is a CHEMICAL, baicalin is a CHEMICAL, DXM is a CHEMICAL, CYP2D is a GENE-N, CYP3A is a GENE-N

25939_task1

Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please typing these entity words according to sentence: baicalin, dextromethorphan, CYP2D, CYP3A, Baicalin, baicalin, dextromethorphan, DXM, CYP2D, CYP3A, baicalin, CYP2D, CYP3A, baicalin, DXM, DXM, DXM, baicalin, baicalin, DXM, CYP3A, baicalin, baicalin, baicalin, DXM, CYP2D, CYP3A Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]

Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.

[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]

[ "CHEMICAL", "GENE-N" ]

baicalin, dextromethorphan, CYP2D, CYP3A, Baicalin, baicalin, dextromethorphan, DXM, CYP2D, CYP3A, baicalin, CYP2D, CYP3A, baicalin, DXM, DXM, DXM, baicalin, baicalin, DXM, CYP3A, baicalin, baicalin, baicalin, DXM, CYP2D, CYP3A

25939_task2

Sentence: Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]

Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Baicalin has been shown to possess many pharmacological effects, including antiviral, antioxidant, anti-cancer and anti-inflammatory properties. In the current study, we reveal the inhibitory effects of baicalin on the metabolism of dextromethorphan (DXM), a dual probe substrate of CYP2D and CYP3A, in rats. Lineweaver-Burk plots demonstrated that baicalin inhibited the activities of CYP2D and CYP3A in a non-competitive manner in rat liver microsomes (RLMs). Concomitant administration of baicalin (0.90g/kg, i.v.) and DXM (10mg/kg, i.v.) increased the maximum drug concentration (Cmax) (37%) and the area under concentration-time curve (AUC) (42%) and decreased the clearance (CL) (27%) of DXM in a randomised, crossover study in rats (P<0.01). The change in the AUC of DXM was significantly correlated with the Cmax and AUC of baicalin (P<0.05). The inhibitory effects of multiple doses of baicalin (0.90g/kg, i.v., 12days) on the metabolism of DXM were similar to those observed following a single dose in rats. The activity of CYP3A in excised liver samples from rats following multiple baicalin treatment was significantly decreased compared to that of the control group (P<0.05), whereas multiple doses of baicalin had no obvious effect on the activity of CYP2D. Taken together, these data demonstrate that baicalin inhibits the metabolism of DXM in a concentration-dependent manner in rats, possibly through inhibiting hepatic CYP2D and CYP3A activities.

[ "Concentration", "-", "dependent", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", ",", "a", "dual", "probe", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "\n", "Baicalin", "has", "been", "shown", "to", "possess", "many", "pharmacological", "effects", ",", "including", "antiviral", ",", "antioxidant", ",", "anti", "-", "cancer", "and", "anti", "-", "inflammatory", "properties", ".", "In", "the", "current", "study", ",", "we", "reveal", "the", "inhibitory", "effects", "of", "baicalin", "on", "the", "metabolism", "of", "dextromethorphan", "(", "DXM", ")", ",", "a", "dual", "probe", "substrate", "of", "CYP2D", "and", "CYP3A", ",", "in", "rats", ".", "Lineweaver", "-", "Burk", "plots", "demonstrated", "that", "baicalin", "inhibited", "the", "activities", "of", "CYP2D", "and", "CYP3A", "in", "a", "non", "-", "competitive", "manner", "in", "rat", "liver", "microsomes", "(", "RLMs", ")", ".", "Concomitant", "administration", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ")", "and", "DXM", "(", "10mg", "/", "kg", ",", "i.v", ".", ")", "increased", "the", "maximum", "drug", "concentration", "(", "Cmax", ")", "(", "37", "%", ")", "and", "the", "area", "under", "concentration", "-", "time", "curve", "(", "AUC", ")", "(", "42", "%", ")", "and", "decreased", "the", "clearance", "(", "CL", ")", "(", "27", "%", ")", "of", "DXM", "in", "a", "randomised", ",", "crossover", "study", "in", "rats", "(", "P<0.01", ")", ".", "The", "change", "in", "the", "AUC", "of", "DXM", "was", "significantly", "correlated", "with", "the", "Cmax", "and", "AUC", "of", "baicalin", "(", "P<0.05", ")", ".", "The", "inhibitory", "effects", "of", "multiple", "doses", "of", "baicalin", "(", "0.90g", "/", "kg", ",", "i.v", ".", ",", "12days", ")", "on", "the", "metabolism", "of", "DXM", "were", "similar", "to", "those", "observed", "following", "a", "single", "dose", "in", "rats", ".", "The", "activity", "of", "CYP3A", "in", "excised", "liver", "samples", "from", "rats", "following", "multiple", "baicalin", "treatment", "was", "significantly", "decreased", "compared", "to", "that", "of", "the", "control", "group", "(", "P<0.05", ")", ",", "whereas", "multiple", "doses", "of", "baicalin", "had", "no", "obvious", "effect", "on", "the", "activity", "of", "CYP2D.", "Taken", "together", ",", "these", "data", "demonstrate", "that", "baicalin", "inhibits", "the", "metabolism", "of", "DXM", "in", "a", "concentration", "-", "dependent", "manner", "in", "rats", ",", "possibly", "through", "inhibiting", "hepatic", "CYP2D", "and", "CYP3A", "activities", "." ]

[ "CHEMICAL", "GENE-N" ]

man is an umlsterm, right is an umlsterm, vocal cord paralysis is an umlsterm, treatment is an umlsterm, medication is an umlsterm, treatment is an umlsterm, time is an umlsterm, speech therapy is an umlsterm, date is an umlsterm

HNO.90470825.eng.abstr_task0

Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .

[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]

[ "umlsterm" ]

man is an umlsterm, right is an umlsterm, vocal cord paralysis is an umlsterm, treatment is an umlsterm, medication is an umlsterm, treatment is an umlsterm, time is an umlsterm, speech therapy is an umlsterm, date is an umlsterm

HNO.90470825.eng.abstr_task1

Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please typing these entity words according to sentence: man, right, vocal cord paralysis, treatment, medication, treatment, time, speech therapy, date Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .

[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]

[ "umlsterm" ]

man, right, vocal cord paralysis, treatment, medication, treatment, time, speech therapy, date

HNO.90470825.eng.abstr_task2

Sentence: A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

A case is reported of a 57-year-old man who was found to have a right vocal cord paralysis that most likely followed prolonged treatment with the anti-arrythmic medication Amiodaron-HCl ( Cordarex ) . Phoniatric treatment was given for 5 1/2 months , during which time microlaryngoscopy and stroboscopy were performed . With the help of speech therapy , mobility of the paralyzed cord was seen to begin to return 3 1/2 months after discontinuing the Amiodaron-HCl . Full cord mobility has not returned to date .

[ "A", "case", "is", "reported", "of", "a", "57-year", "-", "old", "man", "who", "was", "found", "to", "have", "a", "right", "vocal", "cord", "paralysis", "that", "most", "likely", "followed", "prolonged", "treatment", "with", "the", "anti", "-", "arrythmic", "medication", "Amiodaron", "-", "HCl", "(", "Cordarex", ")", ".", "Phoniatric", "treatment", "was", "given", "for", "5", "1/2", "months", ",", "during", "which", "time", "microlaryngoscopy", "and", "stroboscopy", "were", "performed", ".", "With", "the", "help", "of", "speech", "therapy", ",", "mobility", "of", "the", "paralyzed", "cord", "was", "seen", "to", "begin", "to", "return", "3", "1/2", "months", "after", "discontinuing", "the", "Amiodaron", "-", "HCl", ".", "Full", "cord", "mobility", "has", "not", "returned", "to", "date", "." ]

[ "umlsterm" ]

PU.1 is a Protein, macrophage colony - stimulating factor receptor is a Protein, macrophage colony - stimulating factor ( M - CSF ) receptor is a Protein, M - CSF receptor is a Protein, M - CSF receptor is a Protein, PU.1 is a Protein, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, specific site is a Entity, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein

8264604_task0

Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.

[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]

[ "Protein", "Entity" ]

PU.1 is a Protein, macrophage colony - stimulating factor receptor is a Protein, macrophage colony - stimulating factor ( M - CSF ) receptor is a Protein, M - CSF receptor is a Protein, M - CSF receptor is a Protein, PU.1 is a Protein, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, PU.1 is a Protein, specific site is a Entity, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein, M - CSF receptor is a Protein, promoter is a Entity, PU.1 is a Protein

8264604_task1

Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please typing these entity words according to sentence: PU.1, macrophage colony - stimulating factor receptor, macrophage colony - stimulating factor ( M - CSF ) receptor, M - CSF receptor, M - CSF receptor, PU.1, PU.1, M - CSF receptor, promoter, PU.1, PU.1, specific site, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1 Options: Entity, Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.

[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]

[ "Protein", "Entity" ]

PU.1, macrophage colony - stimulating factor receptor, macrophage colony - stimulating factor ( M - CSF ) receptor, M - CSF receptor, M - CSF receptor, PU.1, PU.1, M - CSF receptor, promoter, PU.1, PU.1, specific site, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1, M - CSF receptor, promoter, PU.1

8264604_task2

Sentence: The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. The macrophage colony-stimulating factor (M-CSF) receptor is expressed in a tissue-specific fashion from two distinct promoters in monocytes/macrophages and the placenta. In order to further understand the transcription factors which play a role in the commitment of multipotential progenitors to the monocyte/macrophage lineage, we have initiated an investigation of the factors which activate the M-CSF receptor very early during the monocyte differentiation process. Here we demonstrate that the human monocytic M-CSF receptor promoter directs reporter gene activity in a tissue-specific fashion. Since one of the few transcription factors which have been implicated in the regulation of monocyte genes is the macrophage- and B-cell-specific PU.1 transcription factor, we investigated whether PU.1 binds and activates the M-CSF receptor promoter. Here we demonstrate that both in vitro-translated PU.1 and PU.1 from nuclear extracts bind to a specific site in the M-CSF receptor promoter just upstream from the major transcription initiation site. Mutations in this site which eliminate PU.1 binding decrease M-CSF receptor promoter activity significantly in macrophage cell lines only. Furthermore, PU.1 transactivates the M-CSF receptor promoter in nonmacrophage cells. These results suggest that PU.1 plays a major role in macrophage gene regulation and development by directing the expression of a receptor for a key macrophage growth factor.

[ "The", "macrophage", "transcription", "factor", "PU.1", "directs", "tissue", "-", "specific", "expression", "of", "the", "macrophage", "colony", "-", "stimulating", "factor", "receptor", ".", "\n", "The", "macrophage", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "receptor", "is", "expressed", "in", "a", "tissue", "-", "specific", "fashion", "from", "two", "distinct", "promoters", "in", "monocytes", "/", "macrophages", "and", "the", "placenta", ".", "In", "order", "to", "further", "understand", "the", "transcription", "factors", "which", "play", "a", "role", "in", "the", "commitment", "of", "multipotential", "progenitors", "to", "the", "monocyte", "/", "macrophage", "lineage", ",", "we", "have", "initiated", "an", "investigation", "of", "the", "factors", "which", "activate", "the", "M", "-", "CSF", "receptor", "very", "early", "during", "the", "monocyte", "differentiation", "process", ".", "Here", "we", "demonstrate", "that", "the", "human", "monocytic", "M", "-", "CSF", "receptor", "promoter", "directs", "reporter", "gene", "activity", "in", "a", "tissue", "-", "specific", "fashion", ".", "Since", "one", "of", "the", "few", "transcription", "factors", "which", "have", "been", "implicated", "in", "the", "regulation", "of", "monocyte", "genes", "is", "the", "macrophage-", "and", "B", "-", "cell", "-", "specific", "PU.1", "transcription", "factor", ",", "we", "investigated", "whether", "PU.1", "binds", "and", "activates", "the", "M", "-", "CSF", "receptor", "promoter", ".", "Here", "we", "demonstrate", "that", "both", "in", "vitro", "-", "translated", "PU.1", "and", "PU.1", "from", "nuclear", "extracts", "bind", "to", "a", "specific", "site", "in", "the", "M", "-", "CSF", "receptor", "promoter", "just", "upstream", "from", "the", "major", "transcription", "initiation", "site", ".", "Mutations", "in", "this", "site", "which", "eliminate", "PU.1", "binding", "decrease", "M", "-", "CSF", "receptor", "promoter", "activity", "significantly", "in", "macrophage", "cell", "lines", "only", ".", "Furthermore", ",", "PU.1", "transactivates", "the", "M", "-", "CSF", "receptor", "promoter", "in", "nonmacrophage", "cells", ".", "These", "results", "suggest", "that", "PU.1", "plays", "a", "major", "role", "in", "macrophage", "gene", "regulation", "and", "development", "by", "directing", "the", "expression", "of", "a", "receptor", "for", "a", "key", "macrophage", "growth", "factor", "." ]

[ "Protein", "Entity" ]

tumors is an umlsterm, patients is an umlsterm, therapy is an umlsterm, squamous cell carcinomas is an umlsterm, neoplastic transformation is an umlsterm, risk factors is an umlsterm, alcohol is an umlsterm, tobacco is an umlsterm, abuse is an umlsterm, chemoprevention is an umlsterm, squamous cell carcinomas is an umlsterm, review is an umlsterm, squamous cell carcinomas is an umlsterm, patients is an umlsterm, -carotene is an umlsterm, ascorbic acid is an umlsterm, patients is an umlsterm, leukoplakia is an umlsterm, oral cavity is an umlsterm, patients is an umlsterm, premalignant is an umlsterm, squamous cell carcinoma is an umlsterm, Biopsies is an umlsterm, therapy is an umlsterm, Flow cytometry is an umlsterm, analyses is an umlsterm, overall is an umlsterm, cell is an umlsterm, kinetic is an umlsterm, cell nucleus is an umlsterm, premalignant is an umlsterm, research is an umlsterm, biomarkers is an umlsterm, chemoprevention is an umlsterm

MundKieferGesichtschirurgie.0004s160.eng.abstr_task0

Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .

[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]

[ "umlsterm" ]

tumors is an umlsterm, patients is an umlsterm, therapy is an umlsterm, squamous cell carcinomas is an umlsterm, neoplastic transformation is an umlsterm, risk factors is an umlsterm, alcohol is an umlsterm, tobacco is an umlsterm, abuse is an umlsterm, chemoprevention is an umlsterm, squamous cell carcinomas is an umlsterm, review is an umlsterm, squamous cell carcinomas is an umlsterm, patients is an umlsterm, -carotene is an umlsterm, ascorbic acid is an umlsterm, patients is an umlsterm, leukoplakia is an umlsterm, oral cavity is an umlsterm, patients is an umlsterm, premalignant is an umlsterm, squamous cell carcinoma is an umlsterm, Biopsies is an umlsterm, therapy is an umlsterm, Flow cytometry is an umlsterm, analyses is an umlsterm, overall is an umlsterm, cell is an umlsterm, kinetic is an umlsterm, cell nucleus is an umlsterm, premalignant is an umlsterm, research is an umlsterm, biomarkers is an umlsterm, chemoprevention is an umlsterm

MundKieferGesichtschirurgie.0004s160.eng.abstr_task1

Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please typing these entity words according to sentence: tumors, patients, therapy, squamous cell carcinomas, neoplastic transformation, risk factors, alcohol, tobacco, abuse, chemoprevention, squamous cell carcinomas, review, squamous cell carcinomas, patients, -carotene, ascorbic acid, patients, leukoplakia, oral cavity, patients, premalignant, squamous cell carcinoma, Biopsies, therapy, Flow cytometry, analyses, overall, cell, kinetic, cell nucleus, premalignant, research, biomarkers, chemoprevention Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .

[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]

[ "umlsterm" ]

tumors, patients, therapy, squamous cell carcinomas, neoplastic transformation, risk factors, alcohol, tobacco, abuse, chemoprevention, squamous cell carcinomas, review, squamous cell carcinomas, patients, -carotene, ascorbic acid, patients, leukoplakia, oral cavity, patients, premalignant, squamous cell carcinoma, Biopsies, therapy, Flow cytometry, analyses, overall, cell, kinetic, cell nucleus, premalignant, research, biomarkers, chemoprevention

MundKieferGesichtschirurgie.0004s160.eng.abstr_task2

Sentence: Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Second primary tumors in initially cured patients remain the greatest challenge in therapy for oral squamous cell carcinomas . The concept of field cancerization is the most accepted hypothesis for the cellular and subcellular damages resulting in neoplastic transformation in the upper aerodigestive tract by risk factors such as chronic alcohol and tobacco abuse . Recent studies investigated several agents and regimens with benefit for chemoprevention of oral squamous cell carcinomas . In our review , the results of the most promising agents were studied . Despite discouraging results from recent intervention trials , studies in oral squamous cell carcinomas reported response rates up to 92% . In our investigation , two groups of patients were treated daily with 100 mg -tocopherol , 75 mg -carotene , and 1000 mg ascorbic acid per os . The first group consisted of 24 patients with leukoplakia of the oral cavity . The second group included 24 patients with premalignant lesions after R0-resection of primary oral squamous cell carcinoma . Biopsies were taken from both groups prior to therapy and after 12 weeks follow-up . Flow cytometry analyses were performed and nucleolar organizing regions ( NOR ) were examined . An overall histological response rate of nearly 98% was noticed . Additionally , the pretherapeutic regimen increased cell kinetic parameters , such as the S-phase portion , and the average number of NOR per cell nucleus decreased . These results indicate that the chosen combination has substantial activity in oral premalignant lesions . Nevertheless , basic research is required in investigating valid biomarkers for chemoprevention studies .

[ "Second", "primary", "tumors", "in", "initially", "cured", "patients", "remain", "the", "greatest", "challenge", "in", "therapy", "for", "oral", "squamous", "cell", "carcinomas", ".", "The", "concept", "of", "field", "cancerization", "is", "the", "most", "accepted", "hypothesis", "for", "the", "cellular", "and", "subcellular", "damages", "resulting", "in", "neoplastic", "transformation", "in", "the", "upper", "aerodigestive", "tract", "by", "risk", "factors", "such", "as", "chronic", "alcohol", "and", "tobacco", "abuse", ".", "Recent", "studies", "investigated", "several", "agents", "and", "regimens", "with", "benefit", "for", "chemoprevention", "of", "oral", "squamous", "cell", "carcinomas", ".", "In", "our", "review", ",", "the", "results", "of", "the", "most", "promising", "agents", "were", "studied", ".", "Despite", "discouraging", "results", "from", "recent", "intervention", "trials", ",", "studies", "in", "oral", "squamous", "cell", "carcinomas", "reported", "response", "rates", "up", "to", "92", "%", ".", "In", "our", "investigation", ",", "two", "groups", "of", "patients", "were", "treated", "daily", "with", "100", "mg", "-tocopherol", ",", "75", "mg", "-carotene", ",", "and", "1000", "mg", "ascorbic", "acid", "per", "os", ".", "The", "first", "group", "consisted", "of", "24", "patients", "with", "leukoplakia", "of", "the", "oral", "cavity", ".", "The", "second", "group", "included", "24", "patients", "with", "premalignant", "lesions", "after", "R0-resection", "of", "primary", "oral", "squamous", "cell", "carcinoma", ".", "Biopsies", "were", "taken", "from", "both", "groups", "prior", "to", "therapy", "and", "after", "12", "weeks", "follow", "-", "up", ".", "Flow", "cytometry", "analyses", "were", "performed", "and", "nucleolar", "organizing", "regions", "(", "NOR", ")", "were", "examined", ".", "An", "overall", "histological", "response", "rate", "of", "nearly", "98", "%", "was", "noticed", ".", "Additionally", ",", "the", "pretherapeutic", "regimen", "increased", "cell", "kinetic", "parameters", ",", "such", "as", "the", "S", "-", "phase", "portion", ",", "and", "the", "average", "number", "of", "NOR", "per", "cell", "nucleus", "decreased", ".", "These", "results", "indicate", "that", "the", "chosen", "combination", "has", "substantial", "activity", "in", "oral", "premalignant", "lesions", ".", "Nevertheless", ",", "basic", "research", "is", "required", "in", "investigating", "valid", "biomarkers", "for", "chemoprevention", "studies", "." ]

[ "umlsterm" ]

N - hydroxysuccinimide is a compound, alkaline phosphatase is a protein, ALP is a protein

DS.d1776_task0

Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.

[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]

[ "compound", "protein" ]

N - hydroxysuccinimide is a compound, alkaline phosphatase is a protein, ALP is a protein

DS.d1776_task1

Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please typing these entity words according to sentence: N - hydroxysuccinimide, alkaline phosphatase, ALP Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.

[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]

[ "compound", "protein" ]

N - hydroxysuccinimide, alkaline phosphatase, ALP

DS.d1776_task2

Sentence: Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluoroimmunoassay based on the fluorescent property of quantum dot was used along with immunoassay to detect 2,4-D. CdTe capped with mercaptopropionic acid, was conjugated using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and a coupling reagent like N-hydroxysuccinimide (NHS) to alkaline phosphatase (ALP) which was in turn conjugated to 2,4-D molecule.

[ "Fluoroimmunoassay", "based", "on", "the", "fluorescent", "property", "of", "quantum", "dot", "was", "used", "along", "with", "immunoassay", "to", "detect", "2,4-D.", "CdTe", "capped", "with", "mercaptopropionic", "acid", ",", "was", "conjugated", "using", "N-(3-dimethylaminopropyl)-N", "-", "ethylcarbodiimide", "hydrochloride", "(", "EDC", ")", "and", "a", "coupling", "reagent", "like", "N", "-", "hydroxysuccinimide", "(", "NHS", ")", "to", "alkaline", "phosphatase", "(", "ALP", ")", "which", "was", "in", "turn", "conjugated", "to", "2,4-D", "molecule", "." ]

[ "compound", "protein" ]

Ramiro is a NOMBRE_SUJETO_ASISTENCIA, Alfaro Soto is a NOMBRE_SUJETO_ASISTENCIA, 4835758 is a ID_SUJETO_ASISTENCIA, 28 76235749 90 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28046 is a TERRITORIO, 21/07/1944 is a FECHAS, España is a PAIS, 68 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2013 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, 28 28 79354 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 68 años is a EDAD_SUJETO_ASISTENCIA, marzo de 2005 is a FECHAS, julio de 2007 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, dcrespo@fhalcorcon.es is a CORREO_ELECTRONICO

296_task0

Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Ramiro is a NOMBRE_SUJETO_ASISTENCIA, Alfaro Soto is a NOMBRE_SUJETO_ASISTENCIA, 4835758 is a ID_SUJETO_ASISTENCIA, 28 76235749 90 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 28046 is a TERRITORIO, 21/07/1944 is a FECHAS, España is a PAIS, 68 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2013 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, 28 28 79354 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 68 años is a EDAD_SUJETO_ASISTENCIA, marzo de 2005 is a FECHAS, julio de 2007 is a FECHAS, David Crespo Marcos is a NOMBRE_PERSONAL_SANITARIO, dcrespo@fhalcorcon.es is a CORREO_ELECTRONICO

296_task1

Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please typing these entity words according to sentence: Ramiro, Alfaro Soto, 4835758, 28 76235749 90, Madrid, 28046, 21/07/1944, España, 68 años, 10/05/2013, David Crespo Marcos, 28 28 79354, Varón, 68 años, marzo de 2005, julio de 2007, David Crespo Marcos, dcrespo@fhalcorcon.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Ramiro, Alfaro Soto, 4835758, 28 76235749 90, Madrid, 28046, 21/07/1944, España, 68 años, 10/05/2013, David Crespo Marcos, 28 28 79354, Varón, 68 años, marzo de 2005, julio de 2007, David Crespo Marcos, dcrespo@fhalcorcon.es

296_task2

Sentence: Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Ramiro. Apellidos: Alfaro Soto. NHC: 4835758. NASS: 28 76235749 90. Domicilio: Calle Vía Límite, 12, 4 B. Localidad/ Provincia: Madrid. CP: 28046. Datos asistenciales. Fecha de nacimiento: 21/07/1944. País de nacimiento: España. Edad: 68 años Sexo: H. Fecha de Ingreso: 10/05/2013. Médico: David Crespo Marcos NºCol: 28 28 79354. Informe clínico del paciente: Varón de 68 años, sin alergias medicamentosas conocidas, con antecedentes de HTA, insuficiencia renal crónica leve, fibrilación auricular crónica, déficit de antitrombina III que llevó a isquemia intestinal por trombosis venosa mesentérica nueve años antes, con resección de 150 cm de yeyuno e íleon. En marzo de 2005 acudió al Servicio de Urgencias tras haber presentado en su domicilio dos deposiciones melénicas. Se realizó una endoscopia digestiva alta, visualizándose una porción de mucosa depapilada del duodeno sin sangrado activo. En la colonoscopia se objetivaron múltiples lesiones teleangiectásicas sin sangrado activo. Posteriormente, se realizó estudio con cápsula endoscópica, que reveló múltiples equimosis en duodeno, yeyuno, íleon y ciego. Tras varios episodios similares de HDB que requirieron transfusiones, se repitieron las endoscopias y la cápsula, sin nuevos hallazgos. También se realizó gammagrafía con hematíes marcados, resultando compatible con la existencia de angiodisplasia de intestino delgado. Durante uno de los episodios se realizó una angiografía mesentérica, apreciándose extravasación a nivel de fístula arteriovenosa y realizando embolización con coils, tras la cual presentó un cuadro de abdomen agudo y persistencia del sangrado, realizándose laparotomía y encontrando isquemia de la anastomosis previa, en posible relación con la embolización. Se practica nueva resección de íleon, quedando unos 80 cm con la válvula ileocecal intacta. Pese a la intervención continuó con los cuadros de HDB, por lo que se intentó tratamiento con somatostatina, sin respuesta. En los 28 meses que siguieron al primer episodio el paciente requirió un total de 132 concentrados de hematíes. Ante el fracaso de todas las terapias previas y la no pertinencia de nuevos tratamientos quirúrgicos, se comenzó el tratamiento con talidomida a dosis de 100 mg al día a principios de julio de 2007. Ocho meses después, el paciente no ha presentado nuevos episodios de HDB ni ha requerido de ninguna transfusión. Actualmente el paciente es seguido de forma mensual en consultas externas, se encuentra asintomático salvo por parestesias ocasionales y leves en miembros inferiores, con electromiograma normal. El paciente ha presentado un episodio de TEP bilateral resuelto con el tratamiento anticoagulante. Dados los antecedentes de déficit de antitrombina III y el hecho de que la trombofilia no está descrita entre los posibles efectos secundarios de la talidomida, pensamos que este evento no es achacable al uso de la misma. Responsable clínico: Dr. David Crespo Marcos. Email. dcrespo@fhalcorcon.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Ramiro", ".", "\n", "Apellidos", ":", "Alfaro", "Soto", ".", "\n", "NHC", ":", "4835758", ".", "\n", "NASS", ":", "28", "76235749", "90", ".", "\n", "Domicilio", ":", "Calle", "Vía", "Límite", ",", "12", ",", "4", "B.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "28046", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1944", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "68", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2013", ".", "\n", "Médico", ":", "David", "Crespo", "Marcos", "NºCol", ":", "28", "28", "79354", ".", "\n", "Informe", "clínico", "del", "paciente", ":", " ", "Varón", "de", "68", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ",", "con", "antecedentes", "de", "HTA", ",", "insuficiencia", "renal", "crónica", "leve", ",", "fibrilación", "auricular", "crónica", ",", "déficit", "de", "antitrombina", "III", "que", "llevó", "a", "isquemia", "intestinal", "por", "trombosis", "venosa", "mesentérica", "nueve", "años", "antes", ",", "con", "resección", "de", "150", "cm", "de", "yeyuno", "e", "íleon", ".", "\n", "En", "marzo", "de", "2005", "acudió", "al", "Servicio", "de", "Urgencias", "tras", "haber", "presentado", "en", "su", "domicilio", "dos", "deposiciones", "melénicas", ".", "Se", "realizó", "una", "endoscopia", "digestiva", "alta", ",", "visualizándose", "una", "porción", "de", "mucosa", "depapilada", "del", "duodeno", "sin", "sangrado", "activo", ".", "En", "la", "colonoscopia", "se", "objetivaron", "múltiples", "lesiones", "teleangiectásicas", "sin", "sangrado", "activo", ".", "Posteriormente", ",", "se", "realizó", "estudio", "con", "cápsula", "endoscópica", ",", "que", "reveló", "múltiples", "equimosis", "en", "duodeno", ",", "yeyuno", ",", "íleon", "y", "ciego", ".", "\n", "Tras", "varios", "episodios", "similares", "de", "HDB", "que", "requirieron", "transfusiones", ",", "se", "repitieron", "las", "endoscopias", "y", "la", "cápsula", ",", "sin", "nuevos", "hallazgos", ".", "También", "se", "realizó", "gammagrafía", "con", "hematíes", "marcados", ",", "resultando", "compatible", "con", "la", "existencia", "de", "angiodisplasia", "de", "intestino", "delgado", ".", "Durante", "uno", "de", "los", "episodios", "se", "realizó", "una", "angiografía", "mesentérica", ",", "apreciándose", "extravasación", "a", "nivel", "de", "fístula", "arteriovenosa", "y", "realizando", "embolización", "con", "coils", ",", "tras", "la", "cual", "presentó", "un", "cuadro", "de", "abdomen", "agudo", "y", "persistencia", "del", "sangrado", ",", "realizándose", "laparotomía", "y", "encontrando", "isquemia", "de", "la", "anastomosis", "previa", ",", "en", "posible", "relación", "con", "la", "embolización", ".", "Se", "practica", "nueva", "resección", "de", "íleon", ",", "quedando", "unos", "80", "cm", "con", "la", "válvula", "ileocecal", "intacta", ".", "\n", "Pese", "a", "la", "intervención", "continuó", "con", "los", "cuadros", "de", "HDB", ",", "por", "lo", "que", "se", "intentó", "tratamiento", "con", "somatostatina", ",", "sin", "respuesta", ".", "\n", "En", "los", "28", "meses", "que", "siguieron", "al", "primer", "episodio", "el", "paciente", "requirió", "un", "total", "de", "132", "concentrados", "de", "hematíes", ".", "\n", "Ante", "el", "fracaso", "de", "todas", "las", "terapias", "previas", "y", "la", "no", "pertinencia", "de", "nuevos", "tratamientos", "quirúrgicos", ",", "se", "comenzó", "el", "tratamiento", "con", "talidomida", "a", "dosis", "de", "100", "mg", "al", "día", "a", "principios", "de", "julio", "de", "2007", ".", "Ocho", "meses", "después", ",", "el", "paciente", "no", "ha", "presentado", "nuevos", "episodios", "de", "HDB", "ni", "ha", "requerido", "de", "ninguna", "transfusión", ".", "Actualmente", "el", "paciente", "es", "seguido", "de", "forma", "mensual", "en", "consultas", "externas", ",", "se", "encuentra", "asintomático", "salvo", "por", "parestesias", "ocasionales", "y", "leves", "en", "miembros", "inferiores", ",", "con", "electromiograma", "normal", ".", "El", "paciente", "ha", "presentado", "un", "episodio", "de", "TEP", "bilateral", "resuelto", "con", "el", "tratamiento", "anticoagulante", ".", "Dados", "los", "antecedentes", "de", "déficit", "de", "antitrombina", "III", "y", "el", "hecho", "de", "que", "la", "trombofilia", "no", "está", "descrita", "entre", "los", "posibles", "efectos", "secundarios", "de", "la", "talidomida", ",", "pensamos", "que", "este", "evento", "no", "es", "achacable", "al", "uso", "de", "la", "misma", ".", "\n", "Responsable", "clínico", ":", "Dr", ".", "David", "Crespo", "Marcos", ".", "Email", ".", "dcrespo@fhalcorcon.es", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "FECHAS", "ID_TITULACION_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

hERG is a GENE-Y, amiodarone is a CHEMICAL, amiodarone is a CHEMICAL

18604229_task0

Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]

Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]

[ "CHEMICAL", "GENE-Y" ]

hERG is a GENE-Y, amiodarone is a CHEMICAL, amiodarone is a CHEMICAL

18604229_task1

Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please typing these entity words according to sentence: hERG, amiodarone, amiodarone Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]

Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]

[ "CHEMICAL", "GENE-Y" ]

hERG, amiodarone, amiodarone

18604229_task2

Sentence: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O" ]

Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

[ "Interaction", "with", "the", "hERG", "channel", "and", "cytotoxicity", "of", "amiodarone", "and", "amiodarone", "analogues", "." ]

[ "CHEMICAL", "GENE-Y" ]

Risikofaktoren is an umlsterm, Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Literatur is an umlsterm, Risikofaktoren is an umlsterm, weibliches is an umlsterm, Geschlecht is an umlsterm, Anaesthetika is an umlsterm, Opioide is an umlsterm, Menstruationszyklus is an umlsterm, Risikofaktoren is an umlsterm, Schmerz is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Saeure - Basen - Haushalts is an umlsterm, Adipositas is an umlsterm, Inhalationsanaesthetika is an umlsterm, Opioide is an umlsterm, Patienten is an umlsterm, Frauen is an umlsterm

DerAnaesthesist.00490629.ger.abstr_task0

Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .

[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]

[ "umlsterm" ]

Risikofaktoren is an umlsterm, Uebelkeit is an umlsterm, Erbrechen is an umlsterm, Literatur is an umlsterm, Risikofaktoren is an umlsterm, weibliches is an umlsterm, Geschlecht is an umlsterm, Anaesthetika is an umlsterm, Opioide is an umlsterm, Menstruationszyklus is an umlsterm, Risikofaktoren is an umlsterm, Schmerz is an umlsterm, Hypoxie is an umlsterm, Hyperkapnie is an umlsterm, Saeure - Basen - Haushalts is an umlsterm, Adipositas is an umlsterm, Inhalationsanaesthetika is an umlsterm, Opioide is an umlsterm, Patienten is an umlsterm, Frauen is an umlsterm

DerAnaesthesist.00490629.ger.abstr_task1

Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please typing these entity words according to sentence: Risikofaktoren, Uebelkeit, Erbrechen, Literatur, Risikofaktoren, weibliches, Geschlecht, Anaesthetika, Opioide, Menstruationszyklus, Risikofaktoren, Schmerz, Hypoxie, Hyperkapnie, Saeure - Basen - Haushalts, Adipositas, Inhalationsanaesthetika, Opioide, Patienten, Frauen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .

[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]

[ "umlsterm" ]

Risikofaktoren, Uebelkeit, Erbrechen, Literatur, Risikofaktoren, weibliches, Geschlecht, Anaesthetika, Opioide, Menstruationszyklus, Risikofaktoren, Schmerz, Hypoxie, Hyperkapnie, Saeure - Basen - Haushalts, Adipositas, Inhalationsanaesthetika, Opioide, Patienten, Frauen

DerAnaesthesist.00490629.ger.abstr_task2

Sentence: In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der Vergangenheit wurde eine Vielzahl von Risikofaktoren fuer Uebelkeit und Erbrechen ( Ue& E ) nach Narkosen angefuehrt . Bei kritischer Durchsicht der Literatur faellt jedoch auf , dass nur wenige Faktoren durch Fakten hinreichend belegt sind , waehrend der Einfluss der meisten in Uebersichtsarbeiten angefuehrten Faktoren fraglich ist . Durch Daten belegte Risikofaktoren sind weibliches Geschlecht , eine positive Anamnese von Ue& E , der Nichtraucherstatus , junges Alter , volatile Anaesthetika Lachgas und postoperative Opioide . , Faktoren mit kontroverser Datenlage sind der Menstruationszyklus , die Einleitungshypnotika , die Maskenbeatmung und die Magensonde , die Erfahrung des Anaesthesisten , Muskelrelaxanzien und deren Antagonisierung sowie laparoskopische Eingriffe . Nicht ausreichend belegte Risikofaktoren sind alle anderen Operationen , psychologische Faktoren , Schmerz und Hypoxie . Nicht belegte Faktoren sind postoperative Bewegungsreize , haemodynamische Stabilitaet , Hyperkapnie und Entgleisungen des Saeure-Basen-Haushalts . Ein durch Daten eindeutig widerlegter Risikofaktor ist die Adipositas . Daher laesst sich ein vereinfachtes Modell ableiten : Ue&E nach Narkosen werden hauptsaechlich durch Inhalationsanaesthetika und Opioide bei praedisponierten Patienten ( Frauen Nichtraucher und positive Anamnese ) , hervorgerufen ( Abb. 1 ) .

[ "In", "der", "Vergangenheit", "wurde", "eine", "Vielzahl", "von", "Risikofaktoren", "fuer", "Uebelkeit", "und", "Erbrechen", "(", "Ue", "&", "E", ")", "nach", "Narkosen", "angefuehrt", ".", "Bei", "kritischer", "Durchsicht", "der", "Literatur", "faellt", "jedoch", "auf", ",", "dass", "nur", "wenige", "Faktoren", "durch", "Fakten", "hinreichend", "belegt", "sind", ",", "waehrend", "der", "Einfluss", "der", "meisten", "in", "Uebersichtsarbeiten", "angefuehrten", "Faktoren", "fraglich", "ist", ".", "Durch", "Daten", "belegte", "Risikofaktoren", "sind", "weibliches", "Geschlecht", ",", "eine", "positive", "Anamnese", "von", "Ue", "&", "E", ",", "der", "Nichtraucherstatus", ",", "junges", "Alter", ",", "volatile", "Anaesthetika", "Lachgas", "und", "postoperative", "Opioide", ".", ",", "Faktoren", "mit", "kontroverser", "Datenlage", "sind", "der", "Menstruationszyklus", ",", "die", "Einleitungshypnotika", ",", "die", "Maskenbeatmung", "und", "die", "Magensonde", ",", "die", "Erfahrung", "des", "Anaesthesisten", ",", "Muskelrelaxanzien", "und", "deren", "Antagonisierung", "sowie", "laparoskopische", "Eingriffe", ".", "Nicht", "ausreichend", "belegte", "Risikofaktoren", "sind", "alle", "anderen", "Operationen", ",", "psychologische", "Faktoren", ",", "Schmerz", "und", "Hypoxie", ".", "Nicht", "belegte", "Faktoren", "sind", "postoperative", "Bewegungsreize", ",", "haemodynamische", "Stabilitaet", ",", "Hyperkapnie", "und", "Entgleisungen", "des", "Saeure", "-", "Basen", "-", "Haushalts", ".", "Ein", "durch", "Daten", "eindeutig", "widerlegter", "Risikofaktor", "ist", "die", "Adipositas", ".", "Daher", "laesst", "sich", "ein", "vereinfachtes", "Modell", "ableiten", ":", "Ue&E", "nach", "Narkosen", "werden", "hauptsaechlich", "durch", "Inhalationsanaesthetika", "und", "Opioide", "bei", "praedisponierten", "Patienten", "(", "Frauen", "Nichtraucher", "und", "positive", "Anamnese", ")", ",", "hervorgerufen", "(", "Abb", ".", "1", ")", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Stent is an umlsterm, Polyesterflicken is an umlsterm, ASD is an umlsterm, Stent is an umlsterm, ASD is an umlsterm, Patienten is an umlsterm, ASD is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Komplikationen is an umlsterm

ZfuerKardiologie.80870185.ger.abstr_task0

Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .

[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Stent is an umlsterm, Polyesterflicken is an umlsterm, ASD is an umlsterm, Stent is an umlsterm, ASD is an umlsterm, Patienten is an umlsterm, ASD is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Komplikationen is an umlsterm

ZfuerKardiologie.80870185.ger.abstr_task1

Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please typing these entity words according to sentence: Patienten, Stent, Polyesterflicken, ASD, Stent, ASD, Patienten, ASD, Komplikationen, Patienten, Komplikationen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .

[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]

[ "umlsterm" ]

Patienten, Stent, Polyesterflicken, ASD, Stent, ASD, Patienten, ASD, Komplikationen, Patienten, Komplikationen

ZfuerKardiologie.80870185.ger.abstr_task2

Sentence: Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Der interventionelle Verschluss eines Vorhofseptumdefekts gelingt nur bei , hinsichtlich der Lage und der Groesse des Defekts , gut selektionierten Patienten . Alle Verschlusssysteme haben jedoch ihre speziellen Probleme , das optimale Device scheint bisher noch nicht gefunden zu sein . Seit Ende 1996 steht jedoch der von der Bauart vollstaendig neue Amplatzer Septal Occuder ( ASO ) fuer den ASD-Verschluss , im Rahmen einer internationalen Multicenterstudie , zur Verfuegung . Der ASO ist ein selbstexpandierendes und -zentrierendes Doppelschirmchen aus Nitinoldrahtgeflecht , bei dem beide Schirmanteile mit einem zentralen Stent , dessen Durchmesser der Defektgroesse entspricht , verbunden sind . In beide Schirme und den Stentanteil sind Polyesterflicken eingenaeht , die den Verschluss des Loches beguenstigen . Nach invasiver Groessenmessung des Defekts wird der passende Doppelschirm ausgewaehlt und ueber eine lange 7- oder 8-French-Schleuse, von femoralvenoes ueber den ASD , in den linken Vorhof geschoben . Im linken Vorhof werden der distale Anteil und der zentrale Stentanteil entfaltet und durch Zurueckziehen das Loch verschlossen , so dass der Stent den ASD vollstaendig auskleidet . Danach wird der proximale Anteil entwickelt und der Doppelschirm freigesetzt . Eine Repositionierung des Schirms ist jederzeit problemlos durch Zurueckziehen in die Schleuse moeglich . Innerhalb von 4 Monaten gelang bei 29 von 31 Patienten ( Alter Median 12,1 Jahre , Gewicht Median 45,0 kg ) der vollstaendige Verschluss des ASD mit mittlerem Durchmesser von 11,0 mm ( 6-20 mm ) ohne Komplikationen , bei einer mittleren Durchleuchtungszeit von 8,3 min ( 2,9-21,5 min ) und Katheterverweildauer von 104,9 min . Qp : Qs lag im Mittel bei 1,5 ( 0,9-2,2). Waehrend einer Beobachtungszeit von im Mittel 2,4 Monaten zeigte sich bei allen Patienten ein sicherer Sitz das ASO ohne Restshunt , Arrythmien , thrombembolische Komplikationen und ohne Beeintraechtigung der AV-Klappen-Funktion .

[ "Der", "interventionelle", "Verschluss", "eines", "Vorhofseptumdefekts", "gelingt", "nur", "bei", ",", "hinsichtlich", "der", "Lage", "und", "der", "Groesse", "des", "Defekts", ",", "gut", "selektionierten", "Patienten", ".", "Alle", "Verschlusssysteme", "haben", "jedoch", "ihre", "speziellen", "Probleme", ",", "das", "optimale", "Device", "scheint", "bisher", "noch", "nicht", "gefunden", "zu", "sein", ".", "Seit", "Ende", "1996", "steht", "jedoch", "der", "von", "der", "Bauart", "vollstaendig", "neue", "Amplatzer", "Septal", "Occuder", "(", "ASO", ")", "fuer", "den", "ASD", "-", "Verschluss", ",", "im", "Rahmen", "einer", "internationalen", "Multicenterstudie", ",", "zur", "Verfuegung", ".", "Der", "ASO", "ist", "ein", "selbstexpandierendes", "und", "-zentrierendes", "Doppelschirmchen", "aus", "Nitinoldrahtgeflecht", ",", "bei", "dem", "beide", "Schirmanteile", "mit", "einem", "zentralen", "Stent", ",", "dessen", "Durchmesser", "der", "Defektgroesse", "entspricht", ",", "verbunden", "sind", ".", "In", "beide", "Schirme", "und", "den", "Stentanteil", "sind", "Polyesterflicken", "eingenaeht", ",", "die", "den", "Verschluss", "des", "Loches", "beguenstigen", ".", "Nach", "invasiver", "Groessenmessung", "des", "Defekts", "wird", "der", "passende", "Doppelschirm", "ausgewaehlt", "und", "ueber", "eine", "lange", "7-", "oder", "8-French", "-", "Schleuse", ",", "von", "femoralvenoes", "ueber", "den", "ASD", ",", "in", "den", "linken", "Vorhof", "geschoben", ".", "Im", "linken", "Vorhof", "werden", "der", "distale", "Anteil", "und", "der", "zentrale", "Stentanteil", "entfaltet", "und", "durch", "Zurueckziehen", "das", "Loch", "verschlossen", ",", "so", "dass", "der", "Stent", "den", "ASD", "vollstaendig", "auskleidet", ".", "Danach", "wird", "der", "proximale", "Anteil", "entwickelt", "und", "der", "Doppelschirm", "freigesetzt", ".", "Eine", "Repositionierung", "des", "Schirms", "ist", "jederzeit", "problemlos", "durch", "Zurueckziehen", "in", "die", "Schleuse", "moeglich", ".", "Innerhalb", "von", "4", "Monaten", "gelang", "bei", "29", "von", "31", "Patienten", "(", "Alter", "Median", "12,1", "Jahre", ",", "Gewicht", "Median", "45,0", "kg", ")", "der", "vollstaendige", "Verschluss", "des", "ASD", "mit", "mittlerem", "Durchmesser", "von", "11,0", "mm", "(", "6", "-", "20", "mm", ")", "ohne", "Komplikationen", ",", "bei", "einer", "mittleren", "Durchleuchtungszeit", "von", "8,3", "min", "(", "2,9", "-", "21,5", "min", ")", "und", "Katheterverweildauer", "von", "104,9", "min", ".", "Qp", ":", "Qs", "lag", "im", "Mittel", "bei", "1,5", "(", "0,9", "-", "2,2", ")", ".", "Waehrend", "einer", "Beobachtungszeit", "von", "im", "Mittel", "2,4", "Monaten", "zeigte", "sich", "bei", "allen", "Patienten", "ein", "sicherer", "Sitz", "das", "ASO", "ohne", "Restshunt", ",", "Arrythmien", ",", "thrombembolische", "Komplikationen", "und", "ohne", "Beeintraechtigung", "der", "AV", "-", "Klappen", "-", "Funktion", "." ]

[ "umlsterm" ]

2 or more doses is a Multiplier, methylprednisolone / prednisone is a Scope, Steroids is a Drug, other than is a Negation, methylprednisolone or prednisone is a Scope, Pregnancy is a Condition, estimated glomerular filtration rate ( eGFR ) is a Measurement, < 45 ml / min/1.73m2 is a Value

NCT03511521_exc_task0

Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Multiplier, Negation, Scope, Measurement, Drug

[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]

Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2

[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]

[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]

2 or more doses is a Multiplier, methylprednisolone / prednisone is a Scope, Steroids is a Drug, other than is a Negation, methylprednisolone or prednisone is a Scope, Pregnancy is a Condition, estimated glomerular filtration rate ( eGFR ) is a Measurement, < 45 ml / min/1.73m2 is a Value

NCT03511521_exc_task1

Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please typing these entity words according to sentence: 2 or more doses, methylprednisolone / prednisone, Steroids, other than, methylprednisolone or prednisone, Pregnancy, estimated glomerular filtration rate ( eGFR ), < 45 ml / min/1.73m2 Options: Condition, Value, Multiplier, Negation, Scope, Measurement, Drug

[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]

Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2

[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]

[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]

2 or more doses, methylprednisolone / prednisone, Steroids, other than, methylprednisolone or prednisone, Pregnancy, estimated glomerular filtration rate ( eGFR ), < 45 ml / min/1.73m2

NCT03511521_exc_task2

Sentence: Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Drug", "B-Negation", "I-Negation", "B-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O" ]

Patients with 2 or more doses of methylprednisolone/prednisone per day Steroids other than methylprednisolone or prednisone Pregnancy estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2

[ "Patients", "with", "2", "or", "more", "doses", "of", "methylprednisolone", "/", "prednisone", "per", "day", "\n", "Steroids", "other", "than", "methylprednisolone", "or", "prednisone", "\n", "Pregnancy", "\n", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", "<", "45", "ml", "/", "min/1.73m2", "\n" ]

[ "Measurement", "Scope", "Drug", "Value", "Multiplier", "Negation", "Condition" ]

Polyneuropathie is an umlsterm, Kernspintomographie is an umlsterm, Kopfes is an umlsterm, Hirnatrophie is an umlsterm, Diagnose is an umlsterm, Stoffwechseldefekte is an umlsterm, Leukozyten is an umlsterm, Kindern is an umlsterm, Normalbereichs is an umlsterm, peripheren Nervensystems is an umlsterm, Patienten is an umlsterm

DerNervenarzt.90700745.ger.abstr_task0

Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .

[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]

[ "umlsterm" ]

Polyneuropathie is an umlsterm, Kernspintomographie is an umlsterm, Kopfes is an umlsterm, Hirnatrophie is an umlsterm, Diagnose is an umlsterm, Stoffwechseldefekte is an umlsterm, Leukozyten is an umlsterm, Kindern is an umlsterm, Normalbereichs is an umlsterm, peripheren Nervensystems is an umlsterm, Patienten is an umlsterm

DerNervenarzt.90700745.ger.abstr_task1

Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please typing these entity words according to sentence: Polyneuropathie, Kernspintomographie, Kopfes, Hirnatrophie, Diagnose, Stoffwechseldefekte, Leukozyten, Kindern, Normalbereichs, peripheren Nervensystems, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .

[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]

[ "umlsterm" ]

Polyneuropathie, Kernspintomographie, Kopfes, Hirnatrophie, Diagnose, Stoffwechseldefekte, Leukozyten, Kindern, Normalbereichs, peripheren Nervensystems, Patienten

DerNervenarzt.90700745.ger.abstr_task2

Sentence: Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Wir berichten ueber eine 46jaehrige Patientin mit adulter Polyglukosankoerperkrankheit ( APBD ) . Sie zeigte klinisch mit spaetem Beginn eine spastische Tetraparese , sensomotorische Polyneuropathie und Blasenentleerungsstoerungen . Die Kernspintomographie des Kopfes erbrachte eine ausgedehnte Leukencephalopathie und eine diffuse Hirnatrophie . Die Diagnose erfolgte durch den Nachweis von Polyglukosankoerpern in der Suralisbiopsie . Zum Nachweis moeglicher Stoffwechseldefekte untersuchten wir den Glykogenmetabolismus bei der Patientin und ihren klinisch gesunden Toechtern . Die Branchingenzymaktivitaet war in den Leukozyten der Patientin auf 20-30% und bei den Kindern auf 80% der unteren Grenze des Normalbereichs herabgesetzt , was auf einen moeglichen autosomal-rezessiven Erbgang schliessen laesst . Ein Branchingenzymdefekt bei APBD mit ueberwiegender Beteiligung des zentralen und peripheren Nervensystems wurde bislang bei 3 juedischen Patienten nachgewiesen .

[ "Wir", "berichten", "ueber", "eine", "46jaehrige", "Patientin", "mit", "adulter", "Polyglukosankoerperkrankheit", "(", "APBD", ")", ".", "Sie", "zeigte", "klinisch", "mit", "spaetem", "Beginn", "eine", "spastische", "Tetraparese", ",", "sensomotorische", "Polyneuropathie", "und", "Blasenentleerungsstoerungen", ".", "Die", "Kernspintomographie", "des", "Kopfes", "erbrachte", "eine", "ausgedehnte", "Leukencephalopathie", "und", "eine", "diffuse", "Hirnatrophie", ".", "Die", "Diagnose", "erfolgte", "durch", "den", "Nachweis", "von", "Polyglukosankoerpern", "in", "der", "Suralisbiopsie", ".", "Zum", "Nachweis", "moeglicher", "Stoffwechseldefekte", "untersuchten", "wir", "den", "Glykogenmetabolismus", "bei", "der", "Patientin", "und", "ihren", "klinisch", "gesunden", "Toechtern", ".", "Die", "Branchingenzymaktivitaet", "war", "in", "den", "Leukozyten", "der", "Patientin", "auf", "20", "-", "30", "%", "und", "bei", "den", "Kindern", "auf", "80", "%", "der", "unteren", "Grenze", "des", "Normalbereichs", "herabgesetzt", ",", "was", "auf", "einen", "moeglichen", "autosomal", "-", "rezessiven", "Erbgang", "schliessen", "laesst", ".", "Ein", "Branchingenzymdefekt", "bei", "APBD", "mit", "ueberwiegender", "Beteiligung", "des", "zentralen", "und", "peripheren", "Nervensystems", "wurde", "bislang", "bei", "3", "juedischen", "Patienten", "nachgewiesen", "." ]

[ "umlsterm" ]

Sandro is a NOMBRE_SUJETO_ASISTENCIA, Gonzalez Morales is a NOMBRE_SUJETO_ASISTENCIA, 370562 is a ID_SUJETO_ASISTENCIA, 43 23598635 20 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 27/03/1946 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 21/05/2016 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, 28 28 14723 is a ID_TITULACION_PERSONAL_SANITARIO, Hombre is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, septiembre 2014 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, ale.delgam@gmail.com is a CORREO_ELECTRONICO

396_task0

Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com

[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]

Sandro is a NOMBRE_SUJETO_ASISTENCIA, Gonzalez Morales is a NOMBRE_SUJETO_ASISTENCIA, 370562 is a ID_SUJETO_ASISTENCIA, 43 23598635 20 is a ID_ASEGURAMIENTO, Madrid is a TERRITORIO, 27/03/1946 is a FECHAS, España is a PAIS, 70 años is a EDAD_SUJETO_ASISTENCIA, 21/05/2016 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, 28 28 14723 is a ID_TITULACION_PERSONAL_SANITARIO, Hombre is a SEXO_SUJETO_ASISTENCIA, 70 años is a EDAD_SUJETO_ASISTENCIA, septiembre 2014 is a FECHAS, Alejandro Delgado Gamboa is a NOMBRE_PERSONAL_SANITARIO, ale.delgam@gmail.com is a CORREO_ELECTRONICO

396_task1

Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please typing these entity words according to sentence: Sandro, Gonzalez Morales, 370562, 43 23598635 20, Madrid, 27/03/1946, España, 70 años, 21/05/2016, Alejandro Delgado Gamboa, 28 28 14723, Hombre, 70 años, septiembre 2014, Alejandro Delgado Gamboa, ale.delgam@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com

[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]

Sandro, Gonzalez Morales, 370562, 43 23598635 20, Madrid, 27/03/1946, España, 70 años, 21/05/2016, Alejandro Delgado Gamboa, 28 28 14723, Hombre, 70 años, septiembre 2014, Alejandro Delgado Gamboa, ale.delgam@gmail.com

396_task2

Sentence: Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Sandro. Apellidos: Gonzalez Morales. NHC: 370562. NASS: 43 23598635 20. Domicilio: Calle del Pez 86, Bajo A. Localidad/ Provincia: Madrid. CP:28001. Datos asistenciales. Fecha de nacimiento: 27/03/1946. País: España. Edad: 70 años Sexo: H. Fecha de Ingreso: 21/05/2016. Médico: Alejandro Delgado Gamboa NºCol: 28 28 14723. Informe clínico del paciente: Hombre de 70 años, con neuralgia del nervio pudendo secundaria a una lesión directa posterior a una resección trans-ureteral de próstata (RTU-P). Refería dolor de características neuropáticas (quemazón, parestesias) en genital externo. De intensidad severa (EVA 10/10), asociado con dolor al defecar y miccionar, el cual aliviaba posterior al acto. Como primera medida en la unidad, tras 5 años de dolor, se inició con terapia farmacológica con carbamacepina (200 mg/d), pregabalina (150 mg/12 horas), amitriptilina (25 mg/cada noche) y tramadol (200 mg/12 horas). Por falta de respuesta al tratamiento farmacológico, siguiendo el protocolo de los casos anteriores, se reporta en el cuestionario de depresión Beck y el de salud de Goldberg depresión y ansiedad leve, que no contraindican la colocación del dispositivo, por lo que se efectúa CENPP en septiembre 2014. Se obtuvo una mejoría sintomatológica, por lo que se procedió a la implantación NERSR. Presentó una complicación por fístula de LCR, el cual resolvió a la sexta semana con manejo conservador. Un mes después del tratamiento, el paciente se encontraba libre de dolor. En la actualidad, el paciente presenta una cobertura del 100 % sin medicamentos orales. Cuestionario de depresión de Beck y el de salud de Goldberg con ansiedad leve sin datos de depresión. Remitido por: Dr. Alejandro Delgado Gamboa. Email: ale.delgam@gmail.com

[ "Nombre", ":", "Sandro", ".", "\n", "Apellidos", ":", "Gonzalez", "Morales", ".", "\n", "NHC", ":", "370562", ".", "\n", "NASS", ":", "43", "23598635", "20", ".", "\n", "Domicilio", ":", "Calle", "del", "Pez", "86", ",", "Bajo", "A.", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP:28001", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "27/03/1946", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "70", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/05/2016", ".", "\n", "Médico", ":", "Alejandro", "Delgado", "Gamboa", "NºCol", ":", "28", "28", "14723", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Hombre", "de", "70", "años", ",", "con", "neuralgia", "del", "nervio", "pudendo", "secundaria", "a", "una", "lesión", "directa", "posterior", "a", "una", "resección", "trans", "-", "ureteral", "de", "próstata", "(", "RTU", "-", "P", ")", ".", "Refería", "dolor", "de", "características", "neuropáticas", "(", "quemazón", ",", "parestesias", ")", "en", "genital", "externo", ".", "De", "intensidad", "severa", "(", "EVA", "10/10", ")", ",", "asociado", "con", "dolor", "al", "defecar", "y", "miccionar", ",", "el", "cual", "aliviaba", "posterior", "al", "acto", ".", "Como", "primera", "medida", "en", "la", "unidad", ",", "tras", "5", "años", "de", "dolor", ",", "se", "inició", "con", "terapia", "farmacológica", "con", "carbamacepina", "(", "200", "mg", "/", "d", ")", ",", "pregabalina", "(", "150", "mg/12", "horas", ")", ",", "amitriptilina", "(", "25", "mg", "/", "cada", "noche", ")", "y", "tramadol", "(", "200", "mg/12", "horas", ")", ".", "Por", "falta", "de", "respuesta", "al", "tratamiento", "farmacológico", ",", "siguiendo", "el", "protocolo", "de", "los", "casos", "anteriores", ",", "se", "reporta", "en", "el", "cuestionario", "de", "depresión", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "depresión", "y", "ansiedad", "leve", ",", "que", "no", "contraindican", "la", "colocación", "del", "dispositivo", ",", "por", "lo", "que", "se", "efectúa", "CENPP", "en", "septiembre", "2014", ".", "Se", "obtuvo", "una", "mejoría", "sintomatológica", ",", "por", "lo", "que", "se", "procedió", "a", "la", "implantación", "NERSR", ".", "Presentó", "una", "complicación", "por", "fístula", "de", "LCR", ",", "el", "cual", "resolvió", "a", "la", "sexta", "semana", "con", "manejo", "conservador", ".", "Un", "mes", "después", "del", "tratamiento", ",", "el", "paciente", "se", "encontraba", "libre", "de", "dolor", ".", "En", "la", "actualidad", ",", "el", "paciente", "presenta", "una", "cobertura", "del", "100", "%", "sin", "medicamentos", "orales", ".", "Cuestionario", "de", "depresión", "de", "Beck", "y", "el", "de", "salud", "de", "Goldberg", "con", "ansiedad", "leve", "sin", "datos", "de", "depresión", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Alejandro", "Delgado", "Gamboa", ".", "Email", ":", "ale.delgam@gmail.com", "\n" ]

[ "NOMBRE_PERSONAL_SANITARIO", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_SUJETO_ASISTENCIA", "FECHAS", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "ID_SUJETO_ASISTENCIA" ]

Rheumatoid arthritis is an umlsterm, disease is an umlsterm, cytokines is an umlsterm, blood is an umlsterm, IL-1 is an umlsterm, TNF is an umlsterm, concentrations is an umlsterm, disease is an umlsterm, cortisol is an umlsterm, secretion is an umlsterm, overall is an umlsterm, cortisol is an umlsterm, release is an umlsterm, disease is an umlsterm

ZfuerRheumatologie.0059ii62.eng.abstr_task0

Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .

[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]

[ "umlsterm" ]

Rheumatoid arthritis is an umlsterm, disease is an umlsterm, cytokines is an umlsterm, blood is an umlsterm, IL-1 is an umlsterm, TNF is an umlsterm, concentrations is an umlsterm, disease is an umlsterm, cortisol is an umlsterm, secretion is an umlsterm, overall is an umlsterm, cortisol is an umlsterm, release is an umlsterm, disease is an umlsterm

ZfuerRheumatologie.0059ii62.eng.abstr_task1

Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please typing these entity words according to sentence: Rheumatoid arthritis, disease, cytokines, blood, IL-1, TNF, concentrations, disease, cortisol, secretion, overall, cortisol, release, disease Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .

[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]

[ "umlsterm" ]

Rheumatoid arthritis, disease, cytokines, blood, IL-1, TNF, concentrations, disease, cortisol, secretion, overall, cortisol, release, disease

ZfuerRheumatologie.0059ii62.eng.abstr_task2

Sentence: Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Rheumatoid arthritis ( RA ) is a systemic inflammatory disease with elevated levels of proinflammatory cytokines in peripheral blood , especially IL-6, but also IL-1 and TNF , for example , in different concentrations , depending on disease activity . A disturbed circadian rhytm of cortisol secretion and an overall elevated cortisol release in active RA , depending on disease activity , is known .

[ "Rheumatoid", "arthritis", "(", "RA", ")", "is", "a", "systemic", "inflammatory", "disease", "with", "elevated", "levels", "of", "proinflammatory", "cytokines", "in", "peripheral", "blood", ",", "especially", "IL-6", ",", "but", "also", "IL-1", "and", "TNF", ",", "for", "example", ",", "in", "different", "concentrations", ",", "depending", "on", "disease", "activity", ".", "A", "disturbed", "circadian", "rhytm", "of", "cortisol", "secretion", "and", "an", "overall", "elevated", "cortisol", "release", "in", "active", "RA", ",", "depending", "on", "disease", "activity", ",", "is", "known", "." ]

[ "umlsterm" ]

naloxone - steroid hybrid azine is a CHEMICAL, delta receptors is a GENE-Y, naloxone estrone azine is a CHEMICAL, N - EH is a CHEMICAL, opioid receptor is a GENE-N, naloxone is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, D - Ala2-Leu5-enkephalin is a CHEMICAL, normorphine is a CHEMICAL, N - EH is a CHEMICAL, 3H - D - Ala2-Leu5-enkephalin is a CHEMICAL, 3H - dihydromorphine is a CHEMICAL, 3H - ethylketocyclazocine is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, naloxone is a CHEMICAL, N - EH is a CHEMICAL

21549_task0

Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.

[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

naloxone - steroid hybrid azine is a CHEMICAL, delta receptors is a GENE-Y, naloxone estrone azine is a CHEMICAL, N - EH is a CHEMICAL, opioid receptor is a GENE-N, naloxone is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, D - Ala2-Leu5-enkephalin is a CHEMICAL, normorphine is a CHEMICAL, N - EH is a CHEMICAL, 3H - D - Ala2-Leu5-enkephalin is a CHEMICAL, 3H - dihydromorphine is a CHEMICAL, 3H - ethylketocyclazocine is a CHEMICAL, N - EH is a CHEMICAL, naloxone is a CHEMICAL, naloxone is a CHEMICAL, N - EH is a CHEMICAL

21549_task1

Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please typing these entity words according to sentence: naloxone - steroid hybrid azine, delta receptors, naloxone estrone azine, N - EH, opioid receptor, naloxone, N - EH, naloxone, D - Ala2-Leu5-enkephalin, normorphine, N - EH, 3H - D - Ala2-Leu5-enkephalin, 3H - dihydromorphine, 3H - ethylketocyclazocine, N - EH, naloxone, naloxone, N - EH Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.

[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

naloxone - steroid hybrid azine, delta receptors, naloxone estrone azine, N - EH, opioid receptor, naloxone, N - EH, naloxone, D - Ala2-Leu5-enkephalin, normorphine, N - EH, 3H - D - Ala2-Leu5-enkephalin, 3H - dihydromorphine, 3H - ethylketocyclazocine, N - EH, naloxone, naloxone, N - EH

21549_task2

Sentence: A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O" ]

A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro. The interaction of naloxone estrone azine (N-EH) with various opioid receptor types was studied in vitro. Its potency as an antagonist of opioid effects was compared to that of naloxone on the electrically evoked contractions of mouse vas deferens (Mvd) and guinea pig ileum myenteric plexus longitudinal muscle (Gpi) preparations. N-EH was found to be 9-fold more potent than naloxone in antagonizing the effects of D-Ala2-Leu5-enkephalin in the Mvd and 22-fold less potent in antagonizing normorphine in the Gpi. In the Mvd, the recovery half-time for N-EH was longer than 1000 min. Neither compound showed agonism. The two compounds were also compared for their capacity to displace the binding of 3H-D-Ala2-Leu5-enkephalin, 3H-dihydromorphine, and 3H-ethylketocyclazocine to rat brain membranes under conditions where delta, mu, and kappa sites were labeled. The relative affinities were 0.70, 0.16, and 0.14 for N-EH and 0.05, 0.87, and 0.08 for naloxone, respectively. Thus, compared to naloxone, which is mu selective, N-EH is a delta-selective antagonist.

[ "A", "naloxone", "-", "steroid", "hybrid", "azine", "with", "selective", "and", "long", "-", "acting", "opioid", "antagonism", "at", "delta", "receptors", "in", "vitro", ".", "\n", "The", "interaction", "of", "naloxone", "estrone", "azine", "(", "N", "-", "EH", ")", "with", "various", "opioid", "receptor", "types", "was", "studied", "in", "vitro", ".", "Its", "potency", "as", "an", "antagonist", "of", "opioid", "effects", "was", "compared", "to", "that", "of", "naloxone", "on", "the", "electrically", "evoked", "contractions", "of", "mouse", "vas", "deferens", "(", "Mvd", ")", "and", "guinea", "pig", "ileum", "myenteric", "plexus", "longitudinal", "muscle", "(", "Gpi", ")", "preparations", ".", "N", "-", "EH", "was", "found", "to", "be", "9-fold", "more", "potent", "than", "naloxone", "in", "antagonizing", "the", "effects", "of", "D", "-", "Ala2-Leu5-enkephalin", "in", "the", "Mvd", "and", "22-fold", "less", "potent", "in", "antagonizing", "normorphine", "in", "the", "Gpi", ".", "In", "the", "Mvd", ",", "the", "recovery", "half", "-", "time", "for", "N", "-", "EH", "was", "longer", "than", "1000", "min", ".", "Neither", "compound", "showed", "agonism", ".", "The", "two", "compounds", "were", "also", "compared", "for", "their", "capacity", "to", "displace", "the", "binding", "of", "3H", "-", "D", "-", "Ala2-Leu5-enkephalin", ",", "3H", "-", "dihydromorphine", ",", "and", "3H", "-", "ethylketocyclazocine", "to", "rat", "brain", "membranes", "under", "conditions", "where", "delta", ",", "mu", ",", "and", "kappa", "sites", "were", "labeled", ".", "The", "relative", "affinities", "were", "0.70", ",", "0.16", ",", "and", "0.14", "for", "N", "-", "EH", "and", "0.05", ",", "0.87", ",", "and", "0.08", "for", "naloxone", ",", "respectively", ".", "Thus", ",", "compared", "to", "naloxone", ",", "which", "is", "mu", "selective", ",", "N", "-", "EH", "is", "a", "delta", "-", "selective", "antagonist", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Interleukin-2 is a Protein, promoter is a Entity, interleukin ( IL)-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, reporter constructs with is a Entity, binding sites from the IL-2 promoter is a Entity, sites is a Entity, chi B site is a Entity, NF - AT binding sites is a Entity, IL-2 is a Protein, promoter is a Entity, NF - chi B site is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, human immunodeficiency virus promoter is a Entity, IL-2 is a Protein, IL-2 NF - chi B probe is a Entity, chi B complexes is a Entity, p50 is a Protein, p65 is a Protein, complexes is a Entity, chi B complex is a Entity, IL-2 NF - chi B site is a Entity, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein

459_task0

Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.

[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

Interleukin-2 is a Protein, promoter is a Entity, interleukin ( IL)-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, reporter constructs with is a Entity, binding sites from the IL-2 promoter is a Entity, sites is a Entity, chi B site is a Entity, NF - AT binding sites is a Entity, IL-2 is a Protein, promoter is a Entity, NF - chi B site is a Entity, IL-2 is a Protein, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein, human immunodeficiency virus promoter is a Entity, IL-2 is a Protein, IL-2 NF - chi B probe is a Entity, chi B complexes is a Entity, p50 is a Protein, p65 is a Protein, complexes is a Entity, chi B complex is a Entity, IL-2 NF - chi B site is a Entity, IL-2 is a Protein, promoter is a Entity, IL-2 is a Protein

459_task1

Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please typing these entity words according to sentence: Interleukin-2, promoter, interleukin ( IL)-2, IL-2, IL-2, IL-2, promoter, IL-2, reporter constructs with, binding sites from the IL-2 promoter, sites, chi B site, NF - AT binding sites, IL-2, promoter, NF - chi B site, IL-2, IL-2, promoter, IL-2, human immunodeficiency virus promoter, IL-2, IL-2 NF - chi B probe, chi B complexes, p50, p65, complexes, chi B complex, IL-2 NF - chi B site, IL-2, promoter, IL-2 Options: Entity, Protein

[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.

[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

Interleukin-2, promoter, interleukin ( IL)-2, IL-2, IL-2, IL-2, promoter, IL-2, reporter constructs with, binding sites from the IL-2 promoter, sites, chi B site, NF - AT binding sites, IL-2, promoter, NF - chi B site, IL-2, IL-2, promoter, IL-2, human immunodeficiency virus promoter, IL-2, IL-2 NF - chi B probe, chi B complexes, p50, p65, complexes, chi B complex, IL-2 NF - chi B site, IL-2, promoter, IL-2

459_task2

Sentence: Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells. Instructions: please extract entity words from the input sentence

[ "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O" ]

Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. The regulation of interleukin (IL)-2 gene expression has been investigated mainly in T lymphocytes, the predominant producers of IL-2. However, B cells can also synthesize IL-2. In the present study we analyzed the control of IL-2 promoter activity in Epstein-Barr virus (EBV)-transformed B cell clones which are capable of secreting IL-2 at a low level after stimulation with phorbol 12-myristate 13-acetate and the Ca2+ ionophore ionomycin. Transient transfections using reporter constructs with multiples of transcription factor binding sites from the IL-2 promoter [distal nuclear factor (NF)-AT, proximal NF-AT, AP-1/Octamer (UPS) or NF-chi B (TCEd) sites] were performed. In EBV-transformed B clones, the chi B site exerted the strongest inducible activity; the NF-AT binding sites showed either no or only weak activity compared to Jurkat T cells. An IL-2 promoter bearing a defective NF-chi B site was completely inactive in EBV-transformed B cells, while it still had activity in Jurkat T cells. In seven EBV-B cell clones or lines differing in their capacity to secrete IL-2, the activity of the IL-2 promoter correlated well with the status of IL-2 secretion. Similarly, a human immunodeficiency virus promoter, whose activity is controlled through chi B factors, was found to be active in the IL-2 producing EBV-B cells, but inactive in the non-IL-2-producing cells. Electrophoretic mobility shift assays using protein extracts from EBV-B cells and the IL-2 NF-chi B probe revealed the constitutive generation of chi B complexes in IL-2-secreting cells consisting mainly of heterodimeric p50/p65 complexes. A weaker chi B complex formation and faster-migrating complexes were detected in non-IL-2-secreting cells. These results demonstrate that the IL-2 NF-chi B site is indispensable for the activity of the IL-2 promoter in EBV-transformed B cells, whereas other transcription factors appear to be less important for IL-2 expression in these cells.

[ "Interleukin-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "-", "transformed", "B", "lymphocytes", "is", "controlled", "by", "nuclear", "factor", "-", "chi", "B.", "\n", "The", "regulation", "of", "interleukin", "(", "IL)-2", "gene", "expression", "has", "been", "investigated", "mainly", "in", "T", "lymphocytes", ",", "the", "predominant", "producers", "of", "IL-2", ".", "However", ",", "B", "cells", "can", "also", "synthesize", "IL-2", ".", "In", "the", "present", "study", "we", "analyzed", "the", "control", "of", "IL-2", "promoter", "activity", "in", "Epstein", "-", "Barr", "virus", "(", "EBV)-transformed", "B", "cell", "clones", "which", "are", "capable", "of", "secreting", "IL-2", "at", "a", "low", "level", "after", "stimulation", "with", "phorbol", "12-myristate", "13-acetate", "and", "the", "Ca2", "+", "ionophore", "ionomycin", ".", "Transient", "transfections", "using", "reporter", "constructs", "with", "multiples", "of", "transcription", "factor", "binding", "sites", "from", "the", "IL-2", "promoter", "[", "distal", "nuclear", "factor", "(", "NF)-AT", ",", "proximal", "NF", "-", "AT", ",", "AP-1", "/", "Octamer", "(", "UPS", ")", "or", "NF", "-", "chi", "B", "(", "TCEd", ")", "sites", "]", "were", "performed", ".", "In", "EBV", "-", "transformed", "B", "clones", ",", "the", "chi", "B", "site", "exerted", "the", "strongest", "inducible", "activity", ";", "the", "NF", "-", "AT", "binding", "sites", "showed", "either", "no", "or", "only", "weak", "activity", "compared", "to", "Jurkat", "T", "cells", ".", "An", "IL-2", "promoter", "bearing", "a", "defective", "NF", "-", "chi", "B", "site", "was", "completely", "inactive", "in", "EBV", "-", "transformed", "B", "cells", ",", "while", "it", "still", "had", "activity", "in", "Jurkat", "T", "cells", ".", "In", "seven", "EBV", "-", "B", "cell", "clones", "or", "lines", "differing", "in", "their", "capacity", "to", "secrete", "IL-2", ",", "the", "activity", "of", "the", "IL-2", "promoter", "correlated", "well", "with", "the", "status", "of", "IL-2", "secretion", ".", "Similarly", ",", "a", "human", "immunodeficiency", "virus", "promoter", ",", "whose", "activity", "is", "controlled", "through", "chi", "B", "factors", ",", "was", "found", "to", "be", "active", "in", "the", "IL-2", "producing", "EBV", "-", "B", "cells", ",", "but", "inactive", "in", "the", "non", "-", "IL-2-producing", "cells", ".", "Electrophoretic", "mobility", "shift", "assays", "using", "protein", "extracts", "from", "EBV", "-", "B", "cells", "and", "the", "IL-2", "NF", "-", "chi", "B", "probe", "revealed", "the", "constitutive", "generation", "of", "chi", "B", "complexes", "in", "IL-2-secreting", "cells", "consisting", "mainly", "of", "heterodimeric", "p50", "/", "p65", "complexes", ".", "A", "weaker", "chi", "B", "complex", "formation", "and", "faster", "-", "migrating", "complexes", "were", "detected", "in", "non", "-", "IL-2-secreting", "cells", ".", "These", "results", "demonstrate", "that", "the", "IL-2", "NF", "-", "chi", "B", "site", "is", "indispensable", "for", "the", "activity", "of", "the", "IL-2", "promoter", "in", "EBV", "-", "transformed", "B", "cells", ",", "whereas", "other", "transcription", "factors", "appear", "to", "be", "less", "important", "for", "IL-2", "expression", "in", "these", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

tumor is a Cancer, tumors is a Cancer, tumor is a Cancer, tumor is a Cancer, tumor is a Cancer, endothelial cell is a Cell, tumor is a Cancer, tumor is a Cancer, cancer is a Cancer

PMID-16406676_task0

Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cancer, Cell

[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]

Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.

[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]

[ "Cell", "Cancer" ]

tumor is a Cancer, tumors is a Cancer, tumor is a Cancer, tumor is a Cancer, tumor is a Cancer, endothelial cell is a Cell, tumor is a Cancer, tumor is a Cancer, cancer is a Cancer

PMID-16406676_task1

Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please typing these entity words according to sentence: tumor, tumors, tumor, tumor, tumor, endothelial cell, tumor, tumor, cancer Options: Cancer, Cell

[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]

Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.

[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]

[ "Cell", "Cancer" ]

tumor, tumors, tumor, tumor, tumor, endothelial cell, tumor, tumor, cancer

PMID-16406676_task2

Sentence: Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O" ]

Regulation of tumor angiogenesis by thrombospondin-1. Angiogenesis plays a critical role in the growth and metastasis of tumors. Thrombospondin-1 (TSP-1) is a potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types. Expression of TSP-1 is up-regulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as Myc and Ras. TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and proliferation and by inducing apoptosis. In addition, activation of transforming growth factor beta (TGF-beta) by TSP-1 plays a crucial role in the regulation of tumor progression. An understanding of the molecular basis of TSP-1-mediated inhibition of angiogenesis and tumor progression will aid in the development of novel therapeutics for the treatment of cancer.

[ "Regulation", "of", "tumor", "angiogenesis", "by", "thrombospondin-1", ".", "\n", "Angiogenesis", "plays", "a", "critical", "role", "in", "the", "growth", "and", "metastasis", "of", "tumors", ".", "Thrombospondin-1", "(", "TSP-1", ")", "is", "a", "potent", "angiogenesis", "inhibitor", ",", "and", "down", "-", "regulation", "of", "TSP-1", "has", "been", "suggested", "to", "alter", "tumor", "growth", "by", "modulating", "angiogenesis", "in", "a", "variety", "of", "tumor", "types", ".", "Expression", "of", "TSP-1", "is", "up", "-", "regulated", "by", "the", "tumor", "suppressor", "gene", ",", "p53", ",", "and", "down", "-", "regulated", "by", "oncogenes", "such", "as", "Myc", "and", "Ras", ".", "TSP-1", "inhibits", "angiogenesis", "by", "inhibiting", "endothelial", "cell", "migration", "and", "proliferation", "and", "by", "inducing", "apoptosis", ".", "In", "addition", ",", "activation", "of", "transforming", "growth", "factor", "beta", "(", "TGF", "-", "beta", ")", "by", "TSP-1", "plays", "a", "crucial", "role", "in", "the", "regulation", "of", "tumor", "progression", ".", "An", "understanding", "of", "the", "molecular", "basis", "of", "TSP-1-mediated", "inhibition", "of", "angiogenesis", "and", "tumor", "progression", "will", "aid", "in", "the", "development", "of", "novel", "therapeutics", "for", "the", "treatment", "of", "cancer", ".", "\n" ]

[ "Cell", "Cancer" ]

profilin is a Individual_protein, muscle actin is a Individual_protein, profilin is a Gene/protein/RNA, actin is a Gene/protein/RNA

16_task0

Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA, Individual_protein

[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]

Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.

[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

profilin is a Individual_protein, muscle actin is a Individual_protein, profilin is a Gene/protein/RNA, actin is a Gene/protein/RNA

16_task1

Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please typing these entity words according to sentence: profilin, muscle actin, profilin, actin Options: Gene/protein/RNA, Individual_protein

[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]

Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.

[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

profilin, muscle actin, profilin, actin

16_task2

Sentence: Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin. Instructions: please extract entity words from the input sentence

[ "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "B-Gene/protein/RNA", "O" ]

Acanthamoeba profilin has similar but weaker effects on muscle actin, requiring 5 to 10 times more profilin than with amoeba actin.

[ "Acanthamoeba", "profilin", "has", "similar", "but", "weaker", "effects", "on", "muscle", "actin", ",", "requiring", "5", "to", "10", "times", "more", "profilin", "than", "with", "amoeba", "actin", "." ]

[ "Individual_protein", "Gene/protein/RNA" ]

Human immunodeficiency viruses is a virus, heterologous enhancer / promoters is a DNA_domain_or_region, lymphocyte tropisms is an other_name

83044_task0

Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, DNA_domain_or_region, virus

[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]

[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]

Human immunodeficiency viruses is a virus, heterologous enhancer / promoters is a DNA_domain_or_region, lymphocyte tropisms is an other_name

83044_task1

Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please typing these entity words according to sentence: Human immunodeficiency viruses, heterologous enhancer / promoters, lymphocyte tropisms Options: other_name, DNA_domain_or_region, virus

[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]

[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]

Human immunodeficiency viruses, heterologous enhancer / promoters, lymphocyte tropisms

83044_task2

Sentence: Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms. Instructions: please extract entity words from the input sentence

[ "B-virus", "I-virus", "I-virus", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O" ]

Human immunodeficiency viruses containing heterologous enhancer/promoters are replication competent and exhibit different lymphocyte tropisms.

[ "Human", "immunodeficiency", "viruses", "containing", "heterologous", "enhancer", "/", "promoters", "are", "replication", "competent", "and", "exhibit", "different", "lymphocyte", "tropisms", "." ]

[ "DNA_domain_or_region", "cell_type", "virus", "cell_line", "other_name", "protein_family_or_group", "protein_molecule", "(AND cell_line cell_line)", "DNA_molecule", "" ]

c - fos is a Protein, c - jun is a Protein, AP-1 is a Entity, proto - oncogenes is a Entity, c - jun is a Protein, c - fos is a Protein, AP-1 element is a Entity, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, AP-1 element is a Entity

110_task0

Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.

[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]

[ "Entity", "Protein" ]

c - fos is a Protein, c - jun is a Protein, AP-1 is a Entity, proto - oncogenes is a Entity, c - jun is a Protein, c - fos is a Protein, AP-1 element is a Entity, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, c - fos is a Protein, c - jun is a Protein, AP-1 element is a Entity

110_task1

Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please typing these entity words according to sentence: c - fos, c - jun, AP-1, proto - oncogenes, c - jun, c - fos, AP-1 element, c - fos, c - jun, c - fos, c - fos, c - jun, c - fos, c - jun, c - fos, c - jun, AP-1 element Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.

[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]

[ "Entity", "Protein" ]

c - fos, c - jun, AP-1, proto - oncogenes, c - jun, c - fos, AP-1 element, c - fos, c - jun, c - fos, c - fos, c - jun, c - fos, c - jun, c - fos, c - jun, AP-1 element

110_task2

Sentence: Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Leukotriene B4 stimulates c-fos and c-jun gene transcription and AP-1 binding activity in human monocytes. We have examined the effect of leukotriene B4 (LTB4), a potent lipid proinflammatory mediator, on the expression of the proto-oncogenes c-jun and c-fos. In addition, we looked at the modulation of nuclear factors binding specifically to the AP-1 element after LTB4 stimulation. LTB4 increased the expression of the c-fos gene in a time- and concentration-dependent manner. The c-jun mRNA, which is constitutively expressed in human peripheral-blood monocytes at relatively high levels, was also slightly augmented by LTB4, although to a much lower extent than c-fos. The kinetics of expression of the two genes were also slightly different, with c-fos mRNA reaching a peak at 15 min after stimulation and c-jun at 30 min. Both messages rapidly declined thereafter. Stability of the c-fos and c-jun mRNA was not affected by LTB4, as assessed after actinomycin D treatment. Nuclear transcription studies in vitro showed that LTB4 increased the transcription of the c-fos gene 7-fold and the c-jun gene 1.4-fold. Resting monocytes contained nuclear factors binding to the AP-1 element, but stimulation of monocytes with LTB4 induced greater AP-1-binding activity of nuclear proteins. These results indicate that LTB4 may regulate the production of different cytokines by modulating the yield and/or the function of transcription factors such as AP-1-binding proto-oncogene products.

[ "Leukotriene", "B4", "stimulates", "c", "-", "fos", "and", "c", "-", "jun", "gene", "transcription", "and", "AP-1", "binding", "activity", "in", "human", "monocytes", ".", "\n", "We", "have", "examined", "the", "effect", "of", "leukotriene", "B4", "(", "LTB4", ")", ",", "a", "potent", "lipid", "proinflammatory", "mediator", ",", "on", "the", "expression", "of", "the", "proto", "-", "oncogenes", "c", "-", "jun", "and", "c", "-", "fos", ".", "In", "addition", ",", "we", "looked", "at", "the", "modulation", "of", "nuclear", "factors", "binding", "specifically", "to", "the", "AP-1", "element", "after", "LTB4", "stimulation", ".", "LTB4", "increased", "the", "expression", "of", "the", "c", "-", "fos", "gene", "in", "a", "time-", "and", "concentration", "-", "dependent", "manner", ".", "The", "c", "-", "jun", "mRNA", ",", "which", "is", "constitutively", "expressed", "in", "human", "peripheral", "-", "blood", "monocytes", "at", "relatively", "high", "levels", ",", "was", "also", "slightly", "augmented", "by", "LTB4", ",", "although", "to", "a", "much", "lower", "extent", "than", "c", "-", "fos", ".", "The", "kinetics", "of", "expression", "of", "the", "two", "genes", "were", "also", "slightly", "different", ",", "with", "c", "-", "fos", "mRNA", "reaching", "a", "peak", "at", "15", "min", "after", "stimulation", "and", "c", "-", "jun", "at", "30", "min", ".", "Both", "messages", "rapidly", "declined", "thereafter", ".", "Stability", "of", "the", "c", "-", "fos", "and", "c", "-", "jun", "mRNA", "was", "not", "affected", "by", "LTB4", ",", "as", "assessed", "after", "actinomycin", "D", "treatment", ".", "Nuclear", "transcription", "studies", "in", "vitro", "showed", "that", "LTB4", "increased", "the", "transcription", "of", "the", "c", "-", "fos", "gene", "7-fold", "and", "the", "c", "-", "jun", "gene", "1.4-fold", ".", "Resting", "monocytes", "contained", "nuclear", "factors", "binding", "to", "the", "AP-1", "element", ",", "but", "stimulation", "of", "monocytes", "with", "LTB4", "induced", "greater", "AP-1-binding", "activity", "of", "nuclear", "proteins", ".", "These", "results", "indicate", "that", "LTB4", "may", "regulate", "the", "production", "of", "different", "cytokines", "by", "modulating", "the", "yield", "and", "/", "or", "the", "function", "of", "transcription", "factors", "such", "as", "AP-1-binding", "proto", "-", "oncogene", "products", ".", "\n" ]

[ "Entity", "Protein" ]

tissue factor is a Protein, Sp1 is a Protein, Tissue factor is a Protein, TF is a Protein, TF is a Protein, TF is a Protein, c - Rel is a Protein, p65 is a Protein, Egr-1 is a Protein, Sp1 is a Protein, Sp1 is a Protein, TF is a Protein, Sp1 is a Protein, c - Fos is a Protein, c - Jun is a Protein, TF is a Protein, promoter is a Entity, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, Sp1 is a Protein, TF is a Protein

689_task0

Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.

[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]

[ "Protein", "Entity" ]

tissue factor is a Protein, Sp1 is a Protein, Tissue factor is a Protein, TF is a Protein, TF is a Protein, TF is a Protein, c - Rel is a Protein, p65 is a Protein, Egr-1 is a Protein, Sp1 is a Protein, Sp1 is a Protein, TF is a Protein, Sp1 is a Protein, c - Fos is a Protein, c - Jun is a Protein, TF is a Protein, promoter is a Entity, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Jun is a Protein, p65 is a Protein, c - Fos is a Protein, c - Jun is a Protein, c - Rel is a Protein, p65 is a Protein, Sp1 is a Protein, TF is a Protein

689_task1

Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please typing these entity words according to sentence: tissue factor, Sp1, Tissue factor, TF, TF, TF, c - Rel, p65, Egr-1, Sp1, Sp1, TF, Sp1, c - Fos, c - Jun, TF, promoter, c - Fos, c - Jun, c - Rel, p65, c - Jun, p65, c - Jun, p65, c - Fos, c - Jun, c - Rel, p65, Sp1, TF Options: Entity, Protein

[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.

[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]

[ "Protein", "Entity" ]

tissue factor, Sp1, Tissue factor, TF, TF, TF, c - Rel, p65, Egr-1, Sp1, Sp1, TF, Sp1, c - Fos, c - Jun, TF, promoter, c - Fos, c - Jun, c - Rel, p65, c - Jun, p65, c - Jun, p65, c - Fos, c - Jun, c - Rel, p65, Sp1, TF

689_task2

Sentence: Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O" ]

Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Tissue factor (TF) expression by peripheral blood monocytes during sepsis initiates intravascular thrombosis. Bacterial lipopolysaccharide (LPS) rapidly induces TF gene transcription in monocytes. The human TF promoter contains binding sites for the transcription factors AP-1, c-Rel/p65, Egr-1, and Sp1. NF-kappa B/Rel proteins have been shown to physically interact with both AP-1 and Sp1 proteins. In this study, we investigated the role of these transcription factors in uninduced and LPS-induced TF gene expression in human monocytic THP-1 cells. Deletional analysis indicated that five Sp1 sites mediated basal expression in uninduced cells. The two AP-1 sites bound c-Fos/c-Jun heterodimers in both unstimulated and LPS-stimulated cells. Maximal LPS induction of the TF promoter required the two AP-1 sites and the kappa B site within the LPS response element. Disruption of the conserved spacing between the proximal AP-1 site and the kappa B site abolished LPS induction. Replacement of the two AP-1 sites with intrinsically bent DNA partially restored LPS induction, suggesting an additional structural role for the AP-1 sites. Synergistic transactivation of the LPS response element in Drosophila Schneider cells by coexpression of c-Fos, c-Jun, c-Rel, and p65 or c-Jun and p65 required the transactivation domains of c-Jun and p65. These data indicated that c-Fos/c-Jun, c-Rel/p65, and Sp1 regulate TF gene expression in human monocytic cells.

[ "Regulation", "of", "the", "tissue", "factor", "gene", "in", "human", "monocytic", "cells", ".", "Role", "of", "AP-1", ",", "NF", "-", "kappa", "B", "/", "Rel", ",", "and", "Sp1", "proteins", "in", "uninduced", "and", "lipopolysaccharide", "-", "induced", "expression", ".", "\n", "Tissue", "factor", "(", "TF", ")", "expression", "by", "peripheral", "blood", "monocytes", "during", "sepsis", "initiates", "intravascular", "thrombosis", ".", "Bacterial", "lipopolysaccharide", "(", "LPS", ")", "rapidly", "induces", "TF", "gene", "transcription", "in", "monocytes", ".", "The", "human", "TF", "promoter", "contains", "binding", "sites", "for", "the", "transcription", "factors", "AP-1", ",", "c", "-", "Rel", "/", "p65", ",", "Egr-1", ",", "and", "Sp1", ".", "NF", "-", "kappa", "B", "/", "Rel", "proteins", "have", "been", "shown", "to", "physically", "interact", "with", "both", "AP-1", "and", "Sp1", "proteins", ".", "In", "this", "study", ",", "we", "investigated", "the", "role", "of", "these", "transcription", "factors", "in", "uninduced", "and", "LPS", "-", "induced", "TF", "gene", "expression", "in", "human", "monocytic", "THP-1", "cells", ".", "Deletional", "analysis", "indicated", "that", "five", "Sp1", "sites", "mediated", "basal", "expression", "in", "uninduced", "cells", ".", "The", "two", "AP-1", "sites", "bound", "c", "-", "Fos", "/", "c", "-", "Jun", "heterodimers", "in", "both", "unstimulated", "and", "LPS", "-", "stimulated", "cells", ".", "Maximal", "LPS", "induction", "of", "the", "TF", "promoter", "required", "the", "two", "AP-1", "sites", "and", "the", "kappa", "B", "site", "within", "the", "LPS", "response", "element", ".", "Disruption", "of", "the", "conserved", "spacing", "between", "the", "proximal", "AP-1", "site", "and", "the", "kappa", "B", "site", "abolished", "LPS", "induction", ".", "Replacement", "of", "the", "two", "AP-1", "sites", "with", "intrinsically", "bent", "DNA", "partially", "restored", "LPS", "induction", ",", "suggesting", "an", "additional", "structural", "role", "for", "the", "AP-1", "sites", ".", "Synergistic", "transactivation", "of", "the", "LPS", "response", "element", "in", "Drosophila", "Schneider", "cells", "by", "coexpression", "of", "c", "-", "Fos", ",", "c", "-", "Jun", ",", "c", "-", "Rel", ",", "and", "p65", "or", "c", "-", "Jun", "and", "p65", "required", "the", "transactivation", "domains", "of", "c", "-", "Jun", "and", "p65", ".", "These", "data", "indicated", "that", "c", "-", "Fos", "/", "c", "-", "Jun", ",", "c", "-", "Rel", "/", "p65", ",", "and", "Sp1", "regulate", "TF", "gene", "expression", "in", "human", "monocytic", "cells", "." ]

[ "Protein", "Entity" ]

medical specialties is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, perception is an umlsterm, treatment is an umlsterm, instruments is an umlsterm, cardiac diseases is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, instrument is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, psychometric is an umlsterm, standards is an umlsterm, proven is an umlsterm, use is an umlsterm, Questionnaire is an umlsterm, Quality of Life is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, stages is an umlsterm, chronic venous insufficiency is an umlsterm, Stage is an umlsterm, Stage is an umlsterm, patients is an umlsterm, leg is an umlsterm, fears is an umlsterm, perception is an umlsterm, disease is an umlsterm, set is an umlsterm, clinical studies is an umlsterm, Germany is an umlsterm

DerHautarzt.80490372.eng.abstr_task0

Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .

[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]

[ "umlsterm" ]

medical specialties is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, perception is an umlsterm, treatment is an umlsterm, instruments is an umlsterm, cardiac diseases is an umlsterm, quality of life is an umlsterm, disease - related is an umlsterm, coping behavior is an umlsterm, patients is an umlsterm, chronic venous insufficiency is an umlsterm, instrument is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, psychometric is an umlsterm, standards is an umlsterm, proven is an umlsterm, use is an umlsterm, Questionnaire is an umlsterm, Quality of Life is an umlsterm, patients is an umlsterm, quality of life is an umlsterm, patients is an umlsterm, stages is an umlsterm, chronic venous insufficiency is an umlsterm, Stage is an umlsterm, Stage is an umlsterm, patients is an umlsterm, leg is an umlsterm, fears is an umlsterm, perception is an umlsterm, disease is an umlsterm, set is an umlsterm, clinical studies is an umlsterm, Germany is an umlsterm

DerHautarzt.80490372.eng.abstr_task1

Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please typing these entity words according to sentence: medical specialties, quality of life, disease - related, coping behavior, patients, perception, treatment, instruments, cardiac diseases, quality of life, disease - related, coping behavior, patients, chronic venous insufficiency, instrument, quality of life, patients, psychometric, standards, proven, use, Questionnaire, Quality of Life, patients, quality of life, patients, stages, chronic venous insufficiency, Stage, Stage, patients, leg, fears, perception, disease, set, clinical studies, Germany Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .

[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]

[ "umlsterm" ]

medical specialties, quality of life, disease - related, coping behavior, patients, perception, treatment, instruments, cardiac diseases, quality of life, disease - related, coping behavior, patients, chronic venous insufficiency, instrument, quality of life, patients, psychometric, standards, proven, use, Questionnaire, Quality of Life, patients, quality of life, patients, stages, chronic venous insufficiency, Stage, Stage, patients, leg, fears, perception, disease, set, clinical studies, Germany

DerHautarzt.80490372.eng.abstr_task2

Sentence: Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Across the boundaries of the medical specialties we have realized how important the concepts of quality of life and disease-related coping behavior are to understand the patients ' subjective perception of the medical condition and its treatment . Although standardized instruments are already available for different medical indications and even in the related fields of peripheral vascular and cardiac diseases , phlebology still lacks standardized concepts for evaluating quality of life and/or disease-related coping behavior in patients with chronic venous insufficiency ( CVI ) . We report on a newly developed instrument specifically designed for recording quality of life in patients with CVI . It not only meets the requirements of psychometric standards , but has also proven its applicability in clinical use . The " Tuebingen Questionnaire for measuring Quality of Life in patients with CVI ( TLQ-CVI ) " and the results of a study on quality of life in 142 patients with various stages of chronic venous insufficiency are presented . It was possible to distinguish between Stage I/II and Stage III CVI patients with respect to parameters such as " leg complaints " and " day-to-day fears and worries " . These convey clinically relevant insights into the patient's subjective perception of the disease and how they cope . The information gathered provides a set of reasonable target scores for clinical studies presently being carried out at various study centers in Germany incorporating the TLQ-CVI .

[ "Across", "the", "boundaries", "of", "the", "medical", "specialties", "we", "have", "realized", "how", "important", "the", "concepts", "of", "quality", "of", "life", "and", "disease", "-", "related", "coping", "behavior", "are", "to", "understand", "the", "patients", "'", "subjective", "perception", "of", "the", "medical", "condition", "and", "its", "treatment", ".", "Although", "standardized", "instruments", "are", "already", "available", "for", "different", "medical", "indications", "and", "even", "in", "the", "related", "fields", "of", "peripheral", "vascular", "and", "cardiac", "diseases", ",", "phlebology", "still", "lacks", "standardized", "concepts", "for", "evaluating", "quality", "of", "life", "and", "/", "or", "disease", "-", "related", "coping", "behavior", "in", "patients", "with", "chronic", "venous", "insufficiency", "(", "CVI", ")", ".", "We", "report", "on", "a", "newly", "developed", "instrument", "specifically", "designed", "for", "recording", "quality", "of", "life", "in", "patients", "with", "CVI", ".", "It", "not", "only", "meets", "the", "requirements", "of", "psychometric", "standards", ",", "but", "has", "also", "proven", "its", "applicability", "in", "clinical", "use", ".", "The", "\"", "Tuebingen", "Questionnaire", "for", "measuring", "Quality", "of", "Life", "in", "patients", "with", "CVI", "(", "TLQ", "-", "CVI", ")", "\"", "and", "the", "results", "of", "a", "study", "on", "quality", "of", "life", "in", "142", "patients", "with", "various", "stages", "of", "chronic", "venous", "insufficiency", "are", "presented", ".", "It", "was", "possible", "to", "distinguish", "between", "Stage", "I", "/", "II", "and", "Stage", "III", "CVI", "patients", "with", "respect", "to", "parameters", "such", "as", "\"", "leg", "complaints", "\"", "and", "\"", "day", "-", "to", "-", "day", "fears", "and", "worries", "\"", ".", "These", "convey", "clinically", "relevant", "insights", "into", "the", "patient", "'s", "subjective", "perception", "of", "the", "disease", "and", "how", "they", "cope", ".", "The", "information", "gathered", "provides", "a", "set", "of", "reasonable", "target", "scores", "for", "clinical", "studies", "presently", "being", "carried", "out", "at", "various", "study", "centers", "in", "Germany", "incorporating", "the", "TLQ", "-", "CVI", "." ]

[ "umlsterm" ]

Schmerzmessung is an umlsterm, -dokumentation is an umlsterm, Schmerzskala is an umlsterm

DerSchmerz.80120406.ger.abstr_task0

Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .

[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]

[ "umlsterm" ]

Schmerzmessung is an umlsterm, -dokumentation is an umlsterm, Schmerzskala is an umlsterm

DerSchmerz.80120406.ger.abstr_task1

Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please typing these entity words according to sentence: Schmerzmessung, -dokumentation, Schmerzskala Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .

[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]

[ "umlsterm" ]

Schmerzmessung, -dokumentation, Schmerzskala

DerSchmerz.80120406.ger.abstr_task2

Sentence: Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problem : Die Schmerzmessung und -dokumentation stellt ein interdisziplinaeres Problem dar . In der vorliegenden Untersuchung wurde der Frage nach der Aenderungssensitivitaet und der Konstruktvalidiaet der Revidierten Mehrdimensionalen Schmerzskala ( MSS ) nach Cziske et al. nachgegangen .

[ "Problem", ":", "Die", "Schmerzmessung", "und", "-dokumentation", "stellt", "ein", "interdisziplinaeres", "Problem", "dar", ".", "In", "der", "vorliegenden", "Untersuchung", "wurde", "der", "Frage", "nach", "der", "Aenderungssensitivitaet", "und", "der", "Konstruktvalidiaet", "der", "Revidierten", "Mehrdimensionalen", "Schmerzskala", "(", "MSS", ")", "nach", "Cziske", "et", "al", ".", "nachgegangen", "." ]

[ "umlsterm" ]

embryoid bodies is a Developing_anatomical_structure, cell is a Cell, embryoid bodies is a Developing_anatomical_structure

PMC-2192393-sec-06_task0

Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Developing_anatomical_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.

[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]

[ "Developing_anatomical_structure", "Cell" ]

embryoid bodies is a Developing_anatomical_structure, cell is a Cell, embryoid bodies is a Developing_anatomical_structure

PMC-2192393-sec-06_task1

Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please typing these entity words according to sentence: embryoid bodies, cell, embryoid bodies Options: Developing_anatomical_structure, Cell

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.

[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]

[ "Developing_anatomical_structure", "Cell" ]

embryoid bodies, cell, embryoid bodies

PMC-2192393-sec-06_task2

Sentence: Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "B-Developing_anatomical_structure", "I-Developing_anatomical_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cytology and Histology For semithin sections, embryoid bodies were washed twice in PBS, fixed in 4% paraformaldehyde at 4degreesC overnight, and after dehydration in ethanol were embedded in JB-4 resin (Polysciences, Inc.). 1-4-mum sections were cut with a glass knife. For cytology, the sections were stained with toluidine blue. In cell mixing experiments, the embryoid bodies were prefixed and stained for beta-galactosidase and the sections were counterstained with neutral red. Teratocarcinomas were fixed in Bouin fixative, embedded in Paraplast, and the sections were stained with hematoxylin and eosin. Microphotography was with a ZEISS Axiomat microscope. Films were scanned and figures were prepared with Photoshop 5.5 software.

[ "Cytology", "and", "Histology", "\n", "For", "semithin", "sections", ",", "embryoid", "bodies", "were", "washed", "twice", "in", "PBS", ",", "fixed", "in", "4", "%", "paraformaldehyde", "at", "4degreesC", "overnight", ",", "and", "after", "dehydration", "in", "ethanol", "were", "embedded", "in", "JB-4", "resin", "(", "Polysciences", ",", "Inc", ".", ")", ".", "1", "-", "4-mum", "sections", "were", "cut", "with", "a", "glass", "knife", ".", "For", "cytology", ",", "the", "sections", "were", "stained", "with", "toluidine", "blue", ".", "In", "cell", "mixing", "experiments", ",", "the", "embryoid", "bodies", "were", "prefixed", "and", "stained", "for", "beta", "-", "galactosidase", "and", "the", "sections", "were", "counterstained", "with", "neutral", "red", ".", "Teratocarcinomas", "were", "fixed", "in", "Bouin", "fixative", ",", "embedded", "in", "Paraplast", ",", "and", "the", "sections", "were", "stained", "with", "hematoxylin", "and", "eosin", ".", "Microphotography", "was", "with", "a", "ZEISS", "Axiomat", "microscope", ".", "Films", "were", "scanned", "and", "figures", "were", "prepared", "with", "Photoshop", "5.5", "software", ".", "\n" ]

[ "Developing_anatomical_structure", "Cell" ]

Iobitridol 300 is a Intervention_Pharmacological, iopromide 300 -- a is a Intervention_Pharmacological, total body CT . is a Participant_Condition, iobitriodol 300 mg I / ml and iopromide 300 mg I / ml is a Intervention_Pharmacological, onset is a Outcome_Other, adverse reaction is a Outcome_Adverse-effects, imaging quality is a Outcome_Other, side effects is a Outcome_Adverse-effects, iobitridol is a Intervention_Pharmacological, excellent image quality is a Outcome_Other, low rate of side effects is a Outcome_Adverse-effects, effective nonionic contrast agent is a Outcome_Other

86900_task0

Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Outcome_Adverse-effects

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]

Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .

[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]

Iobitridol 300 is a Intervention_Pharmacological, iopromide 300 -- a is a Intervention_Pharmacological, total body CT . is a Participant_Condition, iobitriodol 300 mg I / ml and iopromide 300 mg I / ml is a Intervention_Pharmacological, onset is a Outcome_Other, adverse reaction is a Outcome_Adverse-effects, imaging quality is a Outcome_Other, side effects is a Outcome_Adverse-effects, iobitridol is a Intervention_Pharmacological, excellent image quality is a Outcome_Other, low rate of side effects is a Outcome_Adverse-effects, effective nonionic contrast agent is a Outcome_Other

86900_task1

Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please typing these entity words according to sentence: Iobitridol 300, iopromide 300 -- a, total body CT ., iobitriodol 300 mg I / ml and iopromide 300 mg I / ml, onset, adverse reaction, imaging quality, side effects, iobitridol, excellent image quality, low rate of side effects, effective nonionic contrast agent Options: Outcome_Other, Intervention_Pharmacological, Participant_Condition, Outcome_Adverse-effects

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]

Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .

[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]

Iobitridol 300, iopromide 300 -- a, total body CT ., iobitriodol 300 mg I / ml and iopromide 300 mg I / ml, onset, adverse reaction, imaging quality, side effects, iobitridol, excellent image quality, low rate of side effects, effective nonionic contrast agent

86900_task2

Sentence: Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O" ]

Iobitridol 300 compared to iopromide 300 -- a double-blind randomized phase-III study of clinical tolerance in total body CT. UNLABELLED PURPOSE , MATERIAL AND METHODS : The clinical safety of iobitriodol 300 mg I/ml and iopromide 300 mg I/ml were compared in a randomized double blind phase-III study conducted on 60 patients undergoing abdominal CT for a variety of indications . Each examination was rated as diagnostic or nondiagnostic and the image quality was noted . Nature , onset , intensity as well as outcome of each adverse reaction were recorded . RESULTS There was no significant difference in imaging quality and side effects between the contrast media . In this study , both iobitridol and iopromide provided excellent image quality and a low rate of side effects . CONCLUSION Iobitridol is a safe and effective nonionic contrast agent for contrast-enhanced body CT .

[ "Iobitridol", "300", "compared", "to", "iopromide", "300", "--", "a", "double", "-", "blind", "randomized", "phase", "-", "III", "study", "of", "clinical", "tolerance", "in", "total", "body", "CT", ".", "UNLABELLED", "PURPOSE", ",", "MATERIAL", "AND", "METHODS", ":", "The", "clinical", "safety", "of", "iobitriodol", "300", "mg", "I", "/", "ml", "and", "iopromide", "300", "mg", "I", "/", "ml", "were", "compared", "in", "a", "randomized", "double", "blind", "phase", "-", "III", "study", "conducted", "on", "60", "patients", "undergoing", "abdominal", "CT", "for", "a", "variety", "of", "indications", ".", "Each", "examination", "was", "rated", "as", "diagnostic", "or", "nondiagnostic", "and", "the", "image", "quality", "was", "noted", ".", "Nature", ",", "onset", ",", "intensity", "as", "well", "as", "outcome", "of", "each", "adverse", "reaction", "were", "recorded", ".", "RESULTS", "There", "was", "no", "significant", "difference", "in", "imaging", "quality", "and", "side", "effects", "between", "the", "contrast", "media", ".", "In", "this", "study", ",", "both", "iobitridol", "and", "iopromide", "provided", "excellent", "image", "quality", "and", "a", "low", "rate", "of", "side", "effects", ".", "CONCLUSION", "Iobitridol", "is", "a", "safe", "and", "effective", "nonionic", "contrast", "agent", "for", "contrast", "-", "enhanced", "body", "CT", "." ]

[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Condition" ]

Fernando is a NOMBRE_SUJETO_ASISTENCIA, López Franco is a NOMBRE_SUJETO_ASISTENCIA, 798246 is a ID_SUJETO_ASISTENCIA, 78 14651695 54 is a ID_ASEGURAMIENTO, Cádiz is a TERRITORIO, 11004 is a TERRITORIO, 23/10/1948 is a FECHAS, España is a PAIS, 69 años is a EDAD_SUJETO_ASISTENCIA, 04/04/2018 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, 11 11 54263 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 69 años is a EDAD_SUJETO_ASISTENCIA, 1985 is a FECHAS, 1996 is a FECHAS, 1999 is a FECHAS, julio de 2006 is a FECHAS, noviembre de 2006 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, Instituto de Medicina Legal is a INSTITUCION, 11071 is a TERRITORIO, Cádiz is a TERRITORIO, 956 203 145 is a NUMERO_TELEFONO, 956 203 146 is a NUMERO_TELEFONO

295_task0

Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]

Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.

[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]

[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Fernando is a NOMBRE_SUJETO_ASISTENCIA, López Franco is a NOMBRE_SUJETO_ASISTENCIA, 798246 is a ID_SUJETO_ASISTENCIA, 78 14651695 54 is a ID_ASEGURAMIENTO, Cádiz is a TERRITORIO, 11004 is a TERRITORIO, 23/10/1948 is a FECHAS, España is a PAIS, 69 años is a EDAD_SUJETO_ASISTENCIA, 04/04/2018 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, 11 11 54263 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 69 años is a EDAD_SUJETO_ASISTENCIA, 1985 is a FECHAS, 1996 is a FECHAS, 1999 is a FECHAS, julio de 2006 is a FECHAS, noviembre de 2006 is a FECHAS, Pedro Martínez - García is a NOMBRE_PERSONAL_SANITARIO, Instituto de Medicina Legal is a INSTITUCION, 11071 is a TERRITORIO, Cádiz is a TERRITORIO, 956 203 145 is a NUMERO_TELEFONO, 956 203 146 is a NUMERO_TELEFONO

295_task1

Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please typing these entity words according to sentence: Fernando, López Franco, 798246, 78 14651695 54, Cádiz, 11004, 23/10/1948, España, 69 años, 04/04/2018, Pedro Martínez - García, 11 11 54263, Varón, 69 años, 1985, 1996, 1999, julio de 2006, noviembre de 2006, Pedro Martínez - García, Instituto de Medicina Legal, 11071, Cádiz, 956 203 145, 956 203 146 Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, PAIS, EDAD_SUJETO_ASISTENCIA, INSTITUCION, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]

Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.

[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]

[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Fernando, López Franco, 798246, 78 14651695 54, Cádiz, 11004, 23/10/1948, España, 69 años, 04/04/2018, Pedro Martínez - García, 11 11 54263, Varón, 69 años, 1985, 1996, 1999, julio de 2006, noviembre de 2006, Pedro Martínez - García, Instituto de Medicina Legal, 11071, Cádiz, 956 203 145, 956 203 146

295_task2

Sentence: Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "I-FECHAS", "I-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "B-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "I-INSTITUCION", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O", "O" ]

Nombre: Fernando. Apellidos: López Franco. NHC: 798246. NASS: 78 14651695 54. Domicilio: Calle San Francisco, 9 2C. Localidad/ Provincia: Cádiz. CP: 11004. Datos asistenciales. Fecha de nacimiento: 23/10/1948. País: España. Edad: 69 años Sexo: H. Fecha de Ingreso: 04/04/2018. Médico: Pedro Martínez-García NºCol: 11 11 54263. Historia del paciente: Varón de 69 años, bebedor y fumador severo, operado en 1985 de un carcinoma epidermoide de suelo de boca y lengua realizándose una hemimandibulectomía con disección radical del cuello izquierdo. En 1996 se procedió a la reconstrucción con injerto libre de cresta iliaca y barra de titanio. En 1999 fue sometido a una laringuectomía total suprahioidea por un nuevo carcinoma epidermoide de laringe con metástasis supraclavicular izquierda (T4N1M0). El cierre del faringostoma se realizó usando un colgajo dermo-platismo-fascial de Herrmann. Posteriormente recibió tratamiento radioterápico con cobalto-60 sobre el lecho quirúrgico y las cadenas cervicales supraclaviculares bilaterales. En julio de 2006 presentó una recidiva de su carcinoma de cavidad oral, tratada quirúrgicamente con resección del muñón de base de lengua y reconstrucción con colgajo miocutáneo pectoral izquierdo. En noviembre de 2006 ingresó por la aparición de disfagia, que le condicionaba una incapacidad total para la alimentación oral y provocó secundariamente una desnutrición severa. Se intentó reiteradamente la colocación una sonda nasogástrica, sin éxito. Se realizó una nasofibroscopia en la que se objetivó una estenosis faringoesofágica infranqueable de aspecto benigno. Se solicitó entonces una endoscopia oral que demostró una zona estenótica de aspecto fibroso en la unión faringoesofágica, asociada a un importante crecimiento piloso en la faringe por inversión de la piel en la cirugía previa, pero sin datos de recidiva tumoral local. La estenosis esofágica resultó infranqueable al endoscopio, por lo que se procedió a la colocación de una gastrostomía quirúrgica según técnica de Witzel. Actualmente el paciente mantiene un adecuado estado nutricional y no existen datos de nueva recidiva tumoral. Remitido por: Dr. Pedro Martínez-García. Instituto de Medicina Legal. C/ Sánchez Barcaiztegui nº 3- 2º. 11071 Cádiz. Tfno: 956 203 145 y 956 203 146.

[ "Nombre", ":", " ", "Fernando", ".", "\n", "Apellidos", ":", "López", "Franco", ".", "\n", "NHC", ":", "798246", ".", "\n", "NASS", ":", "78", "14651695", "54", ".", "\n", "Domicilio", ":", "Calle", "San", "Francisco", ",", "9", "2C.", "\n", "Localidad/", "Provincia", ":", "Cádiz", ".", "\n", "CP", ":", "11004", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "23/10/1948", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "69", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "04/04/2018", ".", "\n", "Médico", ":", "Pedro", "Martínez", "-", "García", "NºCol", ":", "11", "11", "54263", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "69", "años", ",", "bebedor", "y", "fumador", "severo", ",", "operado", "en", "1985", "de", "un", "carcinoma", "epidermoide", "de", "suelo", "de", "boca", "y", "lengua", "realizándose", "una", "hemimandibulectomía", "con", "disección", "radical", "del", "cuello", "izquierdo", ".", "En", "1996", "se", "procedió", "a", "la", "reconstrucción", "con", "injerto", "libre", "de", "cresta", "iliaca", "y", "barra", "de", "titanio", ".", "En", "1999", "fue", "sometido", "a", "una", "laringuectomía", "total", "suprahioidea", "por", "un", "nuevo", "carcinoma", "epidermoide", "de", "laringe", "con", "metástasis", "supraclavicular", "izquierda", "(", "T4N1M0", ")", ".", "El", "cierre", "del", "faringostoma", "se", "realizó", "usando", "un", "colgajo", "dermo", "-", "platismo", "-", "fascial", "de", "Herrmann", ".", "Posteriormente", "recibió", "tratamiento", "radioterápico", "con", "cobalto-60", "sobre", "el", "lecho", "quirúrgico", "y", "las", "cadenas", "cervicales", "supraclaviculares", "bilaterales", ".", "En", "julio", "de", "2006", "presentó", "una", "recidiva", "de", "su", "carcinoma", "de", "cavidad", "oral", ",", "tratada", "quirúrgicamente", "con", "resección", "del", "muñón", "de", "base", "de", "lengua", "y", "reconstrucción", "con", "colgajo", "miocutáneo", "pectoral", "izquierdo", ".", "En", "noviembre", "de", "2006", "ingresó", "por", "la", "aparición", "de", "disfagia", ",", "que", "le", "condicionaba", "una", "incapacidad", "total", "para", "la", "alimentación", "oral", "y", "provocó", "secundariamente", "una", "desnutrición", "severa", ".", "Se", "intentó", "reiteradamente", "la", "colocación", "una", "sonda", "nasogástrica", ",", "sin", "éxito", ".", "Se", "realizó", "una", "nasofibroscopia", "en", "la", "que", "se", "objetivó", "una", "estenosis", "faringoesofágica", "infranqueable", "de", "aspecto", "benigno", ".", "Se", "solicitó", "entonces", "una", "endoscopia", "oral", "que", "demostró", "una", "zona", "estenótica", "de", "aspecto", "fibroso", "en", "la", "unión", "faringoesofágica", ",", "asociada", "a", "un", "importante", "crecimiento", "piloso", "en", "la", "faringe", "por", "inversión", "de", "la", "piel", "en", "la", "cirugía", "previa", ",", "pero", "sin", "datos", "de", "recidiva", "tumoral", "local", ".", "La", "estenosis", "esofágica", "resultó", "infranqueable", "al", "endoscopio", ",", "por", "lo", "que", "se", "procedió", "a", "la", "colocación", "de", "una", "gastrostomía", "quirúrgica", "según", "técnica", "de", "Witzel", ".", "Actualmente", "el", "paciente", "mantiene", "un", "adecuado", "estado", "nutricional", "y", "no", "existen", "datos", "de", "nueva", "recidiva", "tumoral", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Pedro", "Martínez", "-", "García", ".", "Instituto", "de", "Medicina", "Legal", ".", "C/", "Sánchez", "Barcaiztegui", "nº", "3-", "2º.", "11071", "Cádiz", ".", "Tfno", ":", "956", "203", "145", "y", "956", "203", "146", ".", "\n" ]

[ "CALLE", "INSTITUCION", "NOMBRE_PERSONAL_SANITARIO", "FECHAS", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "NUMERO_TELEFONO", "ID_TITULACION_PERSONAL_SANITARIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Nerve is an umlsterm, cell is an umlsterm, cells is an umlsterm, lamina is an umlsterm, nerve is an umlsterm, patient is an umlsterm, Zollinger - Ellison syndrome is an umlsterm, electron is an umlsterm, non - antral is an umlsterm, gastric mucosa is an umlsterm, gastric mucosa is an umlsterm

DerPathologe.50160404.eng.abstr_task0

Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .

[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]

[ "umlsterm" ]

Nerve is an umlsterm, cell is an umlsterm, cells is an umlsterm, lamina is an umlsterm, nerve is an umlsterm, patient is an umlsterm, Zollinger - Ellison syndrome is an umlsterm, electron is an umlsterm, non - antral is an umlsterm, gastric mucosa is an umlsterm, gastric mucosa is an umlsterm

DerPathologe.50160404.eng.abstr_task1

Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please typing these entity words according to sentence: Nerve, cell, cells, lamina, nerve, patient, Zollinger - Ellison syndrome, electron, non - antral, gastric mucosa, gastric mucosa Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .

[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]

[ "umlsterm" ]

Nerve, cell, cells, lamina, nerve, patient, Zollinger - Ellison syndrome, electron, non - antral, gastric mucosa, gastric mucosa

DerPathologe.50160404.eng.abstr_task2

Sentence: Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Nerve fibre-neuroendocrine cell complexes ( NF-NEC-C's ) are neuroendocrine cells located in the lamina propria of the gastrointestinal tract directly connected with nerve fibres of Meissner's plexus . We report on a patient with sporadic Zollinger-Ellison syndrome ( ZES ) with electron microscopically demonstrated multiple NF-NEC-C's in non-antral gastric mucosa . It is suspected that in ZES the hypergastrinaemia may represent a trophic stimulus for the proliferation of NF-NEC-C's in the gastric mucosa .

[ "Nerve", "fibre", "-", "neuroendocrine", "cell", "complexes", "(", "NF", "-", "NEC", "-", "C", "'s", ")", "are", "neuroendocrine", "cells", "located", "in", "the", "lamina", "propria", "of", "the", "gastrointestinal", "tract", "directly", "connected", "with", "nerve", "fibres", "of", "Meissner", "'s", "plexus", ".", "We", "report", "on", "a", "patient", "with", "sporadic", "Zollinger", "-", "Ellison", "syndrome", "(", "ZES", ")", "with", "electron", "microscopically", "demonstrated", "multiple", "NF", "-", "NEC", "-", "C", "'s", "in", "non", "-", "antral", "gastric", "mucosa", ".", "It", "is", "suspected", "that", "in", "ZES", "the", "hypergastrinaemia", "may", "represent", "a", "trophic", "stimulus", "for", "the", "proliferation", "of", "NF", "-", "NEC", "-", "C", "'s", "in", "the", "gastric", "mucosa", "." ]

[ "umlsterm" ]

fosfatasa alcalina is a PROTEINAS, antígeno galactomanano is a PROTEINAS, itraconazol is a NORMALIZABLES, voriconazol is a NORMALIZABLES

413_task0

Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).

[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

fosfatasa alcalina is a PROTEINAS, antígeno galactomanano is a PROTEINAS, itraconazol is a NORMALIZABLES, voriconazol is a NORMALIZABLES

413_task1

Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please typing these entity words according to sentence: fosfatasa alcalina, antígeno galactomanano, itraconazol, voriconazol Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).

[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

fosfatasa alcalina, antígeno galactomanano, itraconazol, voriconazol

413_task2

Sentence: Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 44 años, trabajador en canteras durante 26 años. Antecedentes de tabaquismo y etilismo. Diagnosticado de tuberculosis pulmonar en 2008 y tratado durante 12 meses. Reingresa un año después por hemoptisis y síndrome general de 2 meses de evolución. En la exploración física destacaba febrícula (37,3oC), con roncus y crepitantes bilaterales en la auscultación pulmonar. En la analítica sanguínea cabe reseñar leucocitosis (17.000 células/μl con 77% de neutrófilos, fosfatasa alcalina de 395 μ/l y VSG de 15 mm/h. En la radiografía de tórax se apreciaba un patrón intersticial micronodular bilateral difuso y un conglomerado en LSD y lesión cavitaria de pared gruesa en LSI, similar a estudios previos. En la TAC de tórax se apreció extensa afectación intersticial bilateral micronodular con múltiples adenopatías calcificadas, un gran conglomerado en LSD con calcificaciones en su interior similar a estudios previos, apreciándose aumento de la lesión del lóbulo superior izquierdo (LSI) con nueva cavitación, observándose material flotante en su interior compatible con aspergiloma. Las baciloscopias de esputo fueron negativas y el cultivo de esputo positivo para Aspergillus flavus. La serología también fue positiva para Aspergillus flavus y el antígeno galactomanano presentaba positividad débil. Se inició tratamiento con itraconazol. Acude de nuevo a los 3 meses por hemoptisis con persistencia de cultivos positivos para Aspergillus y se cambia el tratamiento a voriconazol con buena evolución clínica hasta el momento actual (3 meses de tratamiento).

[ "Varón", "de", "44", "años", ",", "trabajador", "en", "canteras", "durante", "26", "años", ".", "Antecedentes", "de", "tabaquismo", "y", "etilismo", ".", "Diagnosticado", "de", "tuberculosis", "pulmonar", "en", "2008", "y", "tratado", "durante", "12", "meses", ".", "Reingresa", "un", "año", "después", "por", "hemoptisis", "y", "síndrome", "general", "de", "2", "meses", "de", "evolución", ".", "En", "la", "exploración", "física", "destacaba", "febrícula", "(", "37,3oC", ")", ",", "con", "roncus", "y", "crepitantes", "bilaterales", "en", "la", "auscultación", "pulmonar", ".", "En", "la", "analítica", "sanguínea", "cabe", "reseñar", "leucocitosis", "(", "17.000", "células", "/", "μl", "con", "77", "%", "de", "neutrófilos", ",", "fosfatasa", "alcalina", "de", "395", "μ", "/", "l", "y", "VSG", "de", "15", "mm", "/", "h.", "En", "la", "radiografía", "de", "tórax", "se", "apreciaba", "un", "patrón", "intersticial", "micronodular", "bilateral", "difuso", "y", "un", "conglomerado", "en", "LSD", "y", "lesión", "cavitaria", "de", "pared", "gruesa", "en", "LSI", ",", "similar", "a", "estudios", "previos", ".", "En", "la", "TAC", "de", "tórax", "se", "apreció", "extensa", "afectación", "intersticial", "bilateral", "micronodular", "con", "múltiples", "adenopatías", "calcificadas", ",", "un", "gran", "conglomerado", "en", "LSD", "con", "calcificaciones", "en", "su", "interior", "similar", "a", "estudios", "previos", ",", "apreciándose", "aumento", "de", "la", "lesión", "del", "lóbulo", "superior", "izquierdo", "(", "LSI", ")", "con", "nueva", "cavitación", ",", "observándose", "material", "flotante", "en", "su", "interior", "compatible", "con", "aspergiloma", ".", "Las", "baciloscopias", "de", "esputo", "fueron", "negativas", "y", "el", "cultivo", "de", "esputo", "positivo", "para", "Aspergillus", "flavus", ".", "La", "serología", "también", "fue", "positiva", "para", "Aspergillus", "flavus", "y", "el", "antígeno", "galactomanano", "presentaba", "positividad", "débil", ".", "Se", "inició", "tratamiento", "con", "itraconazol", ".", "Acude", "de", "nuevo", "a", "los", "3", "meses", "por", "hemoptisis", "con", "persistencia", "de", "cultivos", "positivos", "para", "Aspergillus", "y", "se", "cambia", "el", "tratamiento", "a", "voriconazol", "con", "buena", "evolución", "clínica", "hasta", "el", "momento", "actual", "(", "3", "meses", "de", "tratamiento", ")", ".", "\n" ]

[ "PROTEINAS", "NORMALIZABLES" ]

Patienten is an umlsterm, Status asthmaticus is an umlsterm, medikamentoesen Therapie is an umlsterm, Behandlung is an umlsterm, Theophyllin is an umlsterm, Ketamin is an umlsterm, Intensivtherapie is an umlsterm, Fluessigkeitstherapie is an umlsterm, Bronchiallavage is an umlsterm, Hypoventilation is an umlsterm, lebensbedrohliche is an umlsterm, Patienten is an umlsterm

IntensiveMedizin.00370293.ger.abstr_task0

Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .

[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Status asthmaticus is an umlsterm, medikamentoesen Therapie is an umlsterm, Behandlung is an umlsterm, Theophyllin is an umlsterm, Ketamin is an umlsterm, Intensivtherapie is an umlsterm, Fluessigkeitstherapie is an umlsterm, Bronchiallavage is an umlsterm, Hypoventilation is an umlsterm, lebensbedrohliche is an umlsterm, Patienten is an umlsterm

IntensiveMedizin.00370293.ger.abstr_task1

Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please typing these entity words according to sentence: Patienten, Status asthmaticus, medikamentoesen Therapie, Behandlung, Theophyllin, Ketamin, Intensivtherapie, Fluessigkeitstherapie, Bronchiallavage, Hypoventilation, lebensbedrohliche, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .

[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]

[ "umlsterm" ]

Patienten, Status asthmaticus, medikamentoesen Therapie, Behandlung, Theophyllin, Ketamin, Intensivtherapie, Fluessigkeitstherapie, Bronchiallavage, Hypoventilation, lebensbedrohliche, Patienten

IntensiveMedizin.00370293.ger.abstr_task2

Sentence: Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Im Blick auf rezente Uebersichtsarbeiten praesentieren die Autoren ihre Sicht zum Management des Patienten mit Status asthmaticus . Unter der medikamentoesen Therapie wird die Behandlung mit Betasympathomimetika , Theophyllin , Glukokortikoiden sowie andere Massnahmen zur Bronchospasmolyse ( Ketamin Narkosegase ) und Intensivtherapie ( , Fluessigkeitstherapie , Bronchiallavage Heliox ) , vorgestellt . Bei den apparativen Massnahmen werden die nicht-invasive Beatmung , die kontrollierte maschinelle Hypoventilation , sowie die extrakorporale Membranoxygenierung abgehandelt . Bei Beachtung der hier vorgeschlagenen Vorgangsweise sollte es moeglich sein , die absolut lebensbedrohliche Situation vom Patienten abzuwenden .

[ "Im", "Blick", "auf", "rezente", "Uebersichtsarbeiten", "praesentieren", "die", "Autoren", "ihre", "Sicht", "zum", "Management", "des", "Patienten", "mit", "Status", "asthmaticus", ".", "Unter", "der", "medikamentoesen", "Therapie", "wird", "die", "Behandlung", "mit", "Betasympathomimetika", ",", "Theophyllin", ",", "Glukokortikoiden", "sowie", "andere", "Massnahmen", "zur", "Bronchospasmolyse", "(", "Ketamin", "Narkosegase", ")", "und", "Intensivtherapie", "(", ",", "Fluessigkeitstherapie", ",", "Bronchiallavage", "Heliox", ")", ",", "vorgestellt", ".", "Bei", "den", "apparativen", "Massnahmen", "werden", "die", "nicht", "-", "invasive", "Beatmung", ",", "die", "kontrollierte", "maschinelle", "Hypoventilation", ",", "sowie", "die", "extrakorporale", "Membranoxygenierung", "abgehandelt", ".", "Bei", "Beachtung", "der", "hier", "vorgeschlagenen", "Vorgangsweise", "sollte", "es", "moeglich", "sein", ",", "die", "absolut", "lebensbedrohliche", "Situation", "vom", "Patienten", "abzuwenden", "." ]

[ "umlsterm" ]

Zellulitis is an umlsterm, phlegmonenartig - imponierende is an umlsterm, Erytheme is an umlsterm, Lymphozyten is an umlsterm, Blut- is an umlsterm, Therapie is an umlsterm, Dapson is an umlsterm, Proteins is an umlsterm, Lymphozyten is an umlsterm, Zellen is an umlsterm, Lymphozyten is an umlsterm, Zellkultur is an umlsterm, Interleukin is an umlsterm, Interleukin is an umlsterm, Interferon is an umlsterm, T - Zellen is an umlsterm, Blut- is an umlsterm

DerHautarzt.00510182.ger.abstr_task0

Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .

[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]

[ "umlsterm" ]

Zellulitis is an umlsterm, phlegmonenartig - imponierende is an umlsterm, Erytheme is an umlsterm, Lymphozyten is an umlsterm, Blut- is an umlsterm, Therapie is an umlsterm, Dapson is an umlsterm, Proteins is an umlsterm, Lymphozyten is an umlsterm, Zellen is an umlsterm, Lymphozyten is an umlsterm, Zellkultur is an umlsterm, Interleukin is an umlsterm, Interleukin is an umlsterm, Interferon is an umlsterm, T - Zellen is an umlsterm, Blut- is an umlsterm

DerHautarzt.00510182.ger.abstr_task1

Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please typing these entity words according to sentence: Zellulitis, phlegmonenartig - imponierende, Erytheme, Lymphozyten, Blut-, Therapie, Dapson, Proteins, Lymphozyten, Zellen, Lymphozyten, Zellkultur, Interleukin, Interleukin, Interferon, T - Zellen, Blut- Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .

[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]

[ "umlsterm" ]

Zellulitis, phlegmonenartig - imponierende, Erytheme, Lymphozyten, Blut-, Therapie, Dapson, Proteins, Lymphozyten, Zellen, Lymphozyten, Zellkultur, Interleukin, Interleukin, Interferon, T - Zellen, Blut-

DerHautarzt.00510182.ger.abstr_task2

Sentence: Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]

Das Wells-Syndrom ( eosinophile Zellulitis ) , eine seltene Erkrankung , ist klinisch charakterisiert durch rezidivierende , phlegmonenartig-imponierende Erytheme sowie histologisch durch ein dermales Infiltrat von Lymphozyten und zahlreichen Eosinophilen , die Kollagenfasern umgeben und in typischen Faellen Flammenfiguren bilden . Es wird ueber eine 71jaehrige Patientin mit Wells-Syndrom , Blut- und Knochenmarkseosinophilie und Ansprechen auf eine Therapie mit Dapson berichtet . Im akuten Schub zeigte sich eine Erhoehung des Eosinophilen Cationischen Proteins ( ECP ) im Serum . In der Immunphaenotypisierung der peripheren Lymphozyten war der Anteil der CD3+CD4+ T Zellen erhoeht . Weiterhin wurde beobachtet , dass die peripheren Lymphozyten in Zellkultur spontan signifikante Mengen an Interleukin 5 ( IL-5), aber nicht Interleukin 4 ( IL-4) oder Interferon gamma ( IFN ) freisetzten . Dies legt die Vermutung nahe , dass aktivierte T-Zellen an der Entstehung der Blut- und Gewebeeosinophilie mitbeteiligt sind .

[ "Das", "Wells", "-", "Syndrom", "(", "eosinophile", "Zellulitis", ")", ",", "eine", "seltene", "Erkrankung", ",", "ist", "klinisch", "charakterisiert", "durch", "rezidivierende", ",", "phlegmonenartig", "-", "imponierende", "Erytheme", "sowie", "histologisch", "durch", "ein", "dermales", "Infiltrat", "von", "Lymphozyten", "und", "zahlreichen", "Eosinophilen", ",", "die", "Kollagenfasern", "umgeben", "und", "in", "typischen", "Faellen", "Flammenfiguren", "bilden", ".", "Es", "wird", "ueber", "eine", "71jaehrige", "Patientin", "mit", "Wells", "-", "Syndrom", ",", "Blut-", "und", "Knochenmarkseosinophilie", "und", "Ansprechen", "auf", "eine", "Therapie", "mit", "Dapson", "berichtet", ".", "Im", "akuten", "Schub", "zeigte", "sich", "eine", "Erhoehung", "des", "Eosinophilen", "Cationischen", "Proteins", "(", "ECP", ")", "im", "Serum", ".", "In", "der", "Immunphaenotypisierung", "der", "peripheren", "Lymphozyten", "war", "der", "Anteil", "der", "CD3+CD4", "+", "T", "Zellen", "erhoeht", ".", "Weiterhin", "wurde", "beobachtet", ",", "dass", "die", "peripheren", "Lymphozyten", "in", "Zellkultur", "spontan", "signifikante", "Mengen", "an", "Interleukin", "5", "(", "IL-5", ")", ",", "aber", "nicht", "Interleukin", "4", "(", "IL-4", ")", "oder", "Interferon", "gamma", "(", "IFN", ")", "freisetzten", ".", "Dies", "legt", "die", "Vermutung", "nahe", ",", "dass", "aktivierte", "T", "-", "Zellen", "an", "der", "Entstehung", "der", "Blut-", "und", "Gewebeeosinophilie", "mitbeteiligt", "sind", "." ]

[ "umlsterm" ]

tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, nortriptyline is a DRUG, fluoxetine hydrochloride is a DRUG, Fluoxetine is a DRUG, norfluoxetine is a DRUG_N, reserpine is a DRUG, tricyclic antidepressant is a GROUP, nortriptyline hydrochloride is a DRUG, anticholinergic drugs is a GROUP, sympathomimetic drugs is a GROUP, alcohol is a DRUG, debrisoquin is a DRUG, dextromethorphan is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, tricyclic antidepressants is a GROUP, selective serotonin reuptake inhibitors is a GROUP, tricyclic antidepressants is a GROUP, tricyclic antidepressant is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, phenothiazines is a GROUP, carbamazepine is a DRUG, Type 1C antiarrhythmics is a GROUP, propafenone is a DRUG, flecainide is a DRUG, encainide is a DRUG, quinidine is a DRUG

Nortriptyline_ddi_task0

Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG_N, DRUG

[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.

[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]

[ "GROUP", "DRUG", "DRUG_N" ]

tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, cimetidine is a DRUG, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, nortriptyline is a DRUG, fluoxetine hydrochloride is a DRUG, Fluoxetine is a DRUG, norfluoxetine is a DRUG_N, reserpine is a DRUG, tricyclic antidepressant is a GROUP, nortriptyline hydrochloride is a DRUG, anticholinergic drugs is a GROUP, sympathomimetic drugs is a GROUP, alcohol is a DRUG, debrisoquin is a DRUG, dextromethorphan is a DRUG, tricyclic antidepressants is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, tricyclic antidepressants is a GROUP, selective serotonin reuptake inhibitors is a GROUP, tricyclic antidepressants is a GROUP, tricyclic antidepressant is a GROUP, tricyclic antidepressants is a GROUP, antidepressants is a GROUP, phenothiazines is a GROUP, carbamazepine is a DRUG, Type 1C antiarrhythmics is a GROUP, propafenone is a DRUG, flecainide is a DRUG, encainide is a DRUG, quinidine is a DRUG

Nortriptyline_ddi_task1

Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please typing these entity words according to sentence: tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, cimetidine, tricyclic antidepressants, tricyclic antidepressants, cimetidine, tricyclic antidepressants, antidepressants, nortriptyline, fluoxetine hydrochloride, Fluoxetine, norfluoxetine, reserpine, tricyclic antidepressant, nortriptyline hydrochloride, anticholinergic drugs, sympathomimetic drugs, alcohol, debrisoquin, dextromethorphan, tricyclic antidepressants, tricyclic antidepressants, antidepressants, tricyclic antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, tricyclic antidepressant, tricyclic antidepressants, antidepressants, phenothiazines, carbamazepine, Type 1C antiarrhythmics, propafenone, flecainide, encainide, quinidine Options: GROUP, DRUG_N, DRUG

[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.

[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]

[ "GROUP", "DRUG", "DRUG_N" ]

tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, tricyclic antidepressants, cimetidine, cimetidine, tricyclic antidepressants, tricyclic antidepressants, cimetidine, tricyclic antidepressants, antidepressants, nortriptyline, fluoxetine hydrochloride, Fluoxetine, norfluoxetine, reserpine, tricyclic antidepressant, nortriptyline hydrochloride, anticholinergic drugs, sympathomimetic drugs, alcohol, debrisoquin, dextromethorphan, tricyclic antidepressants, tricyclic antidepressants, antidepressants, tricyclic antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, tricyclic antidepressant, tricyclic antidepressants, antidepressants, phenothiazines, carbamazepine, Type 1C antiarrhythmics, propafenone, flecainide, encainide, quinidine

Nortriptyline_ddi_task2

Sentence: Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "I-DRUG", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "I-GROUP", "O", "B-GROUP", "I-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O", "B-DRUG", "O", "O", "B-GROUP", "I-GROUP", "I-GROUP", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen. Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen. In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine. In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued. The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued. Several of the tricyclic antidepressants have been cited in these reports. There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents. Fluoxetine and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for norfluoxetine), that may affect strategies during conversion from one drug to the other. Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a stimulating effect in some depressed patients. Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs. The patient should be informed that the response to alcohol may be exaggerated. Drugs Metabolized by P450IID6 A subset (3% to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450IID6. Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses. In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions. Concomitant use of tricyclic antidepressants with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.

[ "Steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "are", "reported", "to", "fluctuate", "significantly", "when", "cimetidine", "is", "either", "added", "or", "deleted", "from", "the", "drug", "regimen", ".", "Serious", "anticholinergic", "symptoms", "(", "severe", "dry", "mouth", ",", "urinary", "retention", ",", "blurred", "vision", ")", "have", "been", "associated", "with", "elevations", "in", "the", "serum", "levels", "of", "tricyclic", "antidepressants", "when", "cimetidine", "is", "added", "to", "the", "drug", "regimen", ".", "In", "addition", ",", "higher", "-", "than", "expected", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "have", "been", "observed", "when", "therapy", "is", "initiated", "in", "patients", "already", "taking", "cimetidine", ".", "In", "well", "-", "controlled", "patients", "undergoing", "concurrent", "therapy", "with", "cimetidine", ",", "a", "decrease", "in", "the", "steady", "-", "state", "serum", "concentrations", "of", "tricyclic", "antidepressants", "may", "occur", "when", "cime", "-", "tidine", "therapy", "is", "discontinued", ".", "The", "therapeutic", "efficacy", "of", "tricyclic", "antidepressants", "may", "be", "compromised", "in", "these", "patients", "when", "cimetidine", "is", "discontinued", ".", "Several", "of", "the", "tricyclic", "antidepressants", "have", "been", "cited", "in", "these", "reports", ".", "There", "have", "been", "greater", "than", "2-fold", "increases", "in", "previously", "stable", "plasma", "levels", "of", "other", "antidepressants", ",", "including", "nortriptyline", ",", "when", "fluoxetine", "hydrochloride", "has", "been", "administered", "in", "combination", "with", "these", "agents", ".", "Fluoxetine", "and", "its", "active", "metabolite", ",", "norfluoxe", "-", "tine", ",", "have", "long", "half", "-", "lives", "(", "4", "to", "16", "days", "for", "norfluoxetine", ")", ",", "that", "may", "affect", "strategies", "during", "conversion", "from", "one", "drug", "to", "the", "other", ".", "Administration", "of", "reserpine", "during", "therapy", "with", "a", "tricyclic", "antidepressant", "has", "been", "shown", "to", "produce", "a", " ", "stimulating", " ", "effect", "in", "some", "depressed", "patients", ".", "Close", "supervision", "and", "careful", "adjustment", "of", "the", "dosage", "are", "required", "when", "nortriptyline", "hydrochloride", "is", "used", "with", "other", "anticholinergic", "drugs", "or", "sympathomimetic", "drugs", ".", "The", "patient", "should", "be", "informed", "that", "the", "response", "to", "alcohol", "may", "be", "exaggerated", ".", "Drugs", "Metabolized", "by", "P450IID6", " ", "A", "subset", "(", "3", "%", "to", "10", "%", ")", "of", "the", "population", "has", "reduced", "activity", "of", "certain", "drug", "metabolizing", "enzymes", "such", "as", "the", "cytochrome", "P450", "isoenzyme", "P450IID6", ".", "Such", "individuals", "are", "referred", "to", "as", " ", "poor", "metabolizers", " ", "of", "drugs", "such", "as", "debrisoquin", ",", "dextromethorphan", ",", "and", "the", "tricyclic", "antidepressants", ".", "These", "individuals", "may", "have", "higher", "than", "expected", "plasma", "concentrations", "of", "tricyclic", "antidepressants", "when", "given", "usual", "doses", ".", "In", "addition", ",", "certain", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "many", "antidepressants", "(", "tricyclic", "antidepressants", ",", "selective", "serotonin", "reuptake", "inhibitors", ",", "and", "others", ")", ",", "may", "inhibit", "the", "activity", "of", "this", "isoenzyme", ",", "and", "thus", "may", "make", "normal", "metab", "-", "olizers", "resemble", "poor", "metabolizers", "with", "regard", "to", "concomitant", "therapy", "with", "other", "drugs", "metabolized", "by", "this", "enzyme", "system", ",", "leading", "to", "drug", "interactions", ".", "Concomitant", "use", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "metabolized", "by", "cytochrome", "P450IID6", "may", "require", "lower", "doses", "than", "usually", "prescribed", "for", "either", "the", "tricyclic", "antidepressant", "or", "the", "other", "drug", ".", "Therefore", ",", "co", "-", "administration", "of", "tricyclic", "antidepressants", "with", "other", "drugs", "that", "are", "metabolized", "by", "this", "isoenzyme", ",", "including", "other", "antidepressants", ",", "phenothiazines", ",", "carbamazepine", ",", "and", "Type", "1C", "antiarrhythmics", "(", "eg", ",", "propafenone", ",", "flecainide", ",", "and", "encainide", ")", ",", "or", "that", "inhibit", "this", "enzyme", "(", "eg", ",", "quinidine", ")", ",", "should", "be", "approached", "with", "caution", "." ]

[ "GROUP", "DRUG", "DRUG_N" ]